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Abstract 
  
DNA base pair mismatches occur naturally in cells, typically as a result of errors during 
replication. Cells have evolved a DNA damage response pathway called mismatch repair (MMR) 
that identifies and corrects base pair mismatches in newly synthesized DNA. However, proteins 
involved in MMR can undergo mutations, rendering them incapable of correcting mismatches. 
Such deficiencies in MMR leads to an increase in genetic mutations and are associated with several 
forms of cancer. Because a higher mismatch frequency serves as an early indicator of cancer 
progression, DNA mismatches are a promising target in the design of small molecule therapeutics 
and diagnostics. In this context, transition metal complexes are prime candidates, owing to 
their valuable spectroscopic and photophysical properties and versatile coordination sphere 
geometries. Our laboratory focuses on generating octahedral rhodium and ruthenium complexes 
that selectively target DNA mismatches. A class of rhodium complexes bearing sterically 
expansive planar ligands bind DNA mismatches with high selectivity and exhibit preferential 
cytotoxicity towards MMR-deficient cancer cells. These compounds bind to DNA through 
metalloinsertion, in which the bulky ligand inserts into the duplex at the thermodynamically 
destabilized mismatch site, displacing the mismatched bases into the DNA groove.  
Herein we describe recent advances in the development of luminescent ruthenium 
complexes that selectively probe DNA mismatches. We demonstrate that [Ru(Me4phen)2(dppz)]2+ 
(Me4phen = 3,4,7,8-tetramethyl-1,10-phenanthroline; dppz = dipyrido[3,2-a:2’,3’-c]phenazine) is 
a DNA “light switch” that exhibits a significantly brighter steady-state emission in the presence of 
a DNA duplex containing a mismatch relative to completely well-matched DNA. Importantly, the 
bulky Me4phen ancillary ligands discourage deep intercalation of dppz between well-matched base 
pairs, and instead, [Ru(Me4phen)2(dppz)]2+ favors metalloinsertion at thermodynamically 
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destabilized mismatches. [Ru(Me4phen)2(dppz)]2+ possesses a higher binding affinity towards a 
DNA mismatch relative to well-matched base pairs, and furthermore exhibits a longer excited-
state emission lifetime when bound to a mismatch compared to that when intercalated at well-
matched sites; both of these observations contribute to the dramatic steady-state emission 
enhancement detected with the mismatched DNA duplex. Additionally, we reveal that the right-
handed delta (∆) isomer of [Ru(Me4phen)2(dppz)]2+ is the enantiomer which imparts all mismatch 
selectivity, consistent with the handedness of B-form DNA. 
Another mismatch-specific luminescent probe presented in this work is 
[Ru(bpy)2(BNIQ)]2+ (bpy = 2,2’-bipyridine; BNIQ = benzo[c][1,7]naphthyridine-1-isoquinoline). 
In contrast to [Ru(Me4phen)2(dppz)]2+, the BNIQ complex exploits a bulky inserting ligand that 
selectively undergoes metalloinsertion at a DNA mismatch. This compound too exhibits a brighter 
steady-state emission in the presence of a mismatched duplex compared to entirely well-matched 
DNA, which we attribute to the fact that [Ru(bpy)2(BNIQ)]2+ possesses nearly a 500-fold higher 
binding affinity for the mismatch site compared to well-matched base pairs. Taken together, 
[Ru(Me4phen)2(dppz)]2+ and [Ru(bpy)2(BNIQ)]2+ represent two different yet valid approaches in 
the rational design of mismatch-specific small molecules, one based on ancillary ligand 
functionalization and the other on incorporating a sterically expansive inserting ligand.  
A third approach towards the design of mismatch-specific luminescent ruthenium probes 
that is briefly explored here is the modification of the intercalating dppz ligand of 
[Ru(bpy)2(dppz)]2+. Bearing a dppz ligand substituted with four methyl groups, 
[Ru(bpy)2(tmdppz)]2+ (tmdppz = 3,4,7,8-tetramethyl dipyridophenazine) shows no luminescence 
discrimination between mismatched and well-matched duplexes. This observation ostensibly 
arises from the fact that the appended methyl groups shield the dppz phenazine nitrogen atoms 
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from interactions with water when intercalated within the DNA.   
With mismatch-specific luminescent metalloinsertors such as [Ru(Me4phen)2(dppz)]2+ in 
hand, we have commenced biological investigations to see whether these compounds can serve as 
luminescent proxies for rhodium metalloinsertors in MMR-deficient cancer cells. Confocal 
microscopy of HCT116N and HCT116O cells reveals that [Ru(Me4phen)2(dppz)]2+ does 
preferentially localize to mitochondria, unlike potent cell-selective rhodium complexes such as 
[Rh(chrysi)(phen)(PPO)]2+ (PPO = 2-(pyridine-2-yl)propan-2-ol; chrysi = 5,6-chrysenequinone 
diimine); however, [Ru(Me4phen)2(dppz)]2+ shows some degree of nuclear entry. Here our goal is 
the application of the mismatch-specific luminescent probe in co-localization experiments to 
investigate what proteins are involved in the DNA damage response that is activated upon 
metalloinsertor binding in cellulo.   
The work presented here expands beyond the study of luminescent ruthenium complexes. 
Amino acid conjugates of the earlier-generation rhodium metalloinsertor [Rh(HDPA)2(chrysi)]3+ 
(HDPA = 2,2’-dipyridylamine) were synthesized. While these conjugates exhibit mismatch 
binding affinities comparable to other rhodium metalloinsertors, they lose cell-selective biological 
activity, which may arise from altered uptake and/or sub-cellular localization. Finally, preliminary 
investigations were conducted on [Re(CO)3(pyOEt)(dppn)]+ (pyOEt = ethyl 3-(pyridin-4-
yl)propanoate; dppn = benzodipyridophenazine) and [Ru(CN)(tpy)(dppz)]+ (tpy = terpyridine; CN 
= cyano), which were designed as IR-active probes to study the kinetics of DNA-mediated charge 
transport (CT) by time-resolved infrared (TRIR) spectroscopy. While these complexes do not 
possess the desired spectral TRIR properties as originally intended, steady-state luminescence 
experiments do suggest that this donor-acceptor pair is capable of undergoing DNA-mediated 
electron transfer. 
	   x 
Altogether, this work demonstrates the versatility of transition metal complexes as non-
covalent probes for DNA. Importantly, through the rational modification of their three-
dimensional ligand scaffold, one can achieve site-specific recognition of clinically relevant 
biomarkers such as DNA mismatches.   
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Chapter 1  
 
Introduction: Targeting DNA Mismatches with Transition 
Metal Complexes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: Barton, J.K.; Boynton, A.N.; Boyle, K.M. In DNA-Targeting Molecules as 
Therapeutic Agents; Waring, M.J., Ed.; The Royal Society of Chemistry, Chapter 15 (in press).  
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1.1   Transition Metal Complexes as Non-Covalent Probes for Nucleic Acids  
 
Coordination complexes offer distinct advantages as probes for nucleic acid structure. 
Transition metals possess an array of unique photophysical, spectroscopic, and reactive properties, 
which can be finely tuned by varying the identity of the metal center and surrounding ligands. 
Furthermore, the relative ease with which different ligands can be exchanged for one another 
allows the researcher to explore a range of DNA recognition properties. Owing to this modular 
nature, one can generate families of closely related complexes to assist in structure-function 
studies. The Barton laboratory has focused on developing transition metal complexes that target 
DNA through non-covalent interactions, with an emphasis on rhodium- and ruthenium-based 
agents. Typically, these positively charged, water-soluble compounds are coordinatively saturated 
and substitutionally inert. Additionally, these are rigid, three-dimensional systems with well-
defined stereochemistry, all highly valuable properties in the context of non-covalent DNA 
recognition.   
Perhaps the simplest non-covalent interaction between a cationic transition metal complex 
and DNA is electrostatic association with the duplex (Figure 1.1a). Also referred to as ionic site 
binding, the driving force behind this mode is the electrostatic attraction between the positively 
charged transition metal complex and the negatively charged DNA polyanion.1 However, this 
binding mode offers no site-specific molecular recognition of the DNA. Electrostatic binding is 
embodied by the classic ruthenium polypyridyl complex [Ru(bpy)3]2+ (bpy = 2,2’-bipyridine).2,3,4 
Although the electrostatic interactions may have some stabilizing effects, this attraction results in 
very weak binding affinities towards the duplex, on the order of 102 M-1.2  
Groove binding is another type of non-covalent interaction that a transition metal complex 
may undergo with DNA (Figure 1.1b). This mode involves hydrophobic association in the minor 
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groove of the helix. An example of a minor groove-specific binder is Cu(phen)22+ (phen = 1,10-
phenanthroline), which was thoroughly studied by Sigman et al. and functions as a DNA cleaving 
agent in the presence of hydrogen peroxide.5,6,7 Another complex that is known to associate with 
the DNA helix via groove binding is [Ru(phen)3]2+, whose interactions with DNA have extensively 
been characterized by Barton et al.8 It is critical to note, however, that [Ru(phen)3]2+ is a chiral 
(a) Electrostatic Interaction (b) Groove binding 
(c) Metallointercalation (d) Metalloinsertion 
Figure 1.1. Four modes of non-covalent interactions between transition metal complexes and 
DNA: (a) electrostatic interactions between [Ru(bpy)3]2+ and the negatively-charged DNA, (b) 
groove binding of Cu(phen)22+ in the minor groove of DNA, (c) intercalation of [Rh[(R,R)-
Me2trien]phi]3+ between DNA base pairs, and (d) metalloinsertion of [Rh(bpy)2(chrysi)]3+ into two 
AC mismatched sites. In all images, the DNA sugar-phosphate backbone is shown in blue, well-
matched DNA base pairs are shown in green, and the mismatched bases in part (d) are highlighted 
in purple. Figure created from PDB structures 4C64, 1VTJ, 3GSK, 454D and CCDC structures 
ABAFAN and LUQGEL. 
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molecule; owing to its octahedral coordination geometry and three bidentate phen ligands, it 
possesses a left-handed enantiomer, designated as Λ, and a right-handed enantiomer, or ∆. Early 
work deduced that the Λ isomer exhibits preferential binding with B-DNA through association in 
the minor groove.2,4  
In contrast to Λ-[Ru(phen)3]2+, the ∆ isomer preferentially binds to DNA through a third 
non-covalent interaction called intercalation. In this binding mode, a planar, aromatic, heterocyclic 
ligand stacks between the DNA base pairs, typically from the major groove, causing slight 
unwinding of the helix as well as a small increase in rise (Figure 1.1c).9 Lippard et al. pioneered 
the early development of metallointercalators in the 1970s with their square planar platinum(II) 
complexes.10,11 In the case of [Ru(phen)3]2+, the phen ligands possess a sufficiently extended π-
system to intercalate, albeit partially, between the base pairs of the helix. This intercalation raises 
the binding affinity towards the DNA relative to groove binding or electrostatic associations. 
However, the binding affinity of [Ru(phen)3]2+ towards DNA is still relatively meager, on the order 
of 103 M-1. Increasing the intercalative binding affinity for a transition metal probe can be 
accomplished by increasing the surface area of the intercalating ligand, so as to achieve greater π-
stacking between the base pairs of the helix. 
Two of the best known examples of strongly intercalating ligands are phi (9,10-
phenanthrequinone diimine) and dppz (dipyrido[3,2-a:2’,3’-c]phenazine). Ruthenium(II) 
complexes bearing the dppz ligand, such as [Ru(bpy)2(dppz)]2+, favorably intercalate into B-form 
DNA with an affinity on the order of >106 M-1.12 While [Ru(bpy)2(dppz)]2+ binds somewhat non-
specifically, it does exhibit a preference towards AT-rich regions in the duplex.13 
[Ru(bpy)2(dppz)]2+ and related complexes are described in greater detail in Chapter 2.  
	   5 
Phi is another well-studied intercalating ligand, primarily in the context of rhodium(III) 
complexes. A classic intercalating complex is [Rh(phen)2(phi)]3+, which binds double helical DNA 
with high affinity (≥107 M-1) owing to the ability of the phi ligand to overlap significantly with the 
base pairs.14 Phi complexes of rhodium are capable of cleaving DNA at their intercalative site upon 
irradiation with UV light, a property with tremendous utility for determining site-specific DNA 
binding. For example, [Rh(phen)2(phi)]3+ exhibits some shape-selective recognition by 
preferentially photocleaving DNA at 5’-Py-Py-Pu-3’ sites. This sequence in particular generates a 
greater opening of the major groove, which alleviates steric interactions between the DNA and the 
ancillary phen ligands, allowing the complex to intercalate more deeply. Metallointercalators have 
Figure 1.2. [Rh[(R,R)-Me2trien]phi]3+ binds specifically to  a 5’-TGCA-3’ site in this 1.2 Å 
crystal structure. Van der Waals Me-Me interactions between [Rh[(R,R)-Me2trien]phi]3+ (blue) 
and T (cyan) as well as hydrogen bond interactions between [Rh[(R,R)-Me2trien]phi]3+ and the 
O6 of G (green) are shown as black dotted lines.	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also been developed as sequence-specific recognition agents, exemplified by ∆-α-[Rh[(R,R)-
Me2trien]phi]3+((R,R)-Me2trien = 2R,9R-diamino-4,7-diazadecane), which photocleaves 
specifically at the sequence 5’-TGCA-3’.15 A high-resolution crystal structure of this 
metallointercalator bound to DNA revealed that the DNA slightly unwinds at the binding site to 
permit deep intercalation of the rhodium complex, which occurs from the major groove (Figure 
1.2).16 The sequence-specificity results from an ensemble of non-covalent interactions between 
functionalities on the ancillary Me2trien ligand posed into the major groove by rigid intercalation 
of the octahedral complex. The intercalation results in a doubling of the rise at the binding site, 
and thus, the phi ligand behaves simply as if it were another base pair in the helix. 
The molecules described thus far represent several approaches to target DNA with 
coordination complexes. Moving forward, however, it becomes interesting not only to target DNA, 
but to target DNA in a manner that is relevant in the context of therapeutics or diagnostics. 
Furthermore, this targeting should be selective towards a biomarker of cancer, so as to avoid off-
target damage that is often seen with traditional DNA-binding therapeutics, such as cisplatin.17 
Even the most selective complex described here, ∆-α-[Rh[(R,R)-Me2trien]phi]3+, serves merely as 
a proof-of-concept molecule since its target, 5’-TGCA-3’ DNA, is not specifically implicated in 
any disease. With this considered, it becomes the task of the researcher not only to target DNA, 
but to identify and target DNA biomarkers that are unique to disease. 
1.2   Rhodium Metalloinsertors as Probes for DNA Mismatches  
The Barton laboratory has considered that potential targets for the design of new complexes 
might include sites of DNA damage or DNA lesions, which can be caused by both endogenous 
and exogenous sources such as replication errors or interactions with reactive oxygen species.18,19  
Since the genomic integrity of DNA is essential to mutation-free replication, cells usually have 
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several mechanisms to repair these types of DNA insults.20,21,22 One such repair mechanism, 
mismatch repair (MMR), is responsible for the correction of DNA base pair mismatches, which, 
if left uncorrected, propagate into point mutations upon cellular replication (Figure 1.3).23,24 
Deficiencies in this repair pathway are associated with many types of cancer, including 
tumorigenesis in up to 75% of individuals with Lynch syndrome (a genetic condition involving 
MMR deficiencies) and up to 20% of all solid tumors.25,26 Additionally, cancers featuring 
microsatellite instabilities (MSI) are associated with resistance to many first-line cancer 
treatments, such as cisplatin and alkylating agents.27,28 As such, MMR deficiencies and the 
associated increase in uncorrected DNA base pair mismatches represent a promising target for 
therapeutic and diagnostic design.  
The first example of a small transition metal complex capable of selectively targeting a 
DNA base pair mismatch came in 1997 with the development of a unique rhodium complex, 
[Rh(bpy)2(chrysi)]3+ (chrysi = 5,6-chrysenequinone diimine) (Figure 1.4).29 [Rh(bpy)2(chrysi)]3+ 
Figure 1.3. Cartoon of the mismatch repair (MMR) machinery. A replication error can result in an 
AA mismatch (red), which is identified and corrected by the MMR machinery (bottom). However, 
if the AA mismatch is not processed correctly, a subsequent iteration of replication will result in a 
TA mutation (red). Reprinted with permission from ref. 23, © 2016 Elsevier B.V. 
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was inspired by complexes such as [Rh(phen)2(phi)]3+ and [Rh(phi)2(bpy)]3+, which exploit inert, 
redox capable metal centers that allow them to cleave DNA upon irradiation with UV-light.30,31 
To impart mismatch selectivity upon this family of complexes, the phi ligand framework was 
expanded upon with an additional phenyl ring to generate the chrysi ligand. At 11.3 Å, the chrysi 
ligand is about 2.1 Å wider than phi and about 0.5 Å wider than a well-matched base pair, making 
intercalation a less favorable binding possibility due to steric clashing between the ligand and the 
sugar-phosphate backbone (Figure 1.4). Instead, it was hypothesized that rhodium complexes 
containing this bulky ligand would preferentially interact with DNA at thermodynamically 
destabilized sites, such as mismatches and abasic sites, which may be better able to accommodate 
the expansive ligand. 
As predicted, [Rh(bpy)2(chrysi)]3+ was shown to photocleave DNA in a surprisingly 
selective and robust manner. Initial experiments revealed the rhodium complex could photocleave 
mismatches of all identities, and that the extent of photocleavage (and therefore the level of 
detection) was dependent primarily on the thermodynamic destabilization of the targeted 
mismatch.32 Overall, it was found that 80% of mismatches in all possible sequence contexts (as 
well as thermodynamically destabilized abasic sites and single base bulges) were detected by 
[Rh(bpy)2(chrysi)]3+.33,34 Guanine-containing mismatches are frequently undetected by 
[Rh(bpy)2(chrysi)]3+ due to their low destabilization; they are in fact quite similar to well-matched 
base pairs. Remarkably, in binding a highly destabilized site, such as a CC mismatch, high 
selectivity of the Rh complex is maintained even in a large 2725 base pair linearized plasmid 
containing only a single CC mismatch: incubation of [Rh(bpy)2(chrysi)]3+ with this plasmid 
produced discrete cleavage products that corresponded exclusively with cleavage at the 
mismatched site.33 In comparison, no photocleavage was observed in an analogous well-matched 
	   9 
plasmid.  
These early studies showed that [Rh(bpy)2(chrysi)]3+ was a promising answer to DNA 
mismatch targeting, but it was not fully understood how [Rh(bpy)2(chrysi)]3+ targeted mismatches 
until ∆-[Rh(bpy)2(chrysi)]3+ was co-crystallized with DNA containing an AC mismatch (Figure 
1.4).35 The crystal structure revealed that the rhodium complex did not bind DNA mismatches via 
intercalation, but instead bound DNA through insertion. This distinct binding mode was initially 
proposed by L.S. Lerman in 1961, but the binding mode had not been directly observed until this 
structure.36 Accordingly, [Rh(bpy)2(chrysi)]3+ and future complexes became known as rhodium 
metalloinsertors and their binding mode as metalloinsertion.  
Rh
3+
N
N
N
NHN
N
H
Figure 1.4. (Left) The chrysi ligand is 0.5 Å wider than a well-matched base pair, making 
intercalation unfavorable. (Upper right) The structure of ∆-[Rh(bpy)2(chrysi)]3+. (Lower Right) A 
crystal structure revealed that ∆-Rh(bpy)2(chrysi)]3+ (purple) binds to a mismatch via 
metalloinsertion, in which the complex inserts from the minor groove and extrudes the mismatched 
bases (red) (figure created from PDB structure 3GSK).	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In metalloinsertion, the chrysi ligand of the ∆-enantiomer inserts into the DNA helix from 
the minor groove at a mismatch site by displacing and ejecting the mismatched bases (Figure 1.4). 
This insertion allows the chrysi ligand to replace the destabilized DNA mispair and π-stack with 
the neighboring well-matched bases. Unlike intercalation, there is little unwinding of the DNA nor 
a rise in the DNA helix. This is a highly stable binding interaction, with most metalloinsertors 
having binding affinities on the order of 106 to 107 M-1. Moreover, for most metalloinsertors, the 
binding is highly enantioselective; only the ∆-isomer can fit into the right-handed minor groove. 
The features of this unique binding mode also clarified the thermodynamic dependence of 
metalloinsertion on mismatch stability – proper hydrogen bond contacts between well-matched 
base pairs are too stabilizing to permit insertion of the chrysi ligand. This binding mode was later 
verified with additional crystal structures using AA-mismatched DNA as well as an NMR-solution 
structure using CC-mismatched DNA.37,38 In particular, the NMR structure confirmed that the 
crystallographically observed metalloinsertion was not simply an artifact of crystal packing forces.  
1.3   Rhodium Metalloinsertors as Chemotherapeutics  
After nearly a decade of in vitro work elucidating the binding properties and selectivity of 
rhodium metalloinsertors, it became clear that these complexes could find even greater 
significance as potential therapeutics. As discussed previously, deficiencies in MMR are 
associated with some cancers and can lead to an increase in persistent DNA base pair 
mismatches.39 However, due to the high fidelity and proofreading abilities of DNA polymerases, 
even MMR-deficient cells have extremely few mismatches. Since there are so few mismatch 
targets, it is necessary that a therapeutically relevant small molecule should have a generic affinity 
for all mismatches, not just certain mispairs. As such, rhodium metalloinsertors, which have high 
selectivity and bind an abundance of mismatches in various sequence contexts, are an ideal 
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therapeutic scaffold for MMR-deficient cancers.   
To test if in vitro results would translate to ex vivo cellular models, rhodium 
metalloinsertors were tested via cell proliferation and cell viability assays in isogenic MMR- 
proficient and deficient cell lines. Remarkably, [Rh(bpy)2(chrysi)]3+ preferentially targets MMR-
deficient cells over their MMR-proficient counterparts.40 Since the discovery of this unique 
biological selectivity, several generations of rhodium metalloinsertors have been developed to 
further improve this selective biological activity.41,42 One metalloinsertor in particular, 
[Rh(chrysi)(phen)(PPO)]2+ (PPO = 2-(pyridine-2-yl)propan-2-ol), is highly potent and selective 
towards MMR-deficient cancer cells compared to MMR-proficient cells.43 This compound has 
been shown to inhibit DNA synthesis and induce cell death by necrosis in the MMR-deficient 
HCT116O cell line.43 Recent results have demonstrated that Rh-PPO activates a DNA damage 
response that leads to cell death.44 It is proposed that upon binding to a DNA mismatch via 
metalloinsertion, an event which extrudes the mismatched bases from the helix, a novel lesion is 
created that is recognized by the cellular DNA damage response, and an inability to repair this 
lesion results in cell death. Thus, rhodium metalloinsertors hold great promise as chemotherapeutic 
agents directed towards mismatch repair-deficient cancers.  
1.4   Luminescent Probes for DNA Mismatches 
In addition to developing octahedral rhodium complexes as potential therapeutics targeted 
to mismatches, there is also considerable interest in designing mismatch-specific luminescent 
small molecules to serve as diagnostic probes for the early detection of MMR-deficient cancers, 
which may represent early diagnostics of carcinogenesis. While rhodium metalloinsertors are non-
luminescent upon excitation, one avenue for developing a diagnostic probe for DNA mismatches 
is to fluorescently tag a rhodium metalloinsertor. In one design, a negatively charged fluorophore, 
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Oregon Green 514, was tethered to a positively charged rhodium metalloinsertor to generate the 
conjugate RhOG (Figure 1.5).45 The motivation behind this design was that the fluorescence of the 
dye would be quenched in free solution, or in the presence of well-matched DNA, due to ion-
pairing with the rhodium moiety. However, if a mismatch were present, the rhodium would 
undergo metalloinsertion, causing the negatively charged dye to be repelled by the sugar-
phosphate DNA backbone, resulting in “turn-on” fluorescence. As expected, the fluorescence of 
the RhOG conjugate is considerably quenched relative to free Oregon Green, and compared to an 
equimolar solution of free Oregon Green and free metalloinsertor. Importantly, in fluorescence 
titrations of the conjugate with well-matched and CC-mismatched 17-mer oligonucleotides, the 
conjugate exhibits a 3.2-fold brighter emission intensity in the presence of the sequence containing 
the mismatch. Additionally, PAGE experiments utilizing 32P-labeled oligonucleotides revealed 
Rh
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Figure 1.5. Illustration of the design behind the rhodium metalloinsertor-Oregon Green conjugate 
(RhOG).  	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specific photocleavage at the CC mismatch. However, one drawback of this RhOG conjugate is 
that even in the presence of the mismatched sequence, the maximum fluorescence reached by the 
fluorophore was only 6% that of free Oregon Green; rhodium quenching even in the extended form 
could not be eliminated.   
More recently, another rhodium-fluorophore conjugate has been studied, in which a 
positively charged cyanine dye was tethered to a metalloinsertor scaffold via a PEG linker.46 In 
this design, the cyanine dye was chosen because it weakly fluoresces in aqueous solution but emits 
quite brightly upon intercalating into DNA. The rationale behind this conjugate design was that in 
the presence of well-matched DNA, the rhodium metalloinsertor would have a low affinity for the 
duplex, and thus only a weak emission from the conjugate would be observed in solution. 
Conversely, the metalloinsertor would readily bind to a mismatch site, thus permitting the cyanine 
dye to intercalate between the base pairs of the duplex, yielding a significant increase in 
fluorescence. Indeed, upon the addition of well-matched DNA, no change in the conjugate’s 
cyanine fluorescence is seen; however, upon the addition of a 27-mer duplex containing a single 
CC mismatch, a substantial increase in fluorescence intensity is observed. 
While conjugated organic fluorophores certainly play an important role in the context of 
DNA detection, the use of a singular transition metal center that is inherently luminescent is highly 
attractive owing to synthetic accessibility and the ability to study longer-lived emission lifetimes 
via time-resolved spectroscopy. In particular, ruthenium(II) polypyridyl complexes possess an 
intense metal-to-ligand charge transfer (MLCT) transition which, upon excitation, yields a bright, 
long-lived emission in the visible region. Like the rhodium complexes discussed in this chapter, 
ruthenium(II) polypyridyl compounds are coordinatively saturated, making them inert to ligand 
substitution and stable in aqueous solutions.  
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The ensuing chapters of this thesis discuss recent progress that has been made towards 
developing mismatch-specific luminescent ruthenium(II) complexes. Mismatch-targeting by small 
molecules represents a new strategy for therapeutic and diagnostic design, one based upon the 
application of octahedral metal complexes targeted to thermodynamically destabilized DNA 
mismatches through non-covalent interactions. 
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Chapter 2  
 
[Ru(Me4phen)2(dppz)]2+, a Light Switch for DNA Mismatches  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: Boynton, A.N.; Marcelis, L.; Barton, J.K. J. Am. Chem. Soc. 2016, 138, 5020-5023. 
L. Marcelis calculated [Ru(Me4phen)2(dppz)]2+ binding affinities through titration curve-fitting 
analysis and assisted in excited-state lifetime measurements.  
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2.1 Introduction  
 
The DNA mismatch repair (MMR) pathway identifies and corrects base pair mismatches 
that can occur during replication as a result of failed proofreading by polymerases.1 If left 
uncorrected, DNA base pair mismatches lead to mutations in subsequent rounds of replication.2,3 
Deficiencies in the MMR protein machinery are associated with several forms of cancer, including 
80% of hereditary non-polyposis colon cancers and 15-20% of all solid tumors.4,5 Furthermore, 
commonly used chemotherapeutics such as cisplatin and DNA alkylating agents exhibit a 
decreased effectiveness towards MMR-deficient cancers.6,7  
The design of small molecules that target DNA mismatches holds promise for 
chemotherapeutic and diagnostic applications. As discussed in Chapter 1, a class of octahedral 
rhodium complexes, bearing the sterically expansive chrysi ligand, bind DNA mismatches with 
high selectivity and exhibit preferential cytotoxicity towards MMR-deficient cancer cells.8,9 These 
compounds bind to DNA through metalloinsertion, in which the bulky chrysi ligand inserts into 
the duplex at the thermodynamically destabilized mismatch site, displacing the mismatched bases 
into the DNA groove.10,11  
Luminescent reporters of mismatches may represent early diagnostics of carcinogenesis. 
In an effort to develop new selective, signal-on probes for DNA mismatches, we have focused our 
attention on derivatives of [Ru(bpy)2(dppz)]2+ (dppz = dipyridophenazine), which serve as 
molecular “light switches” for duplex DNA (Figure 2.1).12 While these complexes do luminesce 
in organic, aprotic solvents such as acetonitrile, in aqueous solution, their luminescence is 
quenched due to hydrogen bonding between solvent water molecules and the phenazine nitrogen 
atoms of the dppz ligand. However, upon intercalating into well-matched duplex DNA, these 
compounds luminesce brightly owing to protection of the dppz ligand from the aqueous 
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environment.13,14  
While [Ru(bpy)2(dppz)]2+ intercalates non-specifically into duplex DNA, the complex 
luminesces more brightly in the presence of a DNA mismatch relative to completely well-matched 
DNA (Figure 2.1).15 A crystal structure of Δ-[Ru(bpy)2(dppz)]2+ bound to a 12-mer DNA 
oligonucleotide containing two AA mismatches was obtained at 0.92 Å resolution (Figure 2.1).16 
The asymmetric unit revealed five ruthenium complexes bound to the DNA duplex. In this 
structure, the complex was bound to the DNA in three distinct binding modes: (i) intercalation at 
well-matched sites, (ii) metalloinsertion at the mismatched sites, and (iii) end-capping between 
two duplexes. At the mismatched sites, the complex binds from the minor groove and inserts 
deeply into the base stack, completely extruding the mismatched adenosines. Interestingly, at both 
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Figure 2.1. (Left) [Ru(bpy)2(dppz)]2+ is a molecular “light switch” for duplex DNA in aqueous 
solution, and luminesces more brightly in the presence of DNA containing a mismatch. (Right) Δ-
[Ru(bpy)2(dppz)]2+ was co-crystallized with a short DNA duplex containing two AA mismatches 
(mismatched base pairs are highlighted in purple), and three binding modes of the complex were 
observed: metalloinsertion (red) at the mismatched sites, intercalation (green) at well-matched 
sites, and end-capping between two duplexes (cyan). Figure created from PDB structure 4E1U.     
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AA sites, each adenosine is displaced back towards the minor groove and stacks with the bpy 
ancillary ligands of the ruthenium complex. Furthermore, because the dppz ligand is relatively 
narrow and also symmetric, a minimal widening of the DNA minor groove is observed. This 
crystal structure also illustrates two Δ-[Ru(bpy)2(dppz)]2+ molecules bound via intercalation at 
well-matched sites. Both complexes are intercalated in the minor groove, an observation that 
differs from what is suggested by solution-phase experiments, namely that [Ru(bpy)2(dppz)]2+ 
intercalates at well matched sites via the major groove.17,18,19 However, in this structure, there are 
clear stacking interactions between the bpy ligands of the intercalated complexes and the 
neighboring mismatched adenosines, interactions that ostensibly stabilize the complexes in the 
minor groove at well-matched sites. Thus, these results suggest that there is likely a relatively 
small energetic difference when comparing intercalation from the minor and major groove for 
[Ru(bpy)2(dppz)]2+.  
Despite exhibiting a 1.5 to 2-fold luminescence enhancement in the presence of a DNA 
defect compared to fully well-matched DNA, [Ru(bpy)2(dppz)]2+ is not mismatch-specific. A 
mismatch-specific luminescent compound could be particularly valuable in the context of 
developing diagnostic probes for detecting deficiencies in mismatch repair. In this chapter, we 
investigate the role of ancillary ligand modification for achieving mismatch specificity. In 
particular, we rationalized that incorporating methyl groups on the ancillary ligands of 
[Ru(phen)2(dppz)]2+ and [Ru(bpy)2(dppz)]2+ would disfavor binding to well-matched sites as a 
result of steric clashing between the ancillary ligands and the DNA backbone. Moreover, bulkier 
ancillary ligands would disfavor deep intercalation of dppz at well-matched sites and instead favor 
shielding of the phenazine nitrogen atoms with insertion at a mismatch. Inspiration for this 
rationale arose from two prior reports in the Barton group which described incorporating methyl 
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substituents into the phenanthroline ligands of [Ru(phen)2(dppz)]2+ and [Os(phen)2(dppz)]2+. C. 
Puckett synthesized the methyl-substituted complex [Ru(Me4phen)2(dppz)]2+ (Me4phen = 3,4,7,8-
tetramethyl-1,10-phenanthroline, Figure 2.2) and observed that it displays a significant reduction 
in steady-state emission intensity relative to [Ru(phen)2(dppz)]2+ with calf thymus DNA.20 E. 
Holmlin et al. synthesized a series of [Os(L)2(dppz)]2+ complexes – which also function as DNA 
light switches – bearing various ancillary ligand modifications.21 Of particular interest is the 
observation that [Os(4,7-dmp)2(Me2-dppz)]2+ (4,7-dmp = 4,7-dimethylphenanthroline; Me2-dppz 
= 7,8-dimethyldipyridophenazine) possesses a significantly reduced emission intensity with DNA 
compared to the parent [Os(phen)2(Me2-dppz)]2+ complex. This was attributed to two mechanisms 
working together: first, the methyl groups at the 4-position of phenanthroline likely prevent full 
intercalation of the complex due to steric interactions with the DNA backbone. Second, it was 
found that the 4,7-complex is more sensitive to quenching by water due to an increase in excited-
state pKa at the phenazine nitrogen atoms. The methyl groups at the 4,7 positions stabilize the 
Os(III) oxidation state, meaning that an excited-state reduction of the phenazine portion of the 
dppz ligand is more favorable. Mismatch binding was not investigated in these prior reports; 
however, based on the evidence that appending simple methyl groups onto the ancillary ligands 
discourages intercalation at well-matched sites in duplex DNA, we believed that 
[Ru(Me4phen)2(dppz)]2+ might favor metalloinsertion at mismatched base pairs.   
 
2.2 Experimental Protocols  
2.2.1. Materials  
All chemicals and starting materials were purchased from commercial vendors and used as 
received. Dipyrido[3,2-a:2’,3’-c]phenazine (dppz) was prepared according to the literature.22 UV-
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Visible spectra were recorded on a Beckman DU 7400 UV-Visible spectrophotometer (Beckman 
Coulter). Oligonucleotides were synthesized using standard phosphoramidite chemistry at 
Integrated DNA Technologies (Coralville, IA) and purified by HPLC using a C18 reverse-phase 
column (Varian, Inc.) on a Hewlett-Packard 1100 HPLC. The copper complex Cu(phen)22+ was 
generated in situ by combining CuCl2 with phen ligand in a 1:3 ratio. 
2.2.2. Synthesis  
Ru(Me4phen)2Cl2. Following a modified literature report,23 RuCl3•nH2O (0.217 g, 0.830 
mmol), 3,4,7,8-tetramethyl-1,10-phenanthroline (0.494 g, 2.09 mmol), and LiCl (0.298 g, 7.03 
mmol) were combined in a Schlenk flask under argon. The contents were dissolved in anhydrous 
DMF (5 mL), and the solution was heated to 140°C and stirred for 4 h while being protected from 
light. The contents were cooled to room temperature, diluted with acetone (20 mL), and stored in 
the freezer overnight. The black precipitate was collected by vacuum filtration, washed three times 
with 5 mL portions of H2O and three times with 5 mL portions of diethyl ether, and dried. The 
product was used subsequently without further purification (0.495 g, 73%).   
 Ru(Me2bpy)2Cl2. RuCl3•nH2O (0.281 g, 1.07 mmol) was reacted with 5,5’-dimethyl-2,2’-
dipyridine (0.500 g, 2.71 mmol) and LiCl (0.385 g, 9.08 mmol) in DMF (15 mL) under the 
conditions described for the synthesis of Ru(Me4phen)2Cl2. The product was isolated and used 
subsequently without further purification (0.304 g, 63%). 
[Ru(Me4phen)2(dppz)]X2 (X = PF6 or Cl). Dppz ligand (0.025 g, 0.089 mmol) was 
combined with Ru(Me4phen)2Cl2 (0.057 g, 0.089 mmol) in ethylene glycol (8 mL) and heated to 
130°C and stirred for 5 h. The reaction was cooled to room temperature and diluted with H2O (8 
mL). Excess NH4PF6 was added to precipitate the product, which was collected by filtration, 
washed copiously with H2O and diethyl ether, and dried. (0.084 g, 82%). ESI(+)MS (m/z): [M/2]+ 
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found 428.2. The complex was converted to its water-soluble Cl salt by anion exchange 
chromatography (Sephadex QAE) and further purified by preparative HPLC using an isocratic 
method of 65% MeOH and 35% H2O (containing 0.1% TFA) over 60 min. 1H NMR (500 MHz, 
DMSO-d6) δ 9.58 (dd, J = 8.2, 1.3 Hz, 2H), 8.54 (dd, J = 6.3, 3.4 Hz, 2H), 8.52 (d, J = 0.9 Hz, 
4H), 8.22 (dd, J = 6.6, 3.4 Hz, 2H), 8.13 (dd, J = 5.4, 1.3 Hz, 2H), 7.90 (m, 4H), 7.76 (s, 2H), 2.82 
(d, J = 1.3 Hz, 12H), 2.27 (d, J = 3.7 Hz, 12H). The complex was again converted to its Cl salt by 
anion exchange chromatography to remove TFA anions present from the HPLC purification (ε422 
nm = 21,200 M-1 cm-1).20	  
[Ru(Me2bpy)2(dppz)]X2 (X = PF6 or Cl). Dppz ligand (0.240 g, 0.851 mmol) was combined 
with Ru(Me2bpy)2Cl2 (0.304 g, 0.563 mmol) in ethylene glycol and reacted as described for the 
Me4phen complex, and the product was collected as its PF6 salt (0.521 g, 89%). ESI(+)MS (m/z): 
[M/2]+ found 376.2. The complex was converted to its water-soluble Cl salt by anion exchange 
chromatography (Sephadex QAE) and further purified by preparative HPLC using a gradient of 
H2O (with 0.1% TFA) to CH3CN over 60 min. 1H NMR (500 MHz, DMSO-d6) δ 9.62 (dd, J = 8.2, 
1.3 Hz, 2H), 8.71 (d, J = 8.4 Hz, 2H), 8.67 (d, J = 8.4 Hz, 2H), 8.52 (m, 2H), 8.21 (m, 4H), 8.04 
(m, 4H), 7.94 (dd, J = 8.4, 1.9 Hz, 2H), 7.54 (dt, J = 1.8, 0.8 Hz, 2H), 7.48 (dt, J = 1.4, 0.7 Hz, 
2H), 2.26 (d, J = 0.7 Hz, 6H), 2.08 (d, J = 0.7 Hz, 6H). The complex was again converted to its Cl 
salt by anion exchange chromatography to remove TFA anions present from the HPLC 
purification. 
2.2.3  [Ru(Me4phen)2(dppz)]2+ Enantiomer Separation 
Enantiomeric separations were performed using an Astec CYCLOBOND I 2000 DMP 
semi-preparative chiral HPLC column. Separation was achieved with an isocratic 60% 
acetonitrile/40% 0.1 M KPF6 method over one hour. Following the preparative HPLC runs, the 
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fractions of each enantiomer were pooled and the solvent was evaporated. Each isomer was re-
dissolved in a minimal volume of water/acetonitrile and run through a Sep-Pak C18 cartridge 
(Waters) to remove the potassium ions from the KPF6. The isomers were then converted to their 
water-soluble Cl salts using Sephadex QAE. Isomers were confirmed by circular dichroism and 
assigned as reported.16,24 The lambda (Λ) isomer elutes first, followed by the delta (∆).  
2.2.4. Luminescence Measurements  
Steady-State Luminescence. Luminescence spectra were recorded on an ISS-K2 
spectrofluorometer at 25°C. [Ru(Me4phen)2(dppz)]2+ and [Ru(Me2bpy)2(dppz)]2+ were excited at 
440 nm, and emission spectra were integrated from 564-820 nm. The Cl salts of the complexes 
were used for all experiments. In all cases, [DNA] is defined as the concentration of full sequence.  
Time-Resolved Luminescence. Time-resolved spectroscopic measurements were carried 
out at the Beckman Institute Laser Resource Center (BILRC) and were conducted using 
instrumentation that has been described.25 Briefly, a 460 nm light produced by OPO pumped with 
a 10 Hz, Qswitched Nd:YAG laser (Spectra-Physics Quanta-Ray PRO-Series) was used as an 
excitation source (pump pulse duration ≈8 ns). The emitted light was detected at 650 nm with a 
photomultiplier tube (Hamamatsu R928) following wavelength selection by a double 
monochromator (Instruments SA DH-10). Scattered laser light was removed from the detectors 
using suitable filters. The samples were held in 1 cm path length quartz cuvettes (Starna) equipped 
with stir bars and irradiated at 460 nm with 500−1000 laser pulses at 3 mJ/pulse. Kinetic traces 
were fit to exponential equations of the form I(t) = a0 + Σ an exp(−t/τn), where I(t) is the signal 
intensity as a function of time, a0 is the intensity at long time, an is a pre-exponential factor that 
represents the relative contribution from the nth component to the trace, and τn is the lifetime of 
the nth component, convoluted with a Gaussian function to take into account the Instrument 
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Response Function (fwmh = 8ns). The errors are evaluated to be equal to 5%, but the incertitude 
on the short component (associated with complexes bond to well-matched DNA, i.e. 33-35 ns) 
being close to the IRF time characteristic is subject to a greater error (+/- 8 ns). 
 
2.3 Results and Discussion  
2.3.1. Luminescence of [Ru(Me4phen)2(dppz)]2+ with 27-mer DNA Duplexes 
As expected, [Ru(Me4phen)2(dppz)]2+ is not luminescent in aqueous solution upon 
excitation at 440 nm (MLCT transition). We studied the steady-state luminescence response of the 
complex towards a well-matched 27-mer DNA duplex and the analogous DNA duplex containing 
a single CC mismatch (Figure 2.2). Indeed, the ruthenium complex acts as a DNA light switch. 
Excitation in the presence of either duplex yields emission spectra centered at 640-650 nm (Figure 
2.2). Importantly, we observe appreciable luminescence enhancement with the 27-mer containing 
the single CC mismatch in comparison to the same 27-mer sequence lacking a mismatch. From 
DNA titrations of [Ru(Me4phen)2(dppz)]2+ (Appendix A.1), we calculate binding affinities of 6.8 
x 104 M-1 and 1.8 x 106 M-1 for well-matched and mismatched sites, respectively (Table 2.1). Given 
the 26-fold difference in binding affinities, we can conclude that the complex is quite selective for 
binding to the single base mismatch. 
To determine whether the differential luminescence observed in the steady-state 
experiments is due not only to a higher binding affinity towards the mismatch but also to an 
increase in relative emissivity, we measured excited state emission lifetimes of 
[Ru(Me4phen)2(dppz)]2+ with the well-matched and mismatched 27-mer (Table 2.1). In the 
presence of the well-matched sequence, a short emission lifetime equal to 35 ns is detected. 
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However, with the mismatched duplex, the luminescence decays as a bi-exponential function with 
components equal to 33 ns and 160 ns. We attribute this additional longer lifetime component, 
81% of the overall decay, to the population of excited complex bound to the mismatch. This longer-
lived component is similar in luminescence lifetime of the complex in dry acetonitrile (Table 2.1). 
This similarity in excited state lifetime illustrates how effectively the inserted complex is protected 
from quenching within its mismatched binding site.  
 Well-matched DNA Mismatched DNA CH3CN 
Ka (M-1)a 6.8 x 104 1.8 x 106 - 
Emission Lifetime (ns)b 35 33 (19%), 160 (81%) 189c 
Figure 2.2. (Top) DNA sequences used in this study. (Bottom left) Structure of 
[Ru(Me4phen)2(dppz)]2+. (Bottom right) Steady-state luminescence spectra of rac-
[Ru(Me4phen)2(dppz)]2+ with no DNA (gray), well-matched (blue) duplex, and with the duplex 
containing a single CC mismatch (red). Samples were prepared in 5 mM tris, 200 mM NaCl, pH 
7.5. [Ru] = 2 µM, [DNA duplex] = 2 µM, lex = 440 nm. 
Table 2.1. Binding Affinities and Emission Lifetimes of rac-[Ru(Me4phen)2(dppz)]2+ with Well-
Matched and Mismatched DNA Duplexes 
a Titrations were performed with DNA sequences shown in Figure 2.2 in 5 mM tris, 200 mM NaCl, pH 7.5. [Ru] = 2 µM, lex 
= 440 nm. The binding affinity is expressed per binding site. b Samples containing 4 µM Ru and 4 µM DNA were prepared in 
5 mM tris, 200 mM NaCl, pH 7.5 using DNA sequences shown in Figure 2.2. lex = 460 nm, lem = 650 nm. Percentages 
reflect relative contributions of each lifetime to the overall decay. c Obtained in degassed, anhydrous acetonitrile.   
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2.3.2 [Ru(Me4phen)2(dppz)]2+ Evidence for Metalloinsertion  
 We also investigated whether [Ru(Me4phen)2(dppz)]2+ is capable of probing other types of 
DNA base mismatches using hairpin oligonucleotides (Figure 2.3) containing a variable base pair 
(XY). The emission intensity of the complex with the well-matched GC and AT sequences is 
compared to GG, AA, CT, TT, CA, and CC mismatches, as well as an abasic site (CR). The 
greatest emission enhancement occurs in the presence of the most thermodynamically destabilized 
mismatch, CC, followed by CA. We detect negligible enhancement with the GG mismatch as 
expected given its stability.  Only a small enhancement is observed with the AA mismatch, which 
is generally more stable than CC, CA, and CT mismatches.26,27 Figure 2.3 shows similar emission 
intensities for CT and TT mismatches, although we might anticipate a greater emission intensity 
for CT based on relative stabilities; we have previously noted that for [Ru(bpy)2(dppz)]2+, 
hydrogen bonding interactions between thymine and the dppz ligand at the mismatch may lead to 
partial quenching.15 
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Figure 2.3. Plot of integrated emission intensity of rac-[Ru(Me4phen)2(dppz)]2+ (2 µM) with DNA 
hairpins (2 µM) containing a variable XY base pair. “R” denotes a tetrahydrofuranyl abasic site. 
lex = 440 nm. Samples prepared in 5 mM tris, 50 mM NaCl, pH 7.5.  
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We also examined the luminescence response towards an abasic site (CR), and we find that 
the enhancement is comparable to that with the CC mismatch, consistent with relative stabilities. 
Generally, then, the relative thermodynamic destabilization of the mismatch site correlates with 
the luminescence intensities seen in Figure 2.3. This dependence on the instability of the mismatch 
is consistent with metalloinsertion.28  
Metalloinsertion by octahedral metal complexes occurs from the minor groove side of 
DNA. To probe whether [Ru(Me4phen)2(dppz)]2+ does in fact bind at the mismatch from the minor 
groove, we tested Cu(phen)22+ as a minor groove quencher (Figure 2.4).16,29,30 With the DNA 
mismatch, as [Cu]/[Ru] increases, there is significant quenching of [Ru(Me4phen)2(dppz)]2+ 
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Figure 2.4. (Top) Steady-state Cu(phen)22+ quenching of rac-[Ru(Me4phen)2(dppz)]2+ (2 µM) bound to 
well-matched (left, blue) and mismatched (right, red) DNA (2 µM). Solid lines indicate no Cu present; 
dotted lines are increasing concentrations of Cu such that [Cu]/[Ru] = 7, 40, and 100, respectively. lex 
= 440 nm. Samples were prepared in 5 mM tris, 50 mM NaCl, pH 7.5. The DNA sequences are as in 
Figure 2.2. (Bottom) Steady-state NaI quenching of rac-[Ru(Me4phen)2(dppz)]2+ (2 µM) bound to well-
matched (left, blue) and mismatched (right, red) DNA (2 µM). Solid lines indicate no NaI present, and 
dotted lines represent increasing NaI concentrations of 25, 50, and 75 mM, respectively. lex = 440 nm. 
Samples were prepared in 5 mM tris, 200 mM NaCl, pH 7.5. 
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luminescence (Figure 2.4). Conversely, with well-matched DNA, there is little change in 
luminescence with increasing Cu(phen)22+ concentration. These observations indicate ruthenium 
binding at the mismatch via the minor groove, consistent with metalloinsertion. Moreover, the 
results suggest that binding to well-matched sites by the Me4phen derivative occurs through the 
major groove. This latter conclusion is further supported by quenching experiments employing 
sodium iodide (NaI). Iodide, an anionic quencher, is expected to preferentially quench a small 
molecule bound in the major groove of the DNA helix compared to the minor groove.15 Thus, NaI 
can be used to improve the luminescence differential between mismatched and well-matched 
samples of [Ru(Me4phen)2(dppz)]2+ (Figure 2.4). NaI was employed to preferentially quench the 
luminescence associated with well-matched DNA. It is evident that a more dramatic quenching is 
observed with the well-matched duplex compared to the duplex containing the CC mismatch. This 
suggests that at well-matched sites, the complex is bound in the more accessible major groove. 
However, we do note appreciable quenching of the mismatched signal, implying that the iodide 
quencher is still capable of accessing the mismatch-bound complex. Nonetheless, with this 
quenching method, we are able to completely abolish the well-matched emission signal, while 
maintaining a strong signal associated with mismatch binding, thus improving the luminescence 
differential between the two duplexes.	  	  
2.3.3. Model for [Ru(Me4phen)2(dppz)]2+ Binding to Well-Matched and Mismatched DNA 
To help explain the differential luminescence observed between the mismatched and well-
matched DNA samples, we explored models of [Ru(Me4phen)2(dppz)]2+ bound to well-matched 
and mismatched sites. Using the DNA coordinates from the crystal structure of D-
[Rh(bpy)2(chrysi)]3+ bound by metalloinsertion to an AC mismatch,10 we oriented D-
[Ru(Me4phen)2(dppz)]2+ into the mismatch site from the minor groove while minimizing steric 
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clashes with the Me4phen ancillary ligands and DNA (Figure 2.5). From this view, we can see that 
the dppz ligand is capable of deeply inserting into the mismatch site, allowing for significant 
protection from quenching by water. We also modeled major groove binding using the coordinates 
for intercalation by another rhodium complex.31 For intercalation at a well-matched site, we 
consider two possible binding orientations:14,21 (i) the dppz ligand intercalates in a “head-on” 
fashion (Figure 2.5), leaving both phenazine nitrogen atoms relatively well-surrounded by the base 
stack; (ii) the dppz ligand binds “side-on”, achieving overlap with the bases but with one of the 
phenazine nitrogen atoms being highly exposed to solvent quenching (Figure 2.5). Given the very 
short 35 ns lifetime observed for the complex with the well-matched duplex, we hypothesize that 
this side-on intercalation is the dominant binding mode when [Ru(Me4phen)2(dppz)]2+ is bound to 
a well-matched site.  
2.3.4. Further Investigating the Influence of Methyl Group Incorporation on DNA Binding: 
[Ru(Me2bpy)2(dppz)]2+ 
 
 We prepared another methyl-substituted Ru derivative, [Ru(Me2bpy)2(dppz)]2+ (Me2bpy = 
5,5’-dimethylbipyridine, Figure 2.6), to gain more insight into the role that methyl substituents 
Figure 2.5. Views down the helix axis of D-[Ru(Me4phen)2(dppz)]2+ modeled into the crystal 
structures of DNA duplexes. The ruthenium complex is shown in green with nitrogen atoms in 
blue. (Left) Head-on intercalation at a well-matched site from the major groove. (Middle) Side-
on intercalation at a well-matched site from the major groove. (Right) Metalloinsertion at a 
mismatch site from the minor groove; the extruded mismatched bases are shown in orange.  
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located on the ancillary ligands play with respect to DNA binding. [Ru(Me2bpy)2(dppz)]2+ 
possesses methyl groups at the 5,5’ positions of its bpy ligands, which are analogous to the 3,8 
methyl groups on Me4phen; however, unlike [Ru(Me4phen)2(dppz)]2+, the Me2bpy derivative does 
not contain methyl groups that are axial (para) to the Ru center. Thus, [Ru(Me2bpy)2(dppz)]2+ will 
provide insight into how methyl groups that are oriented more directly towards the DNA helix 
influence DNA interactions.   
 As demonstrated in Figure 2.6, [Ru(Me2bpy)2(dppz)]2+ exhibits an appreciable 
luminescence differential in the presence of the mismatched vs. well-matched DNA duplexes. The 
~7-fold luminescence enhancement observed with the mismatched sequence is a clear 
improvement over the 1.5 to 2-fold luminescence differential seen with the unsubstituted parent 
complex [Ru(bpy)2(dppz)]2+ using the same DNA sequences (Figure 2.1). This result indicates that 
methyl groups oriented toward the DNA helix – as in the 5,5’ methyl groups of Me2bpy and 
Figure 2.6. (Top) DNA sequences used in this study. (Bottom left) Structure of [Ru(Me2bpy)2(dppz)]2+. 
(Bottom right) Steady-state luminescence spectra of rac-[Ru(Me2bpy)2(dppz)]2+ with well-matched 
(blue) duplex and with the duplex containing a single CC mismatch (red). Samples were prepared in 5 
mM tris, 200 mM NaCl, pH 7.5. [Ru] = 2 µM, [DNA duplex] = 2 µM, lex = 440 nm. 
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analogous 3,8 methyl groups of Me4phen – play a major steric role in disfavoring intercalation at 
well-matched sites. However, given that [Ru(Me4phen)2(dppz)]2+ exhibits a ~10-fold emission 
enhancement when a mismatch is present, this suggests that the additional methyl groups located 
axial to the Ru center also play a role in the DNA-binding interactions. Furthermore, excited state 
emission lifetimes of [Ru(Me2bpy)2(dppz)]2+ with the mismatched DNA duplex reveal a long 
component (272 ns, 41% of the overall decay) and shorter component (55 ns, 59% of the overall 
decay). The long-lived 272 ns lifetime is reflective of mismatch binding, while the shorter 
component is presumably well-matched intercalation. With the completely well-matched 
sequence, we observe a predominantly short component (27 ns, 88%), and a small portion of a 
longer lifetime (125 ns, 12%). These data imply that the complex is primarily intercalated in a 
side-on orientation in which the emission is rapidly quenched, with a small population intercalated 
in a perpendicular fashion where the dppz ligand is better protected from the aqueous solvent.  
2.3.5. [Ru(Me4phen)2(dppz)]2+ Enantiomer Separation  
 It is well-established that the right-handed (delta, ∆) enantiomer of [Ru(phen)3]2+-derived 
ruthenium complexes preferentially bind to B-form DNA compared to their left-handed 
counterparts (lambda, Λ).32 Thus, we investigated the chiral preferences in binding to well-
matched and mismatched DNA for [Ru(Me4phen)2(dppz)]2+. Chiral HPLC was utilized to separate 
the ∆ and Λ enantiomers of the complex. An Astec CYCLOBOND I 2000 DMP semi-preparative 
chiral column was employed for enantiomer separation. Separation was achieved using an isocratic 
method of 60% acetonitrile with 40% 0.1 M KPF6 (Figure 2.7). The enantiomers were confirmed 
and assigned using circular dichroism (Figure 2.7). In these separations, the Λ enantiomer elutes 
first, followed by the ∆ enantiomer. With the two isomers in hand, we sought to investigate their 
steady-state and time-resolved luminescent properties with the well-matched and mismatched 27-
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mer DNA duplexes. We see in Figure 2.8 that the dramatic steady-state emission enhancement in 
the presence of the CC mismatch is entirely due to binding by the ∆ isomer; the Λ enantiomer 
exhibits a relatively weak light-switch effect in the presence of either duplex.    
To confirm the steady-state luminescence behavior of these two enantiomers, we measured 
their excited state emission lifetimes in the presence of the DNA duplexes (Figure 2.9). Consistent 
with the steady-state emission spectra, Figure 2.9 illustrates that the excited state emission of ∆-
[Ru(Me4phen)2(dppz)]2+ in the presence of the CC mismatch is substantially longer-lived 
compared to the fully-matched duplex. Furthermore, the Λ complex exhibits relatively fast emission 
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Figure 2.7. (Top) Chemical structures of ∆- and Λ-[Ru(Me4phen)2(dppz)]2+. (Middle) HPLC 
spectrum of rac-[Ru(Me4phen)2(dppz)]2+, obtained with the Astec CYCLOBOND I 2000 DMP 
chiral column, showing separation of the two enantiomers (60% MeCN/40% 0.1M KPF6). 
(Bottom) CD spectra of isolated enantiomers (50 µM samples prepared in water).   
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decays in the presence of both sequences. Importantly, the emission decay of ∆-
[Ru(Me4phen)2(dppz)]2+ with the mismatched sequence reveals a satisfactory fit to a mono-
exponential function, with a corresponding emission lifetime of 161 ns. This value is consistent 
with mismatch-bound complex, and these data imply that the ∆ isomer is exclusively bound at the 
mismatched site. Additionally, this isomer possesses a predominantly short-lived (21 ns) lifetime 
with the fully well-matched sequence, consistent with side-on intercalation of the dppz ligand. A 
small proportion of a longer-lived (115 ns) species is also detected, attributed to head-on 
intercalation of dppz. As expected, Λ-[Ru(Me4phen)2(dppz)]2+ exhibits predominantly short-lived 
lifetimes (12-15 ns) in the presence of either duplex, reflecting a species that is rapidly quenched 
by water. However, with the well-matched sequence, a longer-lived component (121 ns) is also 
detected, indicating that this isomer is capable of intercalation. This longer-lived component is 
enhanced to ~145 ns when the CC site is present, suggesting that binding to the mismatch may 
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Figure 2.8. Steady-state luminescence spectra of Λ- and ∆-[Ru(Me4phen)2(dppz)]2+ (left and right, 
respectively) with the well-matched (blue) duplex and with the duplex containing a single CC 
mismatch (red). Samples were prepared in 5 mM tris, 200 mM NaCl, pH 7.5. [Ru] = 2 µM, [DNA 
duplex] = 2 µM, lex = 440 nm. 
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provide further protection of Λ-[Ru(Me4phen)2(dppz)]2+ from quenching by water.  
2.4 Conclusions 
By incorporating methyl groups into the ancillary ligands of the [Ru(phen)2(dppz)]2+ 
scaffold, we have thus prepared a luminescent light switch that is highly selective in probing a 
DNA mismatch. This selectivity is the result of both a higher binding affinity towards mismatched 
DNA and a longer excited state emission lifetime when bound to a mismatch. Furthermore, 
consistent with the handedness of B-form DNA, we see that ∆-[Ru(Me4phen)2(dppz)]2+ is the 
isomer which imparts all mismatch selectivity. This work demonstrates that ancillary ligand 
modification offers a new approach in the design of mismatch-specific transition metal complexes.  
 
 
  
  
 
 
  
∆ + MM [τ = 161 ns]
∆ + WM [τ1 = 21 ns (82%),  
τ2 = 115 ns (18%)]
Λ + MM [τ1 = 17 ns (78%), 
τ2 =  145 ns (22%)]
Λ + WM [τ1 = 12 ns (86%), 
τ2 = 121 ns (14%)] 
Figure 2.9. Time-resolved luminescence decays of ∆-[Ru(Me4phen)2(dppz)]2+ (left) and Λ-
[Ru(Me4phen)2(dppz)]2+ (right) with well-matched (blue) duplex and with the duplex containing 
a single base pair CC mismatch (red). Insets are the calculated emission lifetimes for the various 
samples, fit to mono- or bi-exponential decays as indicated. Samples were in 5 mM tris, 200 mM 
NaCl, pH 7.5. [Ru] = 4 µM, [DNA duplex] = 4 µM, lex = 460 nm, lem = 650 nm.  
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Chapter 3 
 
[Ru(bpy)2(BNIQ)]2+ is a Highly Selective Luminescent Probe 
for Mismatched and Abasic Sites in DNA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from: Boynton, A.N.; Marcelis, L.; McConnell, A.J.; Barton, J.K. Inorg. Chem. 2017, 56, 
8381-8389. L. Marcelis calculated [Ru(bpy)2(BNIQ)]2+ binding affinities through titration curve-
fitting analysis and assisted in excited state lifetime measurements. A.J. McConnell developed the 
synthesis of BNIQ ligand precursor 2-chlorobenzo[c][1,7]naphthyridine.	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3.1 Introduction  
 
 The design of small molecules that specifically target DNA base mismatches is a promising 
route in the development of therapeutic and diagnostic agents directed towards mismatch repair 
(MMR)-deficient cancers.1,2 The Barton laboratory has found that octahedral rhodium complexes 
bearing sterically expansive aromatic ligands bind to DNA mismatches with high affinity and 
selectivity via metalloinsertion.3,4,5 The archetypal rhodium metalloinsertor is [Rh(bpy)2(chrysi)]3+ 
(chrysi = 5,6-chrysenequinone diimine), shown in Figure 3.1. At 11.3 Å, the chrysi ligand is 
approximately 0.5 Å wider than a well-matched base pair, which makes intercalation a less 
favorable binding mode due to steric clashing between the chrysi ligand and the sugar-phosphate 
backbone of the DNA. A crystal structure of [Rh(bpy)2(chrysi)]3+ bound to an AA mismatch 
revealed that the chrysi ligand inserts into the DNA helix from the minor groove at the 
Rh
3+
N
N
N
NHN
N
H
Figure 3.1. (Left) The chrysi ligand is 0.5 Å wider than a well-matched base pair, making 
intercalation unfavorable. (Upper right) The structure of ∆-[Rh(bpy)2(chrysi)]3+. (Lower Right) 
A crystal structure revealed that ∆-Rh(bpy)2(chrysi)]3+ (purple) binds to a mismatch via 
metalloinsertion, in which the complex inserts from the minor groove and extrudes the 
mismatched bases (red) (figure created from PDB structure 3GSK).	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thermodynamically destabilized mismatch site by displacing the mismatched bases from the base 
stack (Figure 3.1),3 a binding mode called metalloinsertion. Importantly, later generations of 
rhodium metalloinsertors have been shown to exhibit selective cytotoxicity towards cancer cells 
deficient in mismatch repair (MMR) compared to MMR-proficient cells, making these compounds 
promising chemotherapeutic agents for MMR-deficient cancers.6,7 
There is also considerable interest in designing mismatch-specific luminescent small 
molecules to serve as diagnostic probes for the early detection of MMR-deficient cancers. While 
rhodium metalloinsertors are non-emissive following excitation, octahedral ruthenium(II) 
polypyridyl complexes have attracted significant attention as luminescent reporters of 
biomolecules owing to their favorable photophysical and photochemical properties.8 
Ruthenium(II) polypyridyl complexes possess an intense metal-to-ligand charge transfer (MLCT) 
transition which, upon excitation, yields a bright, long-lived emission in the visible region. 
Furthermore, these compounds exhibit high photostability and are coordinatively saturated, 
making them inert to ligand substitution and stable in aqueous solutions. 
In addition to the ancillary ligand modification of [Ru(phen)2(dppz)]2+-type light switch 
compounds discussed in Chapter 2, another logical approach in the design of mismatch-specific 
luminescent ruthenium(II) polypyridyl complexes is to incorporate a sterically expansive aromatic 
ligand that is too large to intercalate into well-matched duplex DNA but can instead insert at 
destabilized sites. Several ligands that have been studied in this context include pqp (6-
phenylquino[8,7-k][1,8]phenanthroline),9 tpqp (7,8,13,14-tetrahydro-6-phenylquino[8,7-
k][1,8]phenanthroline),9 and eilatin10 (Figure 3.2). These ligands were developed as even bulkier 
versions of chrysi; however, unlike diimine-containing ligands, pqp, tpqp, and eilatin were 
designed to coordinate directly to the ruthenium center via the heterocyclic nitrogen atoms. 
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[Ru(bpy)2(pqp)]2+ shows no detectable luminescence, while [Ru(bpy)2(tpqp)]2+ emits weakly in 
aqueous solution. However, [Ru(bpy)2(tpqp)]2+ shows no increase in emission intensity upon the 
addition of either well-matched or mismatched DNA. That being said, luminescence polarization 
and [Fe(CN)6]4- quenching experiments revealed that [Ru(bpy)2(tpqp)]2+ binds more tightly at a 
CC mismatch site compared to well-matched base pairs in the duplex. This preferential binding to 
the mismatch was confirmed by a 1O2 sensitization assay, which showed preferential damage to 
the guanine adjacent to the CC mismatch compared to other guanine sites in the DNA. Another 
study explored the binding of [Ru(bpy)2(eilatin)]2+ to well-matched and mismatched DNA 
duplexes. Eilatin is a symmetric, aromatic ligand that is notably expansive. While competitive 
DNA photocleavage experiments with the metalloinsertor [Rh(bpy)2(chrysi)]3+ revealed some 
preferential binding of [Ru(bpy)2(eilatin)]2+ to a CC mismatch, competition experiments with the 
non-specific metallointercalator [Rh(bpy)2(phi)]3+ showed that the ruthenium complex is still 
readily capable of binding to well-matched sites in the duplex. These results emphasized the notion 
that while a planar, aromatic, bulky ligand such as chrysi can lead to high mismatch specificity, 
Figure 3.2. Several [Ru(bpy)2(L)]2+ complexes that have been investigated as luminescent 
reporters of DNA mismatches, incorporating sterically demanding ligands (L).  	  
Ru
N
N
N
N
N
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simply increasing the steric size does not necessarily correlate with an increase in mismatch 
specificity.  
Described in this chapter is the design and synthesis of a new sterically expansive ligand 
called BNIQ (Figure 3.2, BNIQ = benzo[c][1,7]naphthyridine-1-isoquinoline). The luminescent 
properties of the ruthenium complex bearing this ligand, [Ru(bpy)2(BNIQ)]2+ – both free and in 
the presence of well-matched and mismatched DNA duplexes – were explored using steady-state 
and excited-state lifetime measurements. It was found that [Ru(bpy)2(BNIQ)]2+ is highly selective 
towards destabilized sites in the DNA duplex.  
 
3.2 Experimental Protocols  
 
3.2.1 Materials  
 
All chemicals and starting materials were purchased from commercial vendors and used as 
received. Ru(bpy)2Cl2 was prepared according to the literature.11 UV-Visible spectra were 
recorded on a Beckman DU 7400 UV-Visible spectrophotometer (Beckman Coulter). 
Oligonucleotides were synthesized using standard phosphoramidite chemistry at Integrated DNA 
Technologies (Coralville, IA) and purified by HPLC using a C18 reverse-phase column (Varian, 
Inc.) on a Hewlett-Packard 1100 HPLC. The copper complex Cu(phen)22+ was generated in situ 
by combining CuCl2 with phen ligand in a 3:1 ratio.  
3.2.2. Synthesis  
 5-Amino-2-chloropyridine (1).  2-Chloro-5-nitropyridine (5.49 g, 34.6 mmol) was added 
in portions to a solution of SnCl2•2H2O (39.36 g, 17.4 mmol) in 50 mL concentrated HCl at 0°C. 
The reaction was allowed to warm to room temperature and stirred for 4 h, followed by the addition 
of 5 M Na2CO3 (75 mL) and NH4OH (50 mL). The mixture was extracted with CH2Cl2 (5 x 100 
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mL), dried over MgSO4, filtered, and the solvent was evaporated to give 1 (3.9 g, 88%). 1H NMR 
(500 MHz, CDCl3) δ 7.88 (dd, J = 3.0, 0.6 Hz, 1H), 7.11 (dd, J = 8.5, 0.6 Hz, 1H), 7.01-6.98 (m, 
1H), 3.62 (s, 2H). ESI(+)MS (m/z): [M + H]+ calc. 129.0, found 129.3. 
 Tert-butyl (6-chloro-3-pyridinyl) carbamate (2). Synthesized using an adapted 
procedure.12 A solution of 1 (1.83 g, 14.2 mmol) and Boc2O (4.74 g, 21.8 mmol) in dry dioxane 
(15 mL) was heated under reflux under an Ar atmosphere for 45 h. During the course of the 
reaction, an additional 0.81 g (3.7 mmol) of Boc2O was added to the reaction mixture. The reaction 
mixture was poured into H2O (15 mL) and the product extracted with EtOAc (2 x 25 mL). The 
combined organic layers were washed with brine (15 mL), dried over Mg2SO4, filtered, and the 
solvent was removed. The residue was run through a plug of silica to give 2 (3.1 g, 96%). 1H NMR 
(500 MHz, CDCl3) δ 8.29 (dd, J = 2.9, 0.6 Hz, 1H), 7.99 (s, 1H), 7.28 (dt, J = 8.7, 0.6 Hz, 1H), 
6.86 (s, 1H), 1.55 (s, 9H). ESI(+)MS (m/z): [M + H]+ calc. 229.1, found 229.1.  
 Tert-butyl (6-chloro-4-iodo-3-pyridinyl) carbamate (3). To a solution of TMEDA (3.8 mL, 
25 mmol) in dry THF (15 mL) under Ar was added nBuLi (10 mL, 2.5 M in hexanes) dropwise at 
-78°C. The solution was stirred for 30 min, and subsequently a solution of 2 (1.37 g, 6 mmol) in 
dry THF (5 mL) under Ar was added dropwise. The solution was stirred at -78°C for 1 h and then 
a solution of I2 (3.23 g, 12.7 mmol) in 5 mL dry THF under Ar was added dropwise. The reaction 
was allowed to warm to room temperature and stirred overnight. The reaction was cooled to -78°C, 
and 20 mL of saturated NH4Cl was added. The aqueous and organic layers were separated, and the 
aqueous phase was extracted with EtOAc (3 x 30 mL). The organic layers were combined, dried 
over MgSO4, filtered, and the solvent was removed. The crude material was purified by silica gel 
column chromatography (9:1 hexanes/EtOAc) to give 3 (0.60 g, 28%). 1H NMR (500 MHz, 
CDCl3) δ 8.98 (s, 1H), 7.76 (s, 1H), 6.69 (s, 1H), 1.59 (s, 9H). ESI(+)MS (m/z): [M + H]+ calc. 
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355.0, found 354.8.  
 Tert-butyl (6-chloro-4-(2-formylphenyl)-3-pyridinyl) carbamate (4). A solution of 3 
(0.604 g, 1.71 mmol), 2-formylphenylboronic acid (0.384 g, 2.56 mmol), Pd(PPh3)4 (0.0986 g, 
5 mol %), 2 M Na2CO3 (3 mL), EtOH (2 mL), and toluene (12 mL) was degassed by freeze pump 
thaw (4x) then heated to 90°C under Ar overnight. The reaction mixture was poured over 15 mL 
H2O, the layers were separated, and the aqueous layer was extracted with EtOAc (3 x 20 mL). The 
organic layers were combined, dried over MgSO4, filtered, and the solvent was removed. The 
crude material was purified by silica gel chromatography (4:1 hexanes/EtOAc) to give 4 (0.29 g, 
51%). 1H NMR (500 MHz, CDCl3) δ 8.75 (s, 1H), 7.91-7.88 (m, 1H), 7.76 (s, 1H),7.57-7.52 (m, 
3H), 7.34-7.30 (m, 1H), 6.88 (d, J = 5.2 Hz, 1H), 1.56 (s, 9H). ESI(+)MS (m/z) [M + H]+ calc. 
333.1, found 333.1.  
 2-Chlorobenzo[c][1,7]naphthyridine (5). To 0.291 g 4 (0.877 mmol) was added 5 mL 
CH2Cl2 and 0.5 mL TFA. The solution was stirred overnight, and then 5 mL 5% Na2CO3 was 
added and the solution was stirred vigorously for 1.5 h. The layers were separated, and the aqueous 
layer was extracted with EtOAc (2 x 20 mL). The organic layers were combined, washed with 
brine (1 x 25 mL), dried over MgSO4, filtered, and the solvents were removed. The product was 
purified by column chromatography (4:1 hexanes/EtOAc) to give 5 (0.16 g, 87%). 1H NMR (500 
MHz, CDCl3) δ 9.35 (s, 1H), 9.33 (s, 1H), 8.58 (d, J = 8.1 Hz, 1H), 8.39 (s, 1H), 8.15 (d, 7.9 Hz, 
1H), 7.99 (ddd, J = 8.3 Hz, 7.2 Hz, 1.4 Hz, 1H), 7.92 (ddd, J = 8.1 Hz, 7.1 Hz, 1.1 Hz, 1H). 
ESI(+)MS (m/z) [M + H]+ calc. 215.0, 217.0; found 215.2, 217.0.   
 2-Bromobenzo[c][1,7]naphthyridine (6). To a 5 mL microwave vial was added 0.010 g of 
5 (0.047 mmol), 1 mL HBr, and 2 mL AcOH. The contents were heated at 130°C for 2 h. The 
reaction mixture was then diluted with 50 mL H2O and the solution was neutralized to pH 7 with 
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NaHCO3. The aqueous mixture was then washed with CH2Cl2 (3 x 25 mL), dried over MgSO4, 
and filtered to give 6 (0.0090 g, 75%). 1H NMR (500 MHz, CDCl3) δ 9.39 (s, 1H), 9.32 (s, 1H), 
8.61 (dq, J = 8.5, 1.0 Hz, 1H), 8.59 (s, 1H), 8.18 (ddd, J = 7.9 Hz, 1.4 Hz, 0.7 Hz, 1H), 8.03 (ddd, 
J = 8.3 Hz, 7.1 Hz, 1.4 Hz, 1H), 7.95 (ddd, J = 8.2, 7.2, 1.1 Hz, 1H). ESI(+)MS (m/z) [M + H]+: 
calc. 259.0, 261.0, found 259.0, 261.0. 
 BNIQ ligand (7). To a flame-dried Schlenk flask under Ar was added 0.096 g 
1-iodoisoquinoline (0.37 mmol) and 0.016 g LiCl (0.38 mmol). The flask was evacuated for 2 h, 
and anhydrous THF (1 mL) was added. The contents were stirred and 190 µL i-PrMgCl (2 M 
solution in THF) was added dropwise. The solution was stirred for 1 h, during which the reaction 
turned a dark purple. The contents were cooled to 0°C, and 755 µL ZnCl2 in THF (0.5 M) was 
added and stirred for 15 min at 0°C. A solution of Pd2(dba)3 (0.009 g, 4 mol %) and PCy3 (0.011 g, 
15 mol %) in THF (3 mL) under Ar was then added to the reaction, followed by a solution of 6 
(0.065 g, 0.25 mmol) in THF (3 mL). The dark red-orange solution was stirred for 17 h at 65°C. 
The solvent was removed in vacuo, and the contents were re-dissolved in EtOAc/H2O (25:20 mL). 
The layers were separated and the EtOAc was washed with H2O (2 x 20 mL). The EtOAc was 
evaporated and the crude material was purified by silica gel column chromatography with a solvent 
gradient (6:1 hexanes/EtOAc to 100% EtOAc) to obtain BNIQ ligand 7 (0.040 g, 52%). 1H NMR 
(500 MHz, CDCl3) δ 9.71 (s, 1H), 9.45 (s, 1H), 9.14 (s, 1H), 8.82-8.76 (m, 2H), 8.72 (d, J = 5.6 Hz, 
1H), 8.18 (d, J = 7.9 Hz, 1H), 7.99 (ddd, J = 8.3 Hz, 7.1 Hz, 1.4 Hz, 1H), 7.95 (dt, J = 8.3 Hz, 
1.0 Hz, 1H), 7.91 (ddd, J = 8.0 Hz, 7.1 Hz, 1.1 Hz, 1H), 7.80 (d, J = 5.7 Hz, 1H), 7.75 (ddd, 
J = 8.2 Hz, 6.8 Hz, 1.2 Hz, 1H), 7.66 (ddd, J = 8.3 Hz, 6.8 Hz, 1.3 Hz, 1H). ESI(+)MS (m/z) [M + 
H]+ calc. 308.1, found 308.4.   
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 [Ru(bpy)2(BNIQ)]X2 (8, X = PF6 or Cl). BNIQ ligand (7) (0.015 g, 0.049 mmol) and 
Ru(bpy)2Cl2 (0.025 g, 0.048 mmol) were combined in 4 mL ethylene glycol and heated at 130°C 
for 17 h. The solution was cooled to room temperature, diluted with 5 mL H2O, and excess NH4PF6 
was added to precipitate the product. The precipitate was collected via vacuum filtration, washed 
with H2O (2 x 5 mL), and dried (0.041 g, 82%). The complex was converted to the water-soluble 
Cl salt by anion exchange chromatography (Sephadex QAE) and further purified by preparative 
HPLC using a gradient of H2O (with 0.1% TFA) to CH3CN over 1 h. 1H NMR (500 MHz, DMSO-
d6) δ 9.99 (s, 1H), 9.59 (s, 1H), 9.20-9.15 (m, 2H), 8.97 (d, J = 8.2 Hz, 1H), 8.94-8.86 (m, 3H), 
8.45 (s, 1H), 8.44 (d, J = 8.2 Hz, 1H), 8.30-8.20 (m, 4H), 8.15-8.08 (m, 4H), 8.03 (td, J = 7.0, 1.1 
Hz, 2H), 7.95 (ddd, J = 5.7, 1.4, 0.7 Hz, 1H), 7.85 (dddd, J = 5.4, 4.6, 1.5, 0.7 Hz, 2H), 7.79 (ddd, 
J = 5.6, 1.5, 0.7 Hz), 7.69 (d, J = 6.2 Hz, 1H), 7.64 (ddd, J = 7.6, 5.6, 1.3 Hz, 1H), 7.59 (ddd, J = 
7.6, 5.6, 1.3 Hz, 1H), 7.45 (ddd, 7.2, 5.6, 1.3 Hz, 1H), 7.40 (ddd, J = 7.3, 5.7, 1.3 Hz, 1H). 
ESI(+)MS (m/z) [M/2]+ calc. 360.6, found 360.6. UV-Vis in H2O, l/nm (e x 104/M-1 cm-1): 287 
(8.0), 366 (3.0), 431 (1.7).  
1,1’-biisoquinoline (9). 9 was synthesized according to a reported procedure.13,14 1H 
NMR (500 MHz, CDCl3) δ 8.69 (d, J = 5.7 Hz, 2H), 8.10 (dt, J = 8.3, 0.9 Hz, 2H), 7.98 (dd, J = 
5.7, 0.9 Hz, 2H), 7.80 (ddd, J = 8.2, 6.8, 1.2 Hz, 2H), 7.74 (dq, J = 8.6, 1.0 Hz, 2H), 7.56 (ddd, J 
= 8.3, 6.8, 1.2 Hz, 2H). ESI(+)MS (m/z) [M + H]+ calc. 257.1, found 257.4.  
[Ru(bpy)2(1,1’-biisoq)]X2 (10, X = PF6 or Cl). 1,1’-biisoquinoline (0.030 g, 0.12 mmol) 
and Ru(bpy)2Cl2 (0.067 g, 0.13 mmol) were combined in 15 mL ethylene glycol and heated at 
130°C for 5 h. The reaction was cooled to room temperature, diluted with H2O (15 mL), and excess 
NH4PF6 was added to precipitate the product. The precipitate was collected via vacuum filtration, 
washed with H2O (15 mL), and dried (0.110 g, 87%). The complex was converted to the water-
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soluble Cl salt by anion exchange chromatography (Sephadex QAE) and further purified by 
preparative HPLC using a gradient of H2O (with 0.1% TFA) to CH3CN over 1 h. 1H NMR (500 
MHz, D2O) δ 8.40 (m), 8.33 (dt, J = 8.4, 1.0 Hz) 8.17 (ddd, J = 5.6, 1.5, 0.7 Hz) 8.03 (d, J = 8.3 
Hz) 7.97 (m), 7.92 (m), 7.88 (d, J = 8.3 Hz) 7.84 (m), 7.79 (m), 7.74 (m), 7.69 (m), 7.64 (m), 7.52 
(ddd, J = 8.5, 6.9, 1.3 Hz), 7.48 (J = 8.5, 6.9, 1.3 Hz) 7.24 (m), 7.04 (ddd, J = 7.6, 5.7, 1.3 Hz), 
6.97 (ddd, J = 7.4, 5.7, 1.3 Hz), 6.62 (d, J = 5.7 Hz). ESI(+)MS (m/z) [M/2]+ calc. 335.1, found 
335.1. UV-Vis in H2O, l/nm (e x 104/M-1cm-1): 287 (5.8), 446 (0.96), 516 (1.0). 
3.2.3 Luminescence Measurements 
Steady-State Luminescence. Luminescence spectra were recorded on an ISS-K2 
spectrofluorometer at 25°C. [Ru(bpy)2(BNIQ)]2+ was excited at 440 nm, and emission spectra 
were integrated from 590-850 nm. The chloride salt of the complex was used for all DNA 
experiments. In appropriate figures, [DNA] is defined as the concentration of the full sequence 
oligonucleotide.  
Time-Resolved Luminescence. Time-resolved spectroscopic measurements were carried 
out at the Beckman Institute Laser Resource Center, and were conducted using instrumentation 
that has been described.15 Briefly, a 460 nm light produced by OPO pumped with a 10 Hz, 
Qswitched Nd:YAG laser (Spectra-Physics Quanta-Ray PRO-Series) was used as an excitation 
source (pump pulse duration ≈ 8 ns). The emitted light was detected at 700 nm with a 
photomultiplier tube (Hamamatsu R928) following wavelength selection by a double 
monochromator (Instruments SA DH-10). Scattered laser light was removed from the detectors 
using suitable filters. The samples were held in 1 cm path length quartz cuvettes (Starna) equipped 
with stir bars and irradiated at 460 nm with 500−1000 laser pulses at 3 mJ/pulse. Kinetic traces 
were fit to exponential equations of the form I(t) = a0 + Σ an exp(−t/τn), where I(t) is the signal 
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intensity as a function of time, a0 is the intensity at long time, an is a pre-exponential factor that 
represents the relative contribution from the nth component to the trace, and τn is the lifetime of 
the nth component, convoluted with a Gaussian function to take into account the Instrument 
Response Function (fwmh = 8 ns). The errors are evaluated to be equal to 5%. 
 
3.3 Results and Discussion  
 
3.3.1 BNIQ Ligand Design and Synthesis  
In this work, we designed a new sterically expansive polypyridyl ligand that possesses a 
similar width to the mismatch-specific chrysi ligand but lacks imine protons characteristic of 
chrysi. We have proposed that exchangeable imine protons are responsible for quenching any 
ambient temperature luminescence of compounds like [Ru(bpy)2(chrysi)]2+.16 As such, BNIQ was 
designed to contain heterocyclic nitrogen atoms that coordinate directly to the ruthenium core, 
analogously to bpy or phen, and an additional non-chelating nitrogen atom that could enhance the 
sensitivity of the complex to its environment. BNIQ also possesses similar structural features to 
the tpqp ligand, which has been shown to exhibit some degree of mismatch specificity in binding.9  
	   BNIQ was synthesized in seven steps (Scheme 3.1) from the starting material 2-chloro-5-
nitropyridine. A key step in the ligand synthesis is the conversion of the chloride intermediate 5 
into its bromide analogue 6, a transformation that was executed in order to generate a more reactive 
substrate in the subsequent Negishi coupling. Using an adapted literature procedure for a related 
2-chloropyridine derivative,17 5 was heated in a 2:1 (v/v) mixture of acetic acid/aqueous HBr at 
130°C in a microwave reactor to yield 6. Negishi coupling conditions were adapted from the 
literature18,19 to synthesize the BNIQ ligand (7) from 6 and 1-iodoisoquinoline.  
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3.3.2 Synthesis and Characterization of the [Ru(bpy)2(BNIQ)]2+ Complex  
Coordination of BNIQ to ruthenium (Scheme 3.1) is a facile synthesis, achieved by heating 
the ligand in a 1:1 ratio with Ru(bpy)2Cl2 in ethylene glycol at 130°C. [Ru(bpy)2(BNIQ)]2+ was 
isolated from the reaction mixture as its PF6
- salt before conversion to its water-soluble chloride 
salt by anion exchange chromatography and further purification by preparative HPLC. 
	  	   The UV-Visible spectrum of [Ru(bpy)2(BNIQ)]2+ shows a characteristic MLCT transition 
in the visible region at 430-440 nm (Figure 3.3). Upon excitation at 440 nm in aqueous solution, 
[Ru(bpy)2(BNIQ)]2+ exhibits a broad emission centered at 700 nm that is nearly insensitive to the 
presence of oxygen in solution (Figure 3.3).  
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3.3.3. Steady-State Luminescence of [Ru(bpy)2(BNIQ)]2+ in the Presence of DNA 	  
We investigated the steady-state emission of [Ru(bpy)2(BNIQ)]2+ in the presence of three 
different 27-mer DNA duplexes: one that is completely well-matched, one that contains a single 
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Figure 3.3. UV-Visible (left) and steady-state emission spectra (right) of [Ru(bpy)2(BNIQ)]2+ in 
aerated (solid line) and de-gassed (dotted line) solutions (6 µM in H2O, lex = 440 nm).	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Figure 3.4. Steady-state emission titrations of [Ru(bpy)2(BNIQ)]2+ with well-matched, 
mismatched, and abasic DNA duplexes at 25°C. λex = 440 nm, [Ru] = 4 µM. [DNA] reflects the 
concentration of full sequence. Samples were prepared in 5 mM Tris, 200 mM NaCl, pH 7.5. DNA 
sequences are provided at the top of the figure; the underscore represents the absence of a base in 
the abasic (AB) sequence. Emission spectra were integrated from 590-850 nm. 
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CC mismatch, and one containing an abasic site (sequences provided in Figure 3.4). Titrations 
(Figure 3.4) reveal that the emission intensity of the complex increases upon the addition of each 
duplex; however, the emission intensity is brighter for samples containing the CC and abasic sites  
compared to the well-matched DNA. The maximum ruthenium emission intensities reached for 
the CC mismatch and abasic DNA samples are approximately 1.7-fold larger than the emission 
intensity of free ruthenium complex, and 1.5-fold greater than the well-matched DNA sample.  
The binding affinities evaluated by a global analysis of the titration curves (Table 3.1, 
Appendix A.2) reveal that [Ru(bpy)2(BNIQ)]2+ has a ~500-fold higher affinity for oligomers 
containing CC mismatched or abasic sites (3.5 x 106 and 3.8 x 106 M-1 respectively) compared to 
oligomers with fully well-matched sites (7.3 x 103 M-1). Thus, the titrations demonstrate that this 
new ruthenium complex is very specific for the thermodynamically destabilized sites in DNA.  
  
Interestingly, analysis of the titrations indicates that the differences in emission intensities 
observed in Figure 3.4 are mainly related to the higher affinity of the complex towards mismatched 
and abasic sites. From the analysis of the steady-state titration curves, we evaluated that 
[Ru(bpy)2(BNIQ)]2+ has similar intrinsic emissivity when bound to a well-matched or mismatched 
site (1.36, 1.42, and 1.46 for well-matched, CC, and abasic sequences, respectively) relative to free 
complex. Thus, the inherent brightness of a complex bound to a mismatch site or a well-matched 
site are rather similar, and the dramatic differences in steady-state emission intensities observed 
are correlated with the higher affinity of the compound towards the destabilized base pairs.  
 Well-matched Mismatched Abasic 
Ka (M-1)a 7.3 x 103 3.5 x 106 3.8 x 106 
Table 3.1. Binding Affinities of [Ru(bpy)2(BNIQ)]2+ with Well-Matched, Mismatched, and Abasic 
DNA Duplexes 
a Titrations were performed with DNA sequences shown in Figure 3.4. Samples were prepared in 5 mM Tris, 200 mM 
NaCl, pH 7.5. [Ru] = 4 µM, lex = 440 nm. The binding affinity is expressed per binding site and not per DNA sequence.  
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3.3.4 Time-Resolved Luminescence of [Ru(bpy)2(BNIQ)]2+ with and Without DNA 
 In order to confirm the steady-state behavior, we studied the luminescence lifetimes of 
[Ru(bpy)2(BNIQ)]2+ in the presence of the three DNA duplexes (Table 3.2). The 700 nm emission 
of free complex decays as a monoexponential function with a lifetime of 215 ns in water. In the 
presence of 2 equivalents of the well-matched sequence, this emission decays as a biexponential 
with short (235 ns) and long (487 ns) components. The shorter component, which contributes 
approximately 75% to the overall decay, we assign to free complex in solution. The longer 
component, responsible for the other 25% of the decay, is thus attributed to the complex bound to 
DNA. In the presence of 2 equivalents of the mismatched sequence, the emission decays mono-
exponentially with a lifetime of 416 ns. A comparable single lifetime of 421 ns is found in the 
presence of 2 equivalents of the abasic duplex.  
 
 
 
 
 
Two important conclusions can be drawn from these measurements. First, the absence of a 
short lifetime component with the mismatched or abasic sequences indicates that the complex is 
fully bound to the DNA duplex, which is in agreement with the evaluated binding affinities, based 
on which only 3% of the complex remains free in solution. Second, the lifetimes seen with the 
 Lifetime (ns) 
Milli-Q H2O  215 
Bufferb 217 
D2O 389 
CH3CN (anhydrous)  265 
Well-matched  235 (75%) 
487 (25%) 
Mismatched  416 
Abasic  421 
Table 3.2. [Ru(bpy)2(BNIQ)]2+ Emission Lifetimes in Various Solvents and in the Presence of 
Well-Matched, Mismatched, and Abasic DNA Duplexesa 
alex = 460 nm, lem = 700 nm. For studies with DNA, samples containing 6 µM Ru and 12 µM DNA were prepared 
in 5 mM Tris, 200 mM NaCl, pH 7.5 using DNA sequences shown in Figure 3.4. Percentages reflect the relative 
contributions of each lifetime to the overall decay. b5 mM Tris, 200 mM NaCl, pH 7.5.  
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mismatched and abasic sequence are close to the long component observed with the well-matched 
sequence. As expected from the analysis of the steady-state titrations, the lifetimes associated with 
complex bound to DNA for well-matched, mismatched, and abasic sites are similar. Thus, the 
mono-exponential decay in the 416 and 421 ns lifetimes should correspond to an average de-
excitation process of complexes bound to DNA (well-matched and mismatched/abasic) and the 
small population of free complex in solution. These data support the conclusion that the brighter 
steady-state emission spectra observed with the mismatched and abasic duplexes (Figure 3.4) are 
due primarily to a higher binding affinity towards the destabilized sites compared to well-matched 
base pairs.  
To elucidate the mechanism that gives rise to the enhanced luminescence observed with 
the duplexes, the emission lifetimes of [Ru(bpy)2(BNIQ)]2+ were further characterized in several 
solvent systems (Table 3.2). Interestingly, in anhydrous acetonitrile, the emission lifetime (265 ns) 
is only 50 ns longer than the lifetime in water. Thus, water itself does not dramatically quench the 
luminescence of [Ru(bpy)2(BNIQ)]2+. Nevertheless, upon interacting with DNA, the solvation 
sphere around the complex is greatly altered; in the restricted environment bound to DNA there is 
reduced dissipation of energy from the excited complex to solvent through vibrational modes. The 
importance of the non-radiative decay via vibrational relaxation can be probed using deuterated 
solvent. The effect of solvent deuteration on the emission of [Ru(bpy)3]2+ was first investigated by 
Watts and Van Houten, and it was found that deuteration of H2O leads to a doubling of the 
[Ru(bpy)3]2+ emission lifetime (0.58 to 1.02 µs at 25°C).20,21 It was proposed that the ability of the 
solvent vibrational modes to deactivate the ruthenium excited state was attenuated upon solvent 
deuteration. For [Ru(bpy)2(BNIQ)]2+, a similar phenomenon is occurring, since a significantly 
longer lifetime for the complex in D2O (389 ns, Table 3.2) compared to water is detected. This 
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longer component is more consistent with the longer lifetime detected for complexes bound to 
DNA. One could also argue that the increase in luminescence lifetime for [Ru(bpy)2(BNIQ)]2+ 
when bound to DNA is due to greater rigidity and lower frequency of collisions compared to free 
complex in solution.22 A combination of these factors could give rise to the enhanced luminescence 
observed upon DNA binding.  
3.3.5 [Ru(bpy)2(BNIQ)]2+ Luminescence with Different Base Mismatches  
Owing to the large size of the BNIQ ligand and the observation that [Ru(bpy)2(BNIQ)]2+ 
preferentially targets mismatched and abasic sites in DNA, we hypothesize that the complex binds 
to these defects by metalloinsertion. To test this hypothesis, we investigated whether 
[Ru(bpy)2(BNIQ)]2+ is capable of targeting other types of mismatches in addition to the CC 
mismatch. An important characteristic of metalloinsertors is that the extent of mismatch binding 
correlates with the thermodynamic destabilization associated with the mismatch; the more 
destabilized the mismatch, the easier it is to displace the mismatched bases by the inserted ligand.5 
Thus for luminescent metalloinsertors, we anticipate that the more destabilized the mismatch, the 
tighter the binding of the complex and the larger the observed emission enhancement.23,24,25 
Luminescence titrations were performed with [Ru(bpy)2(BNIQ)]2+ and hairpin 
oligonucleotides containing the variable base pair XY (Figure 3.5). Indeed, we detect the greatest 
emission in the presence of the most destabilized mismatch, CC. Additionally, little emission 
enhancements are seen for the well-matched GC and GG mismatched hairpins. This small change 
is to be expected, given that G-containing mismatches are similar in stability to well-matched base 
pairs.26,27 However, we note a few variations with respect to the predicted trend of mismatch 
instability and luminescence enhancement. [Ru(bpy)2(BNIQ)]2+ exhibits a brighter emission in the 
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presence of the “like-with-like” base mismatches AA and TT relative to CT and CA, even though  
we expect CT and CA to be more destabilized compared to AA and TT.26 Nonetheless, the 
emission of [Ru(bpy)2(BNIQ)]2+ is clearly sensitive to the identity of the single base mismatch, 
consistent with binding through metalloinsertion.  
3.3.6 Luminescence Quenching with Cu(phen)22+  
To further elucidate the binding mode of [Ru(bpy)2(BNIQ)]2+ at the mismatch site, we 
employed the quencher Cu(phen)22+, which binds in the DNA minor groove28,29,30 and has been 
used to selectively quench the luminescence of ruthenium complexes bound to a mismatch in the 
minor groove.23,31 We applied the Cu(phen)22+ quencher to samples containing 
[Ru(bpy)2(BNIQ)]2+ with the well-matched and mismatched duplexes (Figure 3.6). For the 
mismatched sample, as the concentration of Cu(phen)22+ is increased, we observe quenching of the 
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Figure 3.5. Steady-state emission titrations of [Ru(bpy)2(BNIQ)]2+ with DNA hairpins containing 
a variable XY base pair at 25°C. λex = 440 nm, [Ru] = 4 µM. [DNA] reflects concentration of full 
sequence. Samples were prepared in 5 mM Tris, 50 mM NaCl, pH 7.5. Emission spectra were 
integrated from 590-850 nm. 
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luminescence of the ruthenium complex. This quenching suggests that the complex binds to the 
mismatch in the minor groove, consistent with metalloinsertion. Interestingly, the enhanced 
emission associated with binding to the well-matched duplex also decreases as Cu(phen)22+ is 
added. In fact, one can see that at the highest [Cu]/[Ru] for the well-matched DNA sample, the 
emission spectrum overlays precisely with the spectrum corresponding to free ruthenium (Figure 
3.6). Given the very low binding affinity of [Ru(bpy)2(BNIQ)]2+ towards well-matched base pairs 
(7.3 x 103 M-1) compared to the CC mismatch (3.5 x 106 M-1), the observed decrease in emission 
intensity with the well-matched sample is likely a reflection of excess Cu(phen)22+ displacing the 
weakly associated ruthenium complex from well-matched sites in the duplex to yield free 
ruthenium complex in solution. This result suggests that [Ru(bpy)2(BNIQ)]2+ interacts with well-
matched sites from the minor groove.   
3.3.7 Luminescence Quenching with [Fe(CN)6]3-  
We have proposed that [Ru(bpy)2(BNIQ)]2+ binds to the mismatch site via 
metalloinsertion. Therefore, we predict that at the mismatch, the complex is bound deeper and 
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Figure 3.6. Steady-state emission spectra of [Ru(bpy)2(BNIQ)]2+ (4 µM) with well-matched 
(blue) and mismatched (red) DNA duplexes (12 µM) at 25°C. Cu(phen)22+ was added to the 
samples such that [Cu]/[Ru] = 6, 12, 24, and 36 (indicated in light blue for well-matched and 
orange for mismatched samples). Black lines represent samples of Ru in the absence of DNA or 
Cu. λex = 440 nm. Samples were prepared in 5 mM Tris, 200 mM NaCl, pH 7.5. DNA sequences 
shown in Figure 3.4 were used.  
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more tightly compared to well-matched sites.  We used [Fe(CN)6]3- to quench the emission of 
[Ru(bpy)2(BNIQ)]2+ when bound to the well-matched and mismatched duplexes (Table 3.3, Figure 
3.7). [Fe(CN)6]3-, an anionic quencher, is repelled by the negatively charged phosphate backbone 
of the DNA.32 As such, its ability to quench [Ru(bpy)2(BNIQ)]2+ will be dictated by how well the 
ruthenium complex is protected by the DNA duplex.  
As expected, [Fe(CN)6]3- dramatically quenches the emission lifetime of free 
[Ru(bpy)2(BNIQ)]2+ in solution (Table 3.3); we also observe quenching in the steady-state spectra 
(Figure 3.7). In the presence of the well-matched duplex, the shorter lifetime component is nearly 
eliminated, consistent with quenching of free ruthenium. We also see that the steady-state emission 
intensity for the well-matched sample is significantly quenched (Figure 3.7). Conversely, the 
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Figure 3.7. Ferricyanide quenching of free [Ru(bpy)2(BNIQ)]2+ (black) and in the presence of 
well-matched DNA (blue) and mismatched DNA (red). Ferricyanide was added (dotted lines) to 
concentrations of 1.2, 2.3, 3.5, and 5.6 mM. [Ru] = 2 µM, [DNA] = 4 µM, λex = 440 nm.  Samples 
were prepared in 5 mM Tris, 200 mM NaCl, pH 7.5 at 25°C. 
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longer component is quenched by over 50%. This differential quenching of the two lifetime 
components reveals that binding to well-matched sites does in fact protect the complex from 
quenching and likely occurs through intercalation.  
 
 
Importantly, we observe that the emission lifetime associated with binding to the 
mismatched site is quenched to a much lesser extent compared to well-matched binding, which is 
also evident from the steady-state [Fe(CN)6]3- quenching. This observation illustrates that the 
complex is bound deeply at the mismatched site and is less accessible to the quencher. This result 
supports the notion that compared to well-matched sites, the complex binds to destabilized sites 
through an alternate binding mode, ostensibly metalloinsertion.  
3.3.8 Model for [Ru(bpy)2(BNIQ)]2+ Binding to the Destabilized DNA Mismatch  
Figure 3.8 illustrates our model for binding by [Ru(bpy)2(BNIQ)]2+ to a destabilized 
mismatch site. We propose that the complex binds by metalloinsertion. Based upon the increase 
in excited state lifetime, the BNIQ ligand is deeply inserted into the helix, and the Cu titrations 
suggest binding occurs from the minor groove side. Consistent with the relative thermodynamics 
in binding different mismatches, binding of the complex is by metalloinsertion with extrusion of 
the destabilized mismatched bases.  
 
 [Fe] = 0 mM  [Fe] = 8 mM 
Free Ru  215 9 
Well-matched 235 (75%), 487 (25%) 24 (40%), 215 (60%) 
Mismatched  416 335 
Table 3.3. [Ru(bpy)2(BNIQ)]2+ Emission Lifetimes in the Presence and Absence of 
[Fe(CN)6]3- Quenchera 
 
aSamples containing 6 µM Ru and 12 µM DNA were prepared in 5 mM Tris, 200 mM NaCl, pH 7.5 using DNA 
sequences shown in Figure 3.4. lex = 460 nm, lem = 700 nm. Percentages reflect the relative contributions of each 
lifetime to the overall decay. K3[Fe(CN)6](aq) was added to a final concentration of 8 mM.  
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The structure for the [Ru(bpy)2(BNIQ)]2+ complex illustrated in Figure 3.8 was generated 
in Spartan 14 (Wavefunction, Inc.), since a crystal structure of the compound was not obtained. 
This model of the [Ru(bpy)2(BNIQ)]2+ complex revealed that the BNIQ ligand is not entirely 
planar, owing to steric clashing between hydrogen atoms of the 2- and 3-ring systems of the ligand.  
The close proximity of these hydrogen atoms can be easily visualized in a space-filling model of 
the complex (Figure 3.9), in which the ligand must buckle in order to alleviate interactions between 
these hydrogen atoms. This phenomenon is consistent with a complex previously reported in the 
literature, [Ru(bpy)2(1,1’-biisoq)]2+ (Figure 3.9).33,34  A crystal structure of this compound 
established that the 1,1’-biisoquinoline ligand is nonplanar due to steric interactions between 
Figure 3.8. Model of [Ru(bpy)2(BNIQ)]2+ bound to a mismatch via metalloinsertion. Consistent 
with other metalloinsertors, we propose that the large BNIQ ligand is capable of extruding the 
destabilized bases (red) from the DNA π-stack and inserting deeply into the helix. The 
[Ru(bpy)2(BNIQ)]2+ structure was generated in Spartan 14 (Wavefunction, Inc.) and modeled into 
the X-ray crystal structure of [Rh(bpy)2(chrysi)]3+ bound to an AA mismatch (PDB: 3GSK) using 
PyMOL.   
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hydrogens on neighboring ring systems.34 Owing to the similarities between this ligand and BNIQ, 
[Ru(bpy)2(1,1’-biisoq)]2+ was synthesized and its luminescent properties with DNA were 
investigated. The 1,1’-biisoquinoline ligand was synthesized via the Ni-catalyzed homocoupling 
of 1-iodoisoquinoline as reported previously,13,14 and coordinated to ruthenium in an analogous 
fashion to BNIQ (Scheme 3.2).  
   
Figure 3.9. (Top) [Ru(bpy)2(BNIQ)]2+ model (Spartan 14). Space-filling representations of the 
complex reveal that hydrogen atoms on the 2- and 3-ring systems of the BNIQ ligand lie in very 
close proximity, and thus the ligand must buckle to alleviate steric strain. (Bottom) A previously 
reported crystal structure of [Ru(bpy)2(1,1’-biisoq)]2+ showed that the 1,1’-biisoquinoline ligand 
is not planar due to steric clashing between hydrogen atoms on both sides of the ligand, as 
depicted in the drawing above.   
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Scheme 3.2. Synthesis of [Ru(bpy)2(1,1’-biisoq)]2+ (10) from 1-iodoisoquinoline. 	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 The UV-Visible spectrum of [Ru(bpy)2(1,1’-biisoq)]2+ is presented in Figure 3.10, and 
shows a significantly red-shifted absorption profile relative to [Ru(bpy)2(BNIQ)]2+. Upon 
excitation at either 445 nm or 517 nm, the complex exhibits a very weak, low-energy emission 
centered at 780 nm. Upon addition of the well-matched 27-mer DNA duplex, there is no change 
in the emission intensity; however, in the presence of the 27-mer duplex containing the single CC 
mismatch, a small increase in emission intensity is observed. This trend was confirmed in excited-
state lifetime measurements (Table 3.4), in which the lifetime essentially doesn’t change with the 
well-matched sequence but increases by ca. 30 ns with the mismatch. The severe non-planarity of  
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Figure 3.10. (Top) UV-Visible spectrum of [Ru(bpy)2(1,1’-biisoq)]2+ (H2O). (Bottom) Steady-
state emission of [Ru(bpy)2(1,1’-biisoq)]2+ with increasing concentrations of well-matched (blue) 
and mismatched (red) DNA duplexes at 25°C. λex = 460 nm. [DNA] reflects increasing 
concentration of full sequence from 0 to 6 µM. Samples were prepared in 5 mM Tris, 50 mM 
NaCl, pH 7.5. DNA sequences shown in Figure 3.4 were used.  
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1,1’-biisoquinoline must break the aromaticity of its core bipyridine, resulting in an extremely 
weak emission intensity relative to, say, [Ru(bpy)3]2+ or even [Ru(bpy)2(BNIQ)]2+.  This buckling  
 of the 1,1’-biisoquinoline ligand may also disfavor intercalation at well-matched sites because the 
ligand cannot stack well between base pairs. However, the observation that the excited state 
lifetime of [Ru(bpy)2(1,1’-biisoq)]2+ is enhanced with the mismatched sequence implies that the 
compound is capable of binding to the mismatch; this binding must stabilize the complex in a more 
rigid orientation, enhancing its emission lifetime. These observations can be taken to gain a firmer 
understanding of [Ru(bpy)2(BNIQ)]2+ binding to DNA. The non-planarity of BNIQ must play a 
role in disfavoring intercalation between well-matched base pairs, yet still allow for 
[Ru(bpy)2(BNIQ)]2+ to undergo metalloinsertion at a mismatch. 
3.4 Conclusions  
[Ru(bpy)2(BNIQ)]2+ is a novel luminescent complex that exhibits an enhanced emission in 
the presence of a DNA mismatch or abasic site relative to well-matched base pairs. Owing to the 
sterically expansive BNIQ ligand, [Ru(bpy)2(BNIQ)]2+ is highly selective in binding towards these 
defect sites, and we propose that the complex binds to these regions via metalloinsertion. 
Remarkably, the binding is highly specific for the mismatched site given the 500-fold increase in 
binding affinity versus well-matched duplex DNA. This work illustrates that the design of novel 
sterically demanding ligands is a valid approach in the development of mismatch-specific 
coordination complexes.  
 Ru alone Ru + WM Ru + MM 
Lifetime (ns)  54 60 88 
aSamples containing 7 µM Ru, 7 µM DNA (5 mM Tris, 50 mM NaCl, pH 7.4) were prepared (λex = 355 nm, λem = 785 
nm). Emission decays were fit to a monoexponential function.  
  
 
Table 3.4. [Ru(bpy)2(1,1’-biisoq)]2+ Emission Lifetimes in the Absence and Presence of Well-
Matched and Mismatched 27-mer DNA Duplexesa 
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Chapter 4  
 
Pursuing Mismatch Specificity with Dppz Ligand Modification  
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4.1 Introduction  
 
 The [Ru(Me4phen)2(dppz)]2+ and [Ru(bpy)2(BNIQ)]2+ complexes discussed in Chapters 2 
and 3 represent successful efforts in the development of luminescent ruthenium(II) compounds 
that are mismatch-specific. [Ru(Me4phen)2(dppz)]2+ makes use of its bulky Me4phen ligands to 
discriminate against intercalation at well-matched sites and allow for selective metalloinsertion at 
a mismatch. Conversely, [Ru(bpy)2(BNIQ)]2+ achieves its mismatch specificity by way of the 
sterically expansive BNIQ ligand. Two other approaches for obtaining a mismatch-selective 
ruthenium complex have been explored in the Barton laboratory.1 A series of [Ru(bpy)2(L)]2+ 
complexes were synthesized bearing the known inserting ligands chrysi, phzi, acri, or naphthi 
(Figure 4.1). However, it was found that these derivatives were not luminescent at ambient 
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Figure 4.1. A series of [Ru(bpy)2(L)]2+ complexes were previously investigated as potential 
luminescent probes for DNA mismatches. The ligand L was either chrysi and related derivatives 
or a functionalized dppz.  
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temperature in aqueous solution – emission was only observed at 77 K. This quenching was 
ostensibly the result of interactions between the aqueous solvent and ligand imine protons, leading 
to vibrational relaxation. Another family of Ru complexes was synthesized in which the 
intercalating dppz ligand was modified with various functional groups (Figure 4.1). These 
derivatives were designed to achieve mismatch specificity by making the dppz ligand too bulky to 
intercalate between well-matched base pairs in DNA. However, no improvement in the 
luminescence differential between mismatched and well-matched DNA was met with these 
derivatives compared to the parent [Ru(bpy)2(dppz)]2+ complex. Additionally, complexes 
possessing extended aromatic ligands such as pyrene-phen and tactp were found to aggregate in 
aqueous solution. These results demonstrated that appending modifications to the distal ring of the 
phenazine moiety were not sufficient to prevent deep intercalation of the dppz ligand.  
 We hypothesized that adding functional groups to the phenanthroline portion of dppz might 
introduce unfavorable steric interactions with the DNA bases upon intercalating at well-matched 
sites in the duplex, but still allow for metalloinsertion at a mismatch. This chapter describes the 
synthesis and steady-state luminescence characterization of [Ru(bpy)2(tmdppz)]2+ (tmdppz = 
3,4,7,8-tetramethyl dipyridophenazine), which incorporates methyl groups into the phenanthroline 
moiety of dppz in an effort to generate a mismatch-specific complex.  
 
4.2 Experimental Protocols  
4.2.1 Materials  
 All chemicals and starting materials were purchased from commercial vendors and used as 
received. Ru(bpy)2Cl2 was prepared according to the literature.2 UV-Visible spectra were recorded 
on a Beckman DU 7400 UV-Visible spectrophotometer (Beckman Coulter). Oligonucleotides 
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were synthesized using standard phosphoramidite chemistry at Integrated DNA Technologies 
(Coralville, IA) and purified by HPLC using a C18 reverse-phase column (Varian, Inc.) on a 
Hewlett-Packard 1100 HPLC. 
4.2.2 Synthesis  
3,4,7,8-Tetramethyl-1,10-phenanthroline-5,6-dione. To a small round bottom flask was 
added 50 mg 3,4,7,8-tetramethyl-1,10-phenanthroline (0.21 mmol) and 10 equivalents of 
potassium bromide. The flask was chilled with an ice bath and ice-cold sulfuric acid (2 mL) was 
added slowly (dropwise) along the inner wall of the flask (this detail is critical). Subsequently, 
ice-cold nitric acid (1 mL) was also added dropwise to the mixture. The dark red-brown solution 
was stirred and heated to 85°C. The reaction was run for 2 h, cooled to room temperature, poured 
into 50 mL ice-cold DI H2O, and neutralized to pH 6-7 with NaHCO3. The aqueous layer was 
extracted three times with 50 mL aliquots of dichloromethane (DCM). The DCM extracts were 
combined and washed once with 125 mL brine and evaporated, leaving crude product. The mass 
of the desired product was confirmed by LC-MS (267 m/z, [M+H]+).  
 Tetramethyl-dppz (tmdppz): To 80 mg of crude 3,4,7,8-tetramethyl-1,10-phenanthroline-
5,6-dione was added 19 mg 1,2-phenylenediamine in 3 mL ethanol. The contents were brought to 
80°C and stirred for 1.5 h. The reaction was removed and the ethanol was evaporated. The crude 
mixture was re-dissolved in 15 mL DCM, and the DCM was extracted three times with 15 mL of 
0.1 M HCl. The aqueous extract, a deep red-brown, was made basic (pH ~10) with NaOH. Upon 
becoming basic the solution turned a cloudy yellow. The yellow precipitate was filtered through a 
fine glass frit. The precipitate was re-dissolved in ethanol, and the mass of the tmdppz product was 
confirmed by LC-MS (339 m/z, [M+H]+).   
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 [Ru(bpy)2(tmdppz)]Cl2. 14 mg of crude tmdppz ligand was combined with 22 mg 
Ru(bpy)2Cl2 in 3 mL ethylene glycol and refluxed at 130°C for 4 h. The reaction was cooled to 
room temperature, diluted with 3 mL H2O, and excess NH4PF6 was added to crash out red-orange 
precipitate. The precipitate was collected in a fine glass frit and washed with 15 mL cold H2O. The 
crude complex was subjected to Cl anion exchange on a Sephadex QAE resin, and subsequently 
purified using a Sep Pak C18 cartridge. The complex was further purified by preparatory HPLC 
using a gradient of 85% H2O (containing 0.1% TFA)/15% acetonitrile to 35% H2O/65% 
acetonitrile over 50 minutes. The purified complex was once again converted to its Cl salt. ESI-
MS: 376 m/z [M/2]+. 1H NMR (500 MHz, DMSO-d6): δ 8.84 (dd, 4 H), 8.46 (dd, 2H), 8.15 (m, 6 
H), 7.87 (s, 2H), 7.73 (t, 4H), 7.55 (t, 2H), 7.37 (m, 2H), 3.37 (s, 6H), 2.38 (s, 6H).  
4.2.3 Luminescence Measurements 
Steady-State Luminescence. Luminescence spectra were recorded on an ISS-K2 
spectrofluorometer at 25°C. [Ru(bpy)2(tmdppz)]2+ was excited at 440 nm. The Cl salt of the 
complex was used for all DNA experiments.  
  
4.3 Results and Discussion 
 The goal of this work was to investigate whether appending extra steric bulk on the 
phenanthroline portion of the dppz ligand would help discriminate against intercalation at well-
matched sites in the DNA duplex and thus favor binding to a destabilized mismatch. The ligand 
tmdppz (tetramethyl dipyridophenazine, Scheme 4.1) was synthesized with the intention that the 
added methyl groups would prevent deep intercalation of the dppz ligand. Tmdppz was 
synthesized from the commercially-available 3,4,7,8-tetramethyl-1,10-phenanthroline as depicted 
in Scheme 4.1 Following oxidation of the starting material to 3,4,7,8-tetramethyl-1,10-
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phenanthroline-5,6-dione, a final condensation with 1,2-phenylenediamine yielded the desired 
product. The complex [Ru(bpy)2(tmdppz)]2+ was synthesized via coordination of tmdppz to 
Ru(bpy)2Cl2 and purified by HPLC.  
 [Ru(bpy)2(tmdppz)]2+ possesses a UV-Visible spectrum typical of [Ru(bpy)2(dppz)]2+ 
complexes (Figure 4.2): a bpy π-π* transition at 280 nm, the dppz π-π* absorption at 360-370 nm, 
and an MLCT transition at 440-450 nm. Interestingly, this complex is not a true “light switch” like 
its parent [Ru(bpy)2(dppz)]2+. Upon excitation in aqueous solution it does exhibit a weak emission 
spectrum centered at 620 nm (Figure 4.2). This observation is actually not surprising based on 
prior literature. R.M. Hartshorn and J.K. Barton reported a series of [Ru(phen)2(dppz)]2+ 
N
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Scheme 4.1. Synthesis of tmdppz from the commercially-available 3,4,7,8-tetramethyl-1,10-
phenanthroline.   
 
 
Figure 4.2. (Left) UV-Visible spectrum of [Ru(bpy)2(tmdppz)]Cl2 (H2O). (Right) Steady-state 
emission spectrum of [Ru(bpy)2(tmdppz)]Cl2 (8 µM in H2O).  
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derivatives bearing modifications to the dppz ligand.3 One complex in particular, 
[Ru(phen)2(dppm2)]2+ (Figure 4.3), exhibited a weak emission in aqueous solution in the absence 
of DNA, albeit with a very short (~10 ns) lifetime. This observation was attributed to the methyl 
group on the dppm2 ligand creating a more “hydrophobic” micro-environment in the vicinity of 
the adjacent phenazine nitrogen atom, which likely attenuates the interactions between water and 
the phenazine nitrogen atom necessary for complete quenching of the excited state. N. 
Komatsuzaki et al.4 reported the synthesis and characterization of the dimethyl complex 
[Ru(bpy)2(dmdppz)]2+ (Figure 4.3), which is closely related to [Ru(bpy)2(tmdppz)]2+. A crystal 
structure of [Ru(bpy)2(dmdppz)]2+ revealed that the methyl substituents are in close proximity to 
the phenazine nitrogen atoms, and the methyl carbon atoms lie very much within the same plane 
as the dppz framework. Interestingly, the lifetime of [Ru(bpy)2(dmdppz)]2+ is 27 times longer than 
that of [Ru(bpy)2(dppz)]2+ in methanol, illustrating that the increased steric environment resulting 
from the dmdppz methyl groups attenuates solvent interactions with the phenazine nitrogen atoms. 
Amazingly, the emission of [Ru(phen)2(dppm2)]2+ is enhanced ca. 300-fold in the presence of 
DNA.3 Furthermore, it was reported that the steady-state emission intensity of 
Figure 4.3. Chemical structures of [Ru(phen)2(dppm2)]2+ (left) and [Ru(bpy)2(dmdppz)]2+ 
(right).    
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[Ru(phen)2(dppm2)]2+ with DNA was approximately 5-fold brighter than [Ru(phen)2(dppz)]2+ 
with DNA. This is attributed to the extra methyl group on dppm2 further protecting the ligand 
from quenching by water upon intercalation.  
 We thus investigated the steady-state emission of [Ru(bpy)2(tmdppz)]2+ in the presence of 
the well-matched and mismatched 27-mer DNA sequences (Figure 4.4). Remarkably, the emission 
intensity of the complex is enhanced almost 500-fold in the presence of the DNA duplexes. 
However, unlike the parent complex [Ru(bpy)2(dppz)]2+, which exhibits a 1.5- to 2-fold emission 
enhancement in the presence of a CC mismatch compared to well-matched DNA, 
[Ru(bpy)2(tmdppz)]2+ exhibits comparable emission intensities in the presence of both duplexes. 
Two conclusions can be drawn from these observations. First, it is evident that introducing the 
methyl groups into the phenanthroline moiety of dppz does not inhibit intercalation into well-
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Figure 4.4. Steady-state emission spectra of [Ru(bpy)2(tmdppz)]Cl2 (8 µM) in the presence of 
the well-matched and mismatched DNA duplexes (8 µM, full sequence). Samples were prepared 
in 5 mM tris, 50 mM NaCl, pH 7.5, and excited at 440 nm.   
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matched base pairs. Second, the dramatic emission enhancement seen with the well-matched 
sequence suggests that once intercalated, the methyl groups of tmdppz provide substantial 
protection of the ligand from quenching by water. We might anticipate that the compound would 
bind to the mismatch through metalloinsertion, based on the evidence that [Ru(bpy)2(dppz)]2+ 
undergoes metalloinsertion at mismatched sites.5,6 However, even if [Ru(bpy)2(tmdppz)]2+ does 
undergo metalloinsertion at the mismatch, it is evident that this binding mode does not equate to 
luminescence discrimination compared to intercalation at well-matched base pairs.  
 
4.4 Conclusions  
 The aim of this work was to introduce steric bulk into the phenanthroline portion of the 
dppz ligand to discriminate against intercalation at well-matched sites in the DNA duplex. 
Interestingly, [Ru(bpy)2(tmdppz)]2+ exhibits nearly the opposite effect than what was intended, 
namely that any luminescence discrimination between mismatched and well-matched DNA 
appears to be lost. This is likely the result of the methyl substituents providing a shielding effect 
that attenuates the interactions between water and the phenazine nitrogen atoms. This less-efficient 
ability of water to quench the excited state of [Ru(bpy)2(tmdppz)]2+ results in dramatic emission 
enhancement in the presence of the DNA. Even bolder modifications to dppz might be needed to 
discriminate against intercalation. However, the evidence that even small changes to the dppz 
ligand framework can result in unfavorable alterations in the excited-state properties (such as loss 
of the light-switch effect) points to the conclusion that in the pursuit of mismatch selectivity, 
perhaps the dppz ligand is best left alone.  
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Chapter 5 
 
Investigating the Biological Activity of Mismatch-Specific 
Ruthenium Metalloinsertors   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Performed in collaboration with Julie Bailis and Natalie Mariano (Dept. Oncology Research, 
Amgen, Inc., South San Francisco).  
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5.1 Introduction  
 
 As discussed in Chapter 1, the Barton laboratory has developed rhodium metalloinsertors 
capable of targeting mismatch repair (MMR)-deficient cancers.1,2 [Rh(chrysi)(phen)(PPO)]2+ is 
highly potent towards the MMR-deficient cell line HCT116O compared to the MMR-proficient 
HCT116N line (EC50 < 500 nM, Figure 5.1). This compound inhibits DNA synthesis and induces 
cell death by necrosis in HCT116O cells.3 Our research group has collaborated with Julie Bailis 
(Dept. Oncology Research, Amgen, Inc., South San Francisco) to investigate the mechanism of 
action of [Rh(chrysi)(phen)(PPO)]2+ in the HCT116O cell line. Recent work has shown that 
[Rh(chrysi)(phen)(PPO)]2+ activates a DNA damage response that leads to cell death.4 It is 
proposed that upon binding to a DNA mismatch in cellulo through metalloinsertion, a novel lesion 
is created that is recognized by the cellular DNA damage response but is incapable of being 
repaired, thus resulting in cell death. It is possible that [Rh(chrysi)(phen)(PPO)]2+ inserted at a 
mismatch interferes with mismatch processing by repair enzymes. Interestingly, unlike cisplatin, 
[Rh(chrysi)(phen)(PPO)]2+ does not appear to activate apoptosis, and instead leads to irreversible 
cell death likely through a necrotic pathway.3,4   
Figure 5.1. (Left) Structure of [Rh(chrysi)(phen)(PPO)]2+. (Right) Differential cytotoxicity (as 
measured by the MTT assay) of the metalloinsertor towards MMR-proficient HCT116N and 
MMR-deficient HCT116O cell lines.	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 While these metalloinsertors are promising chemotherapeutic agents directed towards 
MMR-deficient cancers, a complete understanding of their mechanism of action is hindered by 
their inability to be visualized within cells, owing to the fact that they are non-luminescent. Thus, 
we must rely on developing fluorescently-tagged metalloinsertors or mismatch-specific 
luminescent analogues. Such derivatives could serve as tools for co-localization experiments of 
DNA damage checkpoint and repair proteins with  sites of DNA mismatches. Current work in our 
group is focusing on generating a fluorescently-tagged [Rh(chrysi)(phen)(PPO)]2+ conjugate. 
Additionally, mismatch-specific ruthenium complexes may be useful in this context. Luminescent 
ruthenium polypyridyl complexes, along with other transition metal centers such as iridium, 
platinum, and rhenium, have seen great utility as cellular imaging agents owing to their water 
solubility, chemical inertness, and photostability.5,6  
 In this work, we explored the mismatch-specific ruthenium complexes discussed in 
Chapters 2 and 3 in a biological context. In particular, we investigated the cytotoxic activity of 
[Ru(Me4phen)2(dppz)]2+, [Ru(Me2bpy)2(dppz)]2+, and [Ru(bpy)2(BNIQ)]2+ in the HCT116N and 
HCT116O cell lines to determine whether the in vitro mismatch-specificity of these complexes 
translated to cell-selective cytotoxicity comparable to rhodium metalloinsertors. Furthermore, in a 
collaboration with Julie Bailis, we have conducted live- and fixed-cell imaging experiments to 
visualize the localization of [Ru(Me4phen)2(dppz)]2+ in the HCT116N and HCT116O lines. 
Information gained from such experiments will be critical to see whether this compound can be a 
useful probe in co-localization experiments with proteins involved in the DNA damage response 
to mismatch binding, such as phosphorylated H2AX.  
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5.2 Experimental Protocols 
5.2.1 Materials 
 Cell media and culture supplements, trypsin-EDTA (0.05%), and phosphate-buffered saline 
were purchased from Invitrogen (Carlsbad, CA). 24 well plates (sterilized and tissue culture-
treated) for confocal microscopy were purchased from Ibidi. Reagents for cell proliferation ELISA 
and the MTT assay were purchased in kit format from Roche Molecular biochemical (Mannheim, 
Germany). Formaldehyde (for cell fixing experiments) was purchased as 16% solutions (w/v, 
methanol-free) in glass-sealed ampules from Thermo Scientific Pierce. Triton X-100 was 
purchased from Sigma. DRAQ5 was purchased as a 5 mM solution from Thermo Scientific. 
Ruthenium complexes (as Cl salts) were synthesized as described in Chapters 2 and 3.  
5.2.2 Cell Culture  
 HCT116N and HCT116O cells were grown in RPMI medium 1640 with the following 
supplementation: 10% FBS, 2 mM L-glutamine, 0.1 mM non-essential amino acids, 1 mM sodium 
pyruvate, 100 units/mL penicillin, 100 µg/mL streptomycin, and 400 µg/mL Geneticin G418. Cells 
were grown in tissue culture flasks (Corning Costar) at 37°C under a 5% CO2 humidified 
atmosphere.  
5.2.3 MTT Cytotoxicity Assay 
HCT116N and HCT116O cells were plated in 96-well plates (50,000 cells/well) and treated 
with a range of ruthenium concentrations (5 wells, or replicates, per concentration per cell line) 
for the desired time duration (24 to 72 hours) at 37°C humidified 5% CO2 atmosphere. After the 
incubation period, MTT was added to the cells (Roche Cell Proliferation Kit I) and the cells were 
incubated for an additional 4 hours. Insoluble formazan crystals were dissolved in solubilizing 
reagent (Roche) over 24 hours (37°C, 5% CO2, humidified atmosphere). The solubilized formazan 
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was quantified at 570 nm with 690 nm as the reference wavelength. Percent cell viability was 
calculated as a function of formazan formed in the ruthenium-treated cells relative to untreated 
cells.  
5.2.4 Cellular Proliferation ELISA  
HCT116N and HCT116O cells were plated on a 96-well plate at 2,000 cells per well and 
incubated at 37°C under 5% CO2 overnight to adhere. Cells were then treated with a range of 
ruthenium concentrations for 72 hours. Ruthenium-containing media was removed and replaced 
with fresh media, and labeled with BrdU for 24 hours. BrdU incorporation was quantified by an 
antibody assay kit. The quantified BrdU incorporation into treated cells was normalized to 
untreated controls to determine the cellular proliferation at each treatment concentration.  
5.2.5 Nuclear Count Assay for Cell Viability (performed at Amgen, Inc.) 
 Cells were plated to Perkin Elmer 96-well View Plates at 5,000 cells per well and incubated 
overnight. Cells were then treated with rac- or ∆-[Ru(Me4phen)2(dppz)]2+ in a dose response 
fashion for 3 days. Cells were fixed in 4% formaldehyde, permeabilized with 0.5% Triton X-100 
in PBS, and then stained with DAPI. The number of nuclei per well was counted using a Cellomics 
ArrayScan (Thermo Fisher) and used to calculate the percent viable cells relative to the number of 
cells from untreated samples.  
5.2.6 Confocal Microscopy  
For live-cell imaging, HCT116N and HCT116O cells were seeded at ca. 30,000 cells/well 
in 24 well confocal imaging plates from Ibidi (1.9 cm2 growth area per well) in 1 mL media and 
allowed to adhere for at least several hours. Cells were then treated with a given ruthenium 
concentration for the desired time period. Following this incubation period, the media was 
removed, and each well was washed three times with 1 mL PBS. Cells were then imaged in 1 mL 
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PBS on a Zeiss LSM 710 Inverted NLO 33A microscope using a 20x objective and exciting the 
ruthenium complex with 460 nm light (Beckman Imaging Facility, Caltech).   
For fixed-cell experiments, cells were seeded as described above in 24 well plates and 
allowed to adhere for at least several hours. Media was then removed, and cells were washed once 
with 1 mL PBS. The cells were then treated with 1 mL 4% formaldehyde for 10 min and washed 
twice with PBS, followed by treatment with 0.5% (v/v in PBS) Triton X-100 for 10 min (note: it 
is important to warm the 0.5% Triton solution to 37°C to allow Triton to fully solubilize in PBS). 
Cells were again washed with PBS and incubated with a 1 mL solution of ruthenium in PBS at the 
desired concentration for 15-20 min. For co-staining experiments with DRAQ5, cells were 
incubated with 5 µM DRAQ5 in PBS for 15 min.  
 
5.3 Results and Discussion 
5.3.1 Biological Activity of Ruthenium Complexes  
 We initially investigated whether the ruthenium complexes that exhibit mismatch 
specificity (as demonstrated from the in vitro steady-state and time-resolved luminescence 
experiments discussed in Chapters 2 and 3) also function as cell-selective cytotoxic agents directed 
towards the MMR-deficient HCT116O cells. This was first performed using the MTT assay 
(Figure 5.1), which assesses cell viability following treatment with a range of metal concentrations. 
This assay reports on cell metabolic activity based on the reduction of the MTT reagent (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) by mitochondrial enzymes. HCT116N 
and HCT116O cells were treated with rac-[Ru(Me4phen)2(dppz)]2+, rac-[Ru(Me2bpy)2(dppz)]2+, 
and rac-[Ru(bpy)2(BNIQ)]2+ for 72 hours at the concentrations indicated in Figure 5.2 below.  
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The BNIQ complex exhibits no cytotoxicity towards either cell line, and the Me2bpy 
compound also shows minimal activity. The Me4phen complex does show activity across a 5-25 
µM range, and maintains some cell selectivity at concentrations below 10 µM. Compared to the 
other two complexes, [Ru(Me4phen)2(dppz)]2+ likely benefits from increased cellular uptake. An 
interesting observation is that as concentrations are increased above 10 µM, the percentage of 
viable cells gradually levels off, which is uncharacteristic of cell-selective rhodium 
metalloinsertors.1-3 Other MTT assays were performed after 24 and 48 hours of 
[Ru(Me4phen)2(dppz)]2+ incubation, but no activity was seen compared to the 72 hour MTT shown 
in Figure 5.2.  
Intrigued by the MTT assay results, we repeated the assay with ∆- and Λ-
[Ru(Me4phen)2(dppz)]2+ alongside the racemic complex (Figure 5.3). As discussed in Chapter 2, 
the ∆ enantiomer of this complex is the isomer which imparts all mismatch selectivity. Thus, we 
would expect the ∆ enantiomer to preferentially bind mismatches in cells and induce cell-selective 
Figure 5.2. MTT assays of ruthenium complexes with HCT116N (green) and HCT116O (red) cell 
lines. Cells were plated in a 96-well format (5 x 104 cells/well) and treated with the indicated metal 
concentrations for 72 hours. Following this incubation period, the cells were labeled with MTT for 
4 hours. 	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cytotoxicity. Interestingly, the MTT results presented in Figure 5.3 imply that the opposite is true: 
the ∆ isomer exhibits negligible activity toward either cell line, but the Λ isomer shows some 
degree of cell-selective activity comparable to the racemic mixture. This is surprising, because the 
Λ isomer demonstrates little selectivity for mismatched DNA in vitro (Chapter 2). However, as 
discussed above, instead of the cell viability continually decreasing down to under 20% (as seen 
for [Rh(chrysi)(phen)(PPO)]2+, Figure 5.1), the cell viability plateaus when treated with rac-
[Ru(Me4phen)2(dppz)]2+. Furthermore, rhodium metalloinsertors have been shown to selectively 
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Figure 5.3. (Top left) Cellular proliferation assay (ELISA) for HCT116N (green) and HCT116O 
(red) cells treated with rac-[Ru(Me4phen)2(dppz)]2+ with the indicated concentrations for 72 
hours. Cell proliferation was quantified by BrdU incorporation during cell replication. (Top right, 
bottom) MTT assay results of rac-, ∆,- and Λ-[Ru(Me4phen)2(dppz)]2+. Cells were plated in a 96-
well format (5 x 104 cells/well) and treated with the indicated metal concentrations for 72 hours. 
Following this incubation period, the cells were labeled with MTT for 4 hours.	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inhibit DNA synthesis in the MMR-deficient HCT116O cell line, as measured by the ELISA assay 
for DNA synthesis.1-3 This assay quantifies the effects on proliferation of the cell lines, as 
expressed by BrdU incorporation. For cell-selective rhodium metalloinsertors, the results of the 
MTT assay typically mirror those of the ELISA – that is, cell-selective inhibition of DNA synthesis 
correlates with cell-selective cytotoxicity.2,3 For rac-[Ru(Me4phen)2(dppz)]2+, we see negligible 
activity in the ELISA assay (Figure 5.3). This result implies that neither enantiomer is capable of 
cell-selective inhibition of DNA synthesis.  
Given that ∆-[Ru(Me4phen)2(dppz)]2+ is capable of selectively binding a mismatch in vitro 
(Chapter 2) with comparable affinity to biologically-active rhodium metalloinsertors (~106 M-1), 
the lack of any activity for ∆-[Ru(Me4phen)2(dppz)]2+ as measured by the ELISA or MTT assays 
must result from the compound’s uptake and/or sub-cellular localization properties. For example, 
preferential localization to the mitochondria could explain the lack of cell selectivity.2 It is also 
possible that the MTT assay is not the best readout for cell viability upon treatment with 
[Ru(Me4phen)2(dppz)]2+. This point is supported by the peculiar result that Λ-
[Ru(Me4phen)2(dppz)]2+ does exhibit some selectivity towards HCT116O cells in the MTT assay 
(Figure 5.3), which is an unexpected observation because this isomer does not show any specificity 
for mismatched DNA in vitro (Chapter 2). Thus, it is unlikely that the differential activity seen for 
Λ-[Ru(Me4phen)2(dppz)]2+ in the MTT assay actually results from the complex preferentially 
targeting mismatched DNA in HCT116O cells. Instead, this isomer too probably localizes to 
mitochondria. Perhaps Λ-[Ru(Me4phen)2(dppz)]2+ partakes in non-specific binding in 
mitochondria and induces an altered metabolic response, giving rise to the diminished cell viability 
seen in Figure 5.3 upon treatment with this isomer.  
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An alternative assay for viability was performed with Julie Bailis (Amgen, Inc.), in which 
HCT116N and HCT116O cells were treated in a dose-response fashion with rac- and ∆-
[Ru(Me4phen)2(dppz)]2+ for 72 hours. Cells were then fixed with 4% formaldehyde, permeabilized 
with 0.5% Triton X-100, and nuclei were stained with DAPI. The number of nuclei per well were 
counted using a Cellomics ArrayScan (Thermo Fisher) high-content system, and the percent viable 
cells were calculated relative to untreated cells. The results of this assay, conducted with the 
racemic complex and its ∆ isomer, are presented in Figure 5.4. The first important observation is 
that in this assay, we see that cell viability is significantly diminished to <10% at the highest 
treatment concentrations (>50 µM), implying that this assay might be a more reliable readout of 
viability compared to the MTT. Second, we observe greater differential activity with the ∆ isomer 
compared to the racemic mix. Because ∆ is the isomer which exhibits mismatch specificity in vitro 
(Chapter 2), the nuclear count assay results are more consistent with mismatch-specific rhodium 
metalloinsertors such as [Rh(chrysi)(phen)(PPO)]2+. However, it should be noted that the 
ruthenium complex is at least an order of magnitude less potent than [Rh(chrysi)(phen)(PPO)]2+.  
 
rac,"HCT116N)"EC50 ="4.1"μM
∆,"HCT116O)"EC50 ="2.7"μM
∆,"HCT116N)"EC50 ="12.8"μM
rac,%HCT116O)"EC50 ="2.5"μM
(μM)
Figure 5.4. HCT116N and HCT116O cells were treated in a dose-response fashion for 72 hours 
with rac- and ∆-[Ru(Me4phen)2(dppz)]2+ and cell viability was assessed by a nuclear count assay. 
Performed with Julie Bailis at Amgen, Inc. 	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 The discrepancy between the MTT and nuclear count assays for viability could possibly be 
explained in terms of [Ru(Me4phen)2(dppz)]2+ localization and/or binding within the cell. C.A. 
Puckett studied the uptake and localization of dppz-based ruthenium complexes such as 
[Ru(bpy)2(dppz)]2+ and [Ru(DIP)2(dppz)]2+ (DIP = 4,7-diphenyl-1,10-phenanthroline) and found 
that the compounds generally exhibit uneven cytoplasmic staining with some evidence of 
mitochondrial localization.7 Based on the “light switch” nature of these dppz complexes, the fact 
that they can be directly visualized within the cytoplasm of cells8,9,10 signifies that they bind to 
cellular structures other than DNA, such as proteins or lipids. If [Ru(Me4phen)2(dppz)]2+ does 
show significant accumulation in the mitochondria, perhaps this off-target binding could affect 
cellular metabolic pathways and result in a lack of selectivity in the MTT assay. The sub-cellular 
localization of [Ru(Me4phen)2(dppz)]2+ is discussed in the following section.  
5.3.2 Confocal Microscopy Imaging of [Ru(Me4phen)2(dppz)]2+ in HCT116N and 
HCT116O Cells  
 
Confocal imaging experiments have been conducted with [Ru(Me4phen)2(dppz)]2+ in the 
HCT116N and HCT116O cells, both at Caltech (Beckman Imaging Facility) and with Julie Bailis 
and Natalie Mariano at Amgen, Inc. One could envision two potential uses for a mismatch-specific 
luminescent metalloinsertor. First, because ∆-[Ru(Me4phen)2(dppz)]2+ exhibits a significantly 
brighter emission intensity when bound to a DNA mismatch compared to well-matched sites 
(Chapter 2), this opens up the possibility for the compound to be used as a diagnostic probe for 
detecting mismatches in MMR-deficient cancer cells. In theory, MMR-deficient cells accumulate 
a greater number of mismatches compared to MMR-proficient cells owing to a 100- to 1000-fold 
increase in mutation rate.11 Second, while it has been shown that the potent, cell-selective 
metalloinsertor [Rh(chrysi)(phen)(PPO)]2+ activates a DNA damage response in HCT116O cells, 
it is not yet known which specific proteins are involved in this response pathway. A mismatch-
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specific luminescent metalloinsertor could help answer this question, because it would allow us to 
investigate the co-localization of the luminescent probe with fluorescently-labeled proteins that 
might be involved in the DNA damage response, such as phosphorylated H2AX (pH2AX), via 
fluorescence microscopy.   
We first explored whether [Ru(Me4phen)2(dppz)]2+ could be utilized as a diagnostic probe 
to preferentially detect mismatches in MMR-deficient cells by conducting microscopy imaging 
experiments in fixed HCT116N and HCT116O cells (Figure 5.5). DRAQ5, a nuclear co-stain 
(shown as red in Figure 5.5), clearly stains the nuclei of the cells. [Ru(Me4phen)2(dppz)]2+ (Figure 
Figure 5.5. Fixed-cell images of rac-[Ru(Me4phen)2dppz]2+ with HCT116N (top row) and 
HCT116O (bottom row) lines. Cells were fixed with 4% formaldehyde, permeabilized with 0.5% 
Triton X-100, and incubated with 10 µM Ru and 5 µM DRAQ5 for 15 min. Ru emission is shown 
in green, and DRAQ5 emission shown in red.	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5.5, green) exhibits diffuse staining predominantly in the cytoplasmic regions surrounding the 
nucleus, although faint nuclear accumulation is observed. However, any difference in nuclear 
brightness for HCT116N vs. HCT116O is not obvious; qualitatively, the ruthenium staining for 
both cell lines appears nearly identical. Even if the HCT116O cells possess more genomic 
mismatches, because the complex “lights up” much of the cell (presumably as a result of binding 
to lipids or proteins), it will be very difficult to detect a discernible luminescence difference 
between the cell lines from microscopy images alone. In order for a signal-on light switch probe 
to achieve this objective, it would need to exhibit negligible affinity for other biomolecules, so as 
to eliminate the high background signal resulting from non-specific binding.  
However, based on the observation that the ∆ and Λ enantiomers of 
[Ru(Me4phen)2(dppz)]2+ do exhibit differences in activity in the MTT assay, we asked the question 
of whether the enantiomers exhibit similar or noticeably different staining patterns in live and fixed 
cells. Figure 5.6 presents live-cell images obtained after incubation with the individual 
enantiomers. The complex is capable of entering live cells, a result that is consistent with prior 
reports of [Ru(L)2(dppz)]2+-type complexes.7 Although a nuclear co-staining dye was not 
employed here, by merging the ruthenium emission with the cell brightfield images (Figure 5.6, 
top row), it is evident that these compounds do not exhibit staining characteristic of significant 
nuclear accumulation. This observation is consistent with those made by C.A. Puckett in 
microscopy experiments with [Ru(DIP)2(dppz)]2+, a complex that displays predominantly punctate 
cytoplasmic staining in live cells.7 Both enantiomers of [Ru(Me4phen)2(dppz)]2+ are capable of 
entering the cells, however, and exhibit similar perinuclear staining that appears more punctate 
than diffuse.  
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The overall staining pattern does change noticeably when the complex is applied to fixed 
cells (Figures 5.5 and 5.6), in which we see a more diffuse ruthenium emission throughout the 
cytoplasm and faint nuclear accumulation. This is not surprising, as the membrane 
permeabilization during fixing ostensibly provides the complex with greater access to regions of 
the cell. However, as illustrated in Figure 5.6, there is no immediately obvious difference in 
staining when comparing the two enantiomers.  
∆ Λ
Live
Fixed
Figure 5.6. (Top) Live-cell images of ∆-[Ru(Me4phen)2(dppz)]2+ (left) and Λ-[Ru(Me4phen)2(dppz)]2+ 
(right) with HCT116O cells. Cells were incubated with 25 µM Ru for 20 hours and imaged in PBS. 
Shown are composite images of the Ru emission (red) and the cell brightfield (gray). (Bottom) Fixed-
cell images of the enantiomers with HCT116O cells. Cells were fixed with 4% formaldehyde, followed 
by 0.5% Triton X-100 permeabilization, and incubated with 5 µM Ru for 10 min and imaged in HBSS.  
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The punctate perinuclear staining in live cells seen in Figure 5.6 suggests mitochondrial 
localization. To confirm this observation, Natalie Mariano, a member of Julie Bailis’ group at 
Amgen, performed live-cell imaging of rac-[Ru(Me4phen)2(dppz)]2+ with nuclear and 
mitochondrial co-stains (Figure 5.7). It is very clear from Figure 5.7 that the punctate ruthenium 
emission co-localizes significantly with the mitochondrial dye MitoTracker, and less so with the 
live cell nuclear stain Hoechst. These results confirm our hypothesis that the relatively “greasy” 
cation [Ru(Me4phen)2(dppz)]2+, similarly to lipophilic rhodium complexes,2 preferentially 
localizes to the mitochondria. 
 Although [Ru(Me4phen)2(dppz)]2+ exhibits significant mitochondrial accumulation, the 
fact that it is even capable of entering cells is an important result. As discussed previously, another 
potential use for a luminescent metalloinsertor is to investigate co-localization of the probe with 
proteins involved in the DNA damage response pathway that is activated upon mismatch binding 
Figure 5.7. Live-cell images of rac-[Ru(Me4phen)2(dppz)]2+ (5 µM) incubated with HCT116N 
(left column) and HCT116O (right column) cells for 24 hours. From top to bottom: Ru emission 
alone (gold), Ru + Hoechst nuclear stain (blue), Ru + Mitotracker (green), and an overlay of all 
three stains. Conducted by Natalie Mariano at Amgen, Inc.  
Ru
Ru#+#Hoechst
Ru#+#MitoTracker
Ru#+#Hoechst#
+#MitoTracker
HCT116N HCT116O
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in cellulo. This is an active area of pursuit with our collaborators at Amgen. Julie Bailis and Natalie 
Mariano have been conducting optimization experiments to determine cell fixing conditions that 
will be best for [Ru(Me4phen)2(dppz)]2+ visualization in future co-localization studies. Upon 
treating live cells with the ruthenium complex for 24 hours followed by fixing, permeabilizing, 
and co-staining with DAPI, the ruthenium is visualized within the cells (Figure 5.8). Again, 
although the compound does exhibit non-specific staining throughout the cells, it can be detected 
in the nuclei. Importantly, with this method (first treating with the ruthenium complex followed 
by fixing the cells), punctate staining within the nuclei is seen – that is, ruthenium foci are 
maintained. This will be vital moving forward in co-localization experiments with fluorescently 
labeled proteins.   
 
5.4 Conclusions  
 
 [Ru(Me4phen)2(dppz)]2+ is capable of entering live cells and can be visualized in both live- 
and fixed-cell imaging experiments. However, the complex significantly accumulates in 
mitochondria and does not exhibit the same degree of activity in the MTT assay as cell-selective 
Figure 5.8. Fixed-cell images of rac-[Ru(Me4phen)2(dppz)]2+ with HCT116N cells. Cells were 
plated at 5,000 cells/well and treated with 5 µM Ru for 24 hours. Cells were then fixed with 4% 
formaldehyde (15 min), permeabilized with 0.5% Triton (15 min), and co-stained with DAPI (15 
min), followed by washing with PBS. Ru emission alone (gold) is shown at left, and Ru + DAPI 
is shown at right. Conducted by Natalie Mariano at Amgen, Inc.  
Ru Ru#+#DAPI
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rhodium metalloinsertors. However, the results of the nuclear count assay for cell viability (Figure 
5.4) are promising because they do show selective activity towards the MMR-deficient HCT116O 
cell line, and this effect is amplified when cells are treated with the ∆ enantiomer. As discussed in 
Chapter 2, there is strong evidence that [Ru(Me4phen)2(dppz)]2+ undergoes metalloinsertion when 
bound to a mismatch, ostensibly flipping out the mismatched bases in an analogous fashion to 
rhodium metalloinsertors. Although [Ru(Me4phen)2(dppz)]2+ exhibits non-specific accumulation 
throughout the cell, it can be detected in nuclei. Ongoing work with our collaborators at Amgen is 
focusing on investigating the co-localization of [Ru(Me4phen)2(dppz)]2+ with phosphorylated 
H2AX (pH2AX), an early marker for DNA damage response activation. This is also being 
explored with a fluorescent conjugate of a rhodium metalloinsertor bearing a cyanine dye.12 The 
goal of this work will be to determine if both compounds act by the same mechanism or a different 
mechanism; for example, one possible outcome is that pH2AX co-localization occurs for both 
compounds, but that a higher percentage of co-localization is observed for one compound 
compared to the other. Another potential outcome is that co-localization occurs with only one of 
the compounds. These experiments aim to provide a more complete picture with respect to the 
generality of metalloinsertion activating a particular DNA damage response in MMR-deficient 
cancer cells.  
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Chapter 6  
 
Amino Acid Conjugation of the Rhodium Metalloinsertor 
[Rh(HDPA)2(chrysi)]3+ 
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6.1 Introduction  
 
 An ongoing effort in the Barton laboratory is to further improve the selectivity of rhodium 
metalloinsertors towards MMR-deficient cancer cells while minimizing undesired off-target 
effects on MMR-proficient cells. While [Rh(phen)(chrysi)(PPO)]2+ is highly potent and exhibits 
cell-selective cytotoxicity towards the MMR-deficient HCT116O cells compared to MMR-
proficient HCT116N cells,1 this is only the case for a low (sub-micromolar) concentration range; 
at higher drug doses, the compound begins to affect the viability of the “healthy” or MMR-
proficient HCT116N cells. This off-targeting is not ideal, and limits the therapeutic dose of 
metalloinsertor that can be employed. Thus, an active area of research is focusing on making 
modifications to rhodium metalloinsertors to improve their selectivity over a larger concentration 
range.  
 One potential way to achieve enhanced selectivity towards the targeted cancerous tissue is 
through antibody-drug conjugation (ADC). ADC utilizes the tumor cell specificity of a monoclonal 
antibody tethered to a cytotoxic agent to increase the fraction of drug delivered to tumor tissues 
and minimize possible negative side effects of systemic drug administration.2 As shown in Figure 
6.1, an ADC typically consists of a drug payload conjugated to an antibody through a linker. The 
ADC localizes to the cancerous tissue expressing the target antigen and is subsequently 
internalized into the cell. Once inside the cell, the drug is released from the antibody typically 
through some cleavage mechanism of the linker.3 An example of such a conjugate is shown in 
Figure 6.1, in which the drug MMAE is conjugated to an antibody via the Val-Cit dipeptide linker; 
upon incorporation into the cell, it is proposed that Cathepsin B enzymatically cleaves at the site 
of this dipeptide, releasing free drug.4 In one study, MMAE was conjugated to the cAC10 antibody, 
which is directed towards the CD30 antigen expressed on Karpas 299 tumor cells. The ADC 
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exhibited significant antitumor activity in vitro and in vivo.5,6 Other similar ADCs bearing various 
dipeptide linkers were reported by Doronina et. al.7  
With this amino acid conjugation idea in mind, we considered whether a similar strategy 
could be employed to enhance the therapeutic window of rhodium metalloinsertors. Figure 6.2 
depicts a possible ADC design, illustrating a rhodium complex that is tethered to an antibody via 
some dipeptide linker. Proteolysis of the dipeptide linker releases a cleavage product bearing a 
Figure 6.1. (Top left) General schematic of an antibody-drug conjugate. Reprinted with 
permission from ref. 2, © 2011 AACR. (Top right) Basic pathway for an ADC into a cell. 
Reprinted with permission from ref. 3, © 2006 Nature Publishing Group. (Bottom) Example of 
an ADC. The drug MMAE is conjugated to the cAC10 antibody through a Val-Cit peptide linker. 
Proteolysis by Cathepsin B at the cleavage site (dotted arrow) within the cell releases free drug 
payload. Adapted from ref. 4.  
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single amino acid; ideally, this product would localize to the nucleus for mismatch binding.  
The focus of this work was to synthesize rhodium complexes bearing single amino acids 
that would serve as the proteolytic cleavage product depicted in Figure 6.2. The goal was to 
synthesize an effective rhodium amino acid conjugate that 1) still demonstrated mismatch 
specificity, and 2) maximized nuclear and minimized mitochondrial uptake. Prior work in our 
group investigated appending peptides to rhodium and ruthenium complexes in an effort to 
improve cellular uptake and nuclear localization. A D-octaarginine appendage conjugated to a 
rhodium ancillary ligand (Figure 6.3) did bestow fast nuclear uptake in HeLa cells, but the complex 
no longer exhibited specific binding to mismatches.8 A shorter peptide appendage, the RrRK 
nuclear targeting signal, was tethered to a ruthenium complex (Figure 6.3) and did impart an 
enhanced cellular uptake compared to free complex, but it was found that a higher concentration 
was required to accumulate in the nucleus compared to an octaarginine conjugate.9 The identity of 
the conjugated peptide also greatly altered the nuclear uptake. For example, an SrSr sequence 
appended to the ruthenium complex exhibited a much lower nuclear accumulation compared to 
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Figure 6.2.  General schematic of an ADC design for a rhodium metalloinsertor. After proteolysis 
of a dipeptide linker AA1-AA2 by some enzyme such as Cathepsin B, a cleavage product bearing 
a single amino acid ideally localizes to the nucleus and specifically binds to a DNA mismatch.  
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the RrRK tetrapeptide.  
 Given the variable characteristics that different peptides can impart on a compound’s 
uptake and localization, this work involved synthesizing a small family of rhodium 
metalloinsertors bearing single amino acids with various R-groups, namely serine, arginine, and 
phenylalanine. The DNA mismatch binding affinities of these complexes were determined, and 
the anti-proliferative and cytotoxic activities of these conjugates were studied in the MMR-
proficient HCT116N and MMR-deficient HCT116O cell lines. 
 
6.2 Experimental Protocols  
6.2.1 Materials 
All reagents and solvents were purchased from commercial suppliers and used without 
further purification. Sep-Pak C18 solid-phase extraction (SPE) cartridges were purchased from 
Waters Chemical Co. (Milford, MA). Media and supplements were purchased from Invitrogen 
(Carlsbad, CA). BrdU, antibodies, buffers, peroxidase substrate, MTT, and acidified lysis buffer 
(10% SDS in 10 mM HCl) solution were purchased in kit format from Roche Molecular 
biochemical (Mannheim, Germany). Oligonucleotides were ordered from Integrated DNA 
Figure 6.3: (Left) Rhodium metalloinsertor conjugated to D-octaarginine. Adapted from ref. 8. 
(Right) Ruthenium complex conjugated to RrRK nuclear targeting signal. Reprinted with 
permission from ref. 9, © 2010 Elsevier Ltd.   
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Technologies and purified by HPLC using a C18 reverse-phase column (Varian, Inc.) on a 
Hewlett-Packard 1100 HPLC. Single-stranded concentrations were quantified by measuring the 
absorbance at 260 nm using extinction coefficients provided from IDT. Radiolabeled [32P]-ATP 
was purchased from MP Biomedicals (Santa Ana, CA). Chrysene-5,6-dione (chrysi) was 
synthesized as described.10 The rhodium complex [Rh(HDPA)(chrysi)(DPA-AcOH)]3+ (HDPA = 
2,2’-dipyridylamine; DPA-AcOH = di(pyridine-2-yl)glycine was synthesized according to the 
methods described by A. Weidmann.11,12 
6.2.2 Synthesis  
 [Rh(HDPA)(chrysi)(DPA-Ser-OMe)]3+. In a scintillation vial containing 11.5 mg 
[Rh(HDPA)(chrysi)(DPA-AcOH)]3+ (0.0105 mmol) was added 12.5 mg HATU (0.0329 mmol, 
3.13 eq.) and 6.6 mg L-serine methyl ester hydrochloride (0.042 mmol, 4.0 eq). The vial contents 
were dried under vacuum (lyophilization) for 3.5 hours. The contents were then dissolved in ca. 2 
mL anhydrous DMF, and subsequently 11 µL DIEA (diisopropylethylamine, 0.063 mmol, 6.0 eq.) 
were added. The vial was flushed with argon for 15 minutes, and the reaction was stirred under 
argon for 14 hours at room temperature. The solvents were evaporated via lyophilization, and the 
crude reaction product was carried directly into the next step.   
 [Rh(HDPA)(chrysi)(DPA-Ser)]3+. Crude [Rh(HDPA)(chrysi)(DPA-Ser-OMe)]3+ was 
dissolved in 50 mL of 4:1 water:ethanol (v/v). The orange-red solution was stirred in a 250 mL 
found bottom flask and basified to pH ~10 with 1 N NaOH, yielding a yellow-green color change; 
the reaction was then stirred for 2 hours. The reaction was neutralized to a pH of 5-6 using 1 N 
HCl, producing a red color change, and the solvents were evaporated, leaving a rust-orange solid. 
The complex was purified by preparatory HPLC using a C18 reverse-phase column (Varian, Inc.) 
on a Hewlett Packard 1100 HPLC (85:15 to 40:60 H2O (0.1% TFA):MeCN) and then converted 
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to its chloride salt via anion exchange on a Sephadex QAE column primed with 1 M MgCl2. ESI-
MS m/z: calc. [M – 2H]+ 844.2, obs. 843.9.  
 [Rh(HDPA)(chrysi)(DPA-Arg)]3+. Synthesized analogously to [Rh(HDPA)(chrysi)(DPA-
Ser)]3+ via peptide coupling with L-arginine methyl ester hydrochloride followed by ester de-
protection as described above. The product was purified by preparatory HPLC and converted to 
its chloride salt via anion exchange on a Sephadex QAE column. ESI-MS m/z: calc. [M – 2H]+ 
913.3, obs. 913.0; calc. [(M – H)/2]+ 457.1, obs. 457.3.  
 [Rh(HDPA)(chrysi)(DPA-Phe)]3+. Synthesized analogously to [Rh(HDPA)(chrysi)(DPA-
Ser]3+ via peptide coupling with L-phenylalanine methyl ester hydrochloride followed by ester de-
protection as described above. The product was purified by preparatory HPLC and converted to 
its chloride salt via anion exchange on a Sephadex QAE column. ESI-MS m/z: calc. [M – 2H]+ 
904.2, obs. 904.0; calc. [(M – H)/2]+ 452.6, obs. 452.8.  
6.2.3 Photocleavage Competition Titrations and Binding Constant Determination 
 Photocleavage competition titrations with the amino acid metalloinsertor conjugates and 
[Rh(bpy)2(chrysi)]3+ were performed using 32P-labeled oligonucleotides and polyacrylamide gel 
electrophoresis (PAGE) as described previously.1,11,13 Briefly, the single-stranded 29-mer DNA 
hairpin sequence 5’-GGCAGGCATGGCTTTTTGCCATCCCTGCC-3’ (underline denotes a CC 
mismatch) was labeled at the 5’-end with 32P by incubating the DNA with 32P-ATP and 
polynucleotide kinase (PNK) at 37°C for 2 hours and purified using gel electrophoresis. A small 
portion of the labeled DNA (<1% total DNA) was added to 2 µM unlabeled oligonucleotide in 100 
mM NaCl, 20 mM NaPi, pH 7.1 buffer. The hairpin was annealed by heating to 90°C and slowly 
cooling back to room temperature over 1.5 hours. Stock solutions of each amino acid rhodium 
conjugate ranging from 0.1 µM (or 0.5 µM) to 50 µM were prepared in Milli-Q water. A 4 µM 
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rac-[Rh(bpy)2(chrysi)]Cl3 sample was also prepared. Working samples were prepared by 
combining 2 µM annealed DNA (10 µL), 4 µM [Rh(bpy)2(chrysi)]3+ (5 µL), and 5 µL of a given 
rhodium conjugate stock in a microcentrifuge tube at 37°C for 10 min to give 1 µM 
[Rh(bpy)2(chrysi)]3+ and 1 µM DNA as final concentrations. Control samples were also prepared: 
light control (DNA only) and dark control (highest conjugate concentration with DNA and no 
irradiation). Samples were irradiated on an Oriel (Darmstadt, Germany) 1000-W Hg/Xe solar 
simulator (340-440 nm) for 15 min. Samples were subsequently dried on a SpeedVac concentrator 
and electrophoresed in a 20% denaturing polyacrylamide gel. The gel was exposed to a phosphor 
screen, and the amount of DNA in each band was analyzed via autoradiography and quantified by 
phosphorimagery (ImageQuant). The fraction of cleaved DNA in each lane of a gel (corresponding 
to cleavage by [Rh(bpy)2(chrysi)]3+) was quantified and expressed as a percentage of the total 
DNA in that lane. The percent cleaved was plotted against the log of the rhodium conjugate 
concentration. OriginPro 8.5 was used to fit the plots to a sigmoidal curve, and the midpoint value 
(log of rhodium conjugate concentration at the plot inflection point) was converted to 
concentration. The binding constant of the conjugate was determined in Mathematica 6.0 by 
solving simultaneous equilibria of DNA, [Rh(bpy)2(chrysi)]3+, and the conjugate.  
6.2.4 Cell Culture and MTT Cytotoxicity Assay  
 Basic cell culture of the HCT116N and HCT11O cell lines, as well as the MTT cytotoxicity 
assay, were performed as discussed in Chapter 5.  
6.2.5 Cellular Proliferation ELISA  
 HCT116N and HCT116O cells were plated on a 96-well plate at 2,000 cells/well and 
incubated at 37°C under 5% CO2 overnight to adhere. Cells were then treated with a range of 
rhodium conjugate concentrations (0-10 µM) for 24 or 48 hours. At the end of these respective 
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time points, rhodium-containing media was removed and replaced with fresh media. Cells were 
grown for the remainder of the 72 hour growth period. 24 hours prior to analysis, cells were labeled 
with BrdU, and BrdU incorporation was quantified by an antibody assay kit. The quantified BrdU 
incorporation into treated cells was normalized to untreated controls to determine the cellular 
proliferation at each rhodium treatment concentration.  
6.2.6 ICP-MS Analysis for Whole-Cell Uptake 
 The whole-cell uptake of the Rh(DPA-Arg) and Rh(DPA-Phe) metalloinsertor conjugates 
was performed as described.13 Briefly, HCT116O cells were plated at 1 x 106 cells/well in 6-well 
plates (3 mL media per well). The cells were incubated overnight to adhere. The following day, 
cells were treated with 10 µM rhodium complex. Following incubation for the indicated time 
points (6, 12, and 24 hours), the media in each well was carefully removed, and the cell monolayer 
was washed with 3 mL PBS. 800 µL of 1% SDS was then added to lyse the cells. The cell lysates 
were collected and sonicated on a Qsonica Ultrasonic processor for 10 seconds at 20% amplitude. 
For ICP-MS analysis, 750 µL of each cell lysate was combined with 750 µL 2% HNO3 (v/v). The 
remaining lysate was quantified for total protein content using a bicinchoninic assay (BCA). The 
lysate/HNO3 solutions were subjected to ICP-MS analysis to determine 103Rh counts in each 
sample. The rhodium counts were normalized to the amount of protein as determined from the 
BCA, which gives ng Rh/mg protein values that can be compared amongst the different time point 
samples and Rh(DPA-Arg) and Rh(DPA-Phe) complexes. Three replicates per time point were 
recorded for each complex.  
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6.3 Results and Discussion  
6.3.1 General Design Considerations  
 The goal of this work was to generate metalloinsertor conjugates bearing single amino acid 
moieties. While the prospect of applying metalloinsertor amino acid conjugates towards antibody-
drug conjugation was being considered at the inception of this project, our initial investigations 
focused on exploring how modifying a metalloinsertor with single amino acids affected 1) 
mismatch binding affinity, and 2) cell-selective anti-proliferation and cytotoxicity. The aim was 
to screen several conjugates containing different amino acids to see whether any exhibited 
favorable cell-selective activity by minimizing mitochondrial localization and maximizing nuclear 
uptake. Work on this project began prior to the more recently-developed metalloinsertors bearing 
a unique Rh-O coordination such as [Rh(phen)(chrysi)(PPO)]2+ (Chapter 5, Figure 5.1), which 
exhibit high cell selectivity and potency. As such, this work focused on conjugating the 
metalloinsertor scaffold which, at the time, exhibited the best combination of cell selectivity and 
potency: [Rh(HDPA)2(chrysi)]3+ (Figure 6.4).14  
Figure 6.4. (Left) Structure of the rhodium metalloinsertor [Rh(HDPA)2(chrysi)]3+. (Right) 
Selective cytotoxicity of the metalloinsertor towards MMR-deficient HCT116O cells as measured 
by the MTT assay. HCT116N and HCT116O cells were plated in a 96-well format at 50,000 
cells/well and treated with 0-25 µM [Rh(HDPA)2(chrysi)]3+. After 72 hours, the cells were labeled 
with MTT for 4 hours.  
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 Conjugation of the [Rh(HDPA)2(chrysi)]3+ scaffold can be achieved by substituting one of 
the HDPA ligands with DPA-AcOH (di(pyridine-2-yl)glycine, Figure 6.5). The free carboxylic 
acid group on DPA-AcOH is very amenable to amide-bond coupling, thus making this site ideal 
for peptide conjugation. The complex [Rh(HDPA)(chrysi)(DPA-AcOH)]3+ has previously been 
used as a precursor for a bimetallic rhodium-oxaliplatin conjugate.11 
 In this work, three conjugates of [Rh(HDPA)(chrysi)(DPA-AcOH)]3+ were generated, each 
bearing a different amino acid (arginine, serine, and phenylalanine, Figure 6.5). These derivatives 
were synthesized via peptide coupling between the free carboxylic acid group on 
[Rh(HDPA)(chrysi)(DPA-AcOH)]3+ and methyl ester-protected amino acids, followed by ester de-
protection (see Experimental Protocols).  
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Figure 6.5. Amino acid conjugates investigated in this study. The precursor 
[Rh(HDPA)(chrysi)(DPA-AcOH)]3+ (referred to as Rh(DPA-AcOH), top) is amenable to peptide 
conjugation through amide coupling with its free carboxylic acid group (red).  
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6.3.2 Characterizing the CC Mismatch Binding Affinity of Amino Acid Conjugates 
 Whenever a new rhodium metalloinsertor conjugate is generated, it is imperative to 
characterize the binding affinity for a DNA mismatch to ensure that the added functionalities have 
not hindered the ability to bind to DNA. This is achieved using a photocleavage competition 
titration between the metalloinsertor conjugate and [Rh(bpy)2(chrysi)]3+ as described.13 While 
[Rh(bpy)2(chrysi)]3+ promotes DNA strand cleavage upon irradiation, newer generations of 
metalloinsertors, including [Rh(HDPA)2(chrysi)]3+ and its derivatives, do not. As described in the 
Experimental Protocols, samples are prepared containing constant concentrations of 32P-labeled 
CC hairpin DNA and mismatch-specific [Rh(bpy)2(chrysi)]3+, but varying concentrations of the 
metalloinsertor conjugate. The extent of DNA photocleavage by [Rh(bpy)2(chrysi)]3+ as a function 
of increasing conjugate concentration can be determined from gel electrophoresis and 
phosphorimaging. If the metalloinsertor conjugate binds mismatches, it is expected that as its 
concentration is increased, it will compete with [Rh(bpy)2(chrysi)]3+ for the CC binding site.  
 A representative photocleavage gel from a competition assay with [Rh(bpy)2(chrysi)]3+ and 
the serine metalloinsertor conjugate Rh(DPA-Ser) is presented in Figure 6.6. As expected, as the 
concentration of Rh(DPA-Ser) is increased relative to [Rh(bpy)2(chrysi)]3+, the observed 
photocleavage by [Rh(bpy)2(chrysi)]3+ decreases, indicating that the conjugate is competing for 
binding at the mismatch. This can be quantified by plotting the percentage of DNA photocleaved 
as a function of conjugate concentration (Figure 6.6). By fitting the points to a sigmoidal curve, 
the concentration of rhodium complex at the midpoint (inflection point) of each plot can be 
calculated in OriginPro. From this concentration, the binding constant of the conjugate for the CC 
mismatch is calculated in Mathematica 6.0 by solving simultaneous equilibria involving the DNA, 
[Rh(bpy)2(chrysi)]3+, and the conjugate. 
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 All three amino acid conjugates compete for mismatch site binding with 
[Rh(bpy)2(chrysi)]3+. From the photocleavage competition titrations, binding affinities for the CC 
mismatch were determined for each complex: KB(CC) = 5.8 x 106 M-1 for Rh(DPA-Ser), 2.0 x 106 
M-1 for Rh(DPA-Phe), and 4.2 x 106 M-1 for Rh(DPA-Arg). These values, all on the order of 106, 
are consistent with other HDPA-based metalloinsertors.13 Thus, these data reveal that the amino 
acid conjugates are capable of binding to the mismatch.  
 
Figure 6.6. Binding affinities determined through DNA photocleavage. (Top) Samples containing 
1 µM [Rh(bpy)2(chrysi)]3+, 1 µM radiolabeled CC hairpin DNA, and varying concentrations of 
Rh(DPA-Ser) conjugate (0.1 to 50 µM) were irradiated and electrophoresed through a 20% 
denaturing PAGE gel. Several control samples were included: a light control (LC, DNA only with 
irradiation), a dark control (DC, [Rh(bpy)2(chrysi)]3+ + conjugate + DNA with no irradiation), and 
a positive control (PC, DNA + [Rh(bpy)2(chrysi)]3+ + irradiation, no conjugate). (Bottom) 
Representative sigmoidal curve fit of data from photocleavage competition titration between 
[Rh(bpy)2(chrysi)]3+ and 0.1-50 µM Rh(DPA-Ser).  
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6.3.3 Biological Activity of Amino Acid Conjugates 
 We next investigated the anti-proliferative and cytotoxic activity of these conjugates in the 
MMR-proficient HCT116N and MMR-deficient HCT11O cell lines. The ELISA for DNA 
synthesis was employed to quantify the relative effects of the metalloinsertors on cell proliferation. 
HCT116N and HCT116O cells were incubated with a range of conjugate concentrations (Figure 
6.7) for 24 or 48 hours; after each incubation time point, rhodium-containing media was removed 
and replaced with fresh media and the cells were allowed to grow for the remainder of the 72-hour 
growth period. The cellular proliferation is represented by the percentage of BrdU incorporated 
into the cells treated with conjugate relative to untreated cells. [Rh(HDPA)2(chrysi)]3+ was 
included as a control.  
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Figure 6.7. Inhibitory effects of [Rh(HDPA)2(chrysi)]3+ and amino acid conjugates on cellular 
proliferation as determined by the ELISA. Cells were treated with rhodium for 48 hours.  
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 As expected, the control complex, [Rh(HDPA)2(chrysi)]3+, exhibits cell-selective anti-
proliferative activity towards the MMR-deficient HCT116O line. However, none of the amino acid 
conjugates demonstrate this cell-selective activity after 24 hours (not shown) or 48 hours of 
rhodium treatment. In fact, the conjugates display very little activity at all, in either cell line. This 
phenomenon has been reported before for the metalloinsertor [Rh(chrysi)(phen)(MeDPA)]3+, 
which after 24 hours does not display significant inhibition of DNA synthesis toward either cell 
line over a 0-25 µM concentration range.13 
 Although the conjugates do not demonstrate cell-selective inhibition of DNA synthesis, we 
pursued their cytotoxic effects in the cell lines by the MTT assay. Metalloinsertors that exhibit cell 
selectivity in the ELISA typically also exhibit cell-selective cytotoxicity.1,13 Over a 0-25 µM 
concentration range, none of the amino acid conjugates exhibit significant cytotoxicity towards 
Figure 6.8. Cytotoxicity of rhodium amino acid conjugates as measured by the MTT assay. Cells 
were treated with the concentration range of rhodium indicated for 72 hours.  
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either cell line, although the Rh(DPA-Arg) complex slowly decreases cell viability with increasing 
concentration (Figure 6.8). We tested the Rh(DPA-Arg) complex at even higher MTT assay 
concentrations (0-50 µM, Figure 6.8), and indeed we see that the conjugate displays comparable 
cytotoxicity towards both cell lines, down to ca. 20% viability. Increasing the cell treatment 
concentration of Rh(DPA-Ser) and Rh(DPA-Phe) to 50 µM does not induce any cytotoxicity (not 
shown).  
 Given that these conjugates are capable of binding to a mismatch in vitro with comparable 
affinity to other biologically-active metalloinsertors, the lack of any activity (as for Rh(DPA-Phe) 
and Rh(DPA-Ser)) or lack of cell-selective activity (as for Rh(DPA-Arg)) must lie in uptake and/or 
sub-cellular localization properties. To investigate whether the differences in MTT activity 
observed for the Rh(DPA-Arg) and Rh(DPA-Phe) conjugates was related to differences in whole-
cell uptake, an ICP-MS assay for whole-cell rhodium was conducted. HCT116O cells were treated 
with complex for 6, 12, and 24 hours, and subsequently lysed with 1% SDS and sonication. A 
portion of the cell lysate was combined with 2% HNO3 for ICP-MS analysis and the remainder of 
the lysate was quantified for protein content via the BCA assay. ICP-MS rhodium counts were 
normalized to the protein content calculated in the BCA assay to express the rhodium uptake levels 
as ‘ng Rh/mg protein’ (Figure 6.9).  
As illustrated in Figure 6.9, the Rh(DPA-Arg) and Rh(DPA-Phe) conjugates do not 
demonstrate significant differences in whole-cell uptake over 24 hours. Thus, the fact that MTT 
activity is observed for Rh(DPA-Arg) (albeit not cell-selective) but not for Rh(DPA-Phe) suggests 
that Rh(DPA-Arg) localizes to the mitochondria; in general, metalloinsertors that demonstrate cell-
selective biological activity accumulate less in the mitochondria, while those that show greater 
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mitochondrial accumulation lose cell selectivity.13 A key structural difference amongst the amino 
acid conjugates studied here is the presence of the  guanidinium group in Rh(DPA-Arg), which is 
expected to carry a positive charge at physiological pH. This might influence its localization 
properties relative to the other two complexes. Furthermore, it should be noted that the carboxylic 
acid group (drawn protonated in Figure 6.5) likely carries a negative charge at physiological pH. 
Other metalloinsertors do not carry a negatively charged carboxyl group, so perhaps this is also 
involved in the lack of activity. Performing sub-cellular localization ICP-MS assays for nuclear 
and mitochondrial rhodium content would paint a clearer picture as to whether the lack of any 
biological activity for Rh(DPA-Ser) and Rh(DPA-Phe) lies within their specific accumulation in 
organelles. The lack of any activity for these two derivatives at high concentrations (>25 µM) is 
surprising. At these concentrations, we’d expect at least some accumulation in the nucleus or 
mitochondria and the triggering of a biological response. We could hypothesize that the bulky 
amino acid, together with its negatively-charged carboxyl group, plays a role in altering the protein 
recognition of the mismatch-bound metalloinsertor lesion. Alternatively, perhaps there are other 
unseen mechanisms at play such as endosomal or lysosomal trapping.15,16  
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Figure 6.9. ICP-MS assay for whole-cell rhodium accumulation. HCT116O cells were treated 
with 10 µM conjugate for 6, 12, and 24 hours, and following cell lysis, the rhodium content was 
analyzed by ICP-MS. Error bars represent three replicates per time point.  
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6.4 Conclusions 
 The goal of this work was to generate amino acid-conjugated metalloinsertors based off 
the [Rh(HDPA)2(chrysi)]3+ scaffold. The hope was that these conjugates would exhibit selective 
activity toward the MMR-deficient cells, thus rendering them potential candidates for antibody-
drug conjugation. While all three conjugates investigated here demonstrate mismatch binding 
affinities comparable to other metalloinsertors, cell-selective biological activity is non-existent. 
Only the Rh(DPA-Arg) complex demonstrates any activity in the MTT assay, but it is not selective 
for either cell line, possibly due to mitochondrial accumulation. Since conducting these 
experiments, a newer generation of metalloinsertors ([Rh(chrysi)(phen)(L)]2+, L = PPO, DPE, 
PyOctanol, PPE)1 bearing a Rh-O coordination have been more fully characterized and exhibit 
significant cell selectivity with high potency. Current work in the lab is focusing on synthesizing 
antibody-drug conjugates based off this new generation of compounds with the ultimate goal of 
improving specificity towards mismatch repair-deficient tumors.  
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Chapter 7 
 
Investigating Rhenium and Ruthenium Complexes as Probes 
for DNA-Mediated Charge Transport  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Performed in collaboration with A. Vlcek, Queen Mary University of London, School of 
Biological and Chemical Sciences.  
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7.1 Introduction 
While most of the work described in this thesis relates to developing rhodium and 
ruthenium complexes that target DNA mismatches, the Barton laboratory has also focused on the 
study of transition metal complexes as probes for DNA-mediated charge transport (CT).1,2 
Consecutive base pairs in the DNA helix are packed closely with one another, creating a 
continuous aromatic π system through which charge can be transmitted, much like stacked sheets 
of graphite.3 In 1993, C. Murphy et al. demonstrated DNA-mediated CT between two transition 
metal complexes (Figure 7.1).4 The ruthenium intercalator [Ru(phen)2(dppz)]2+ was covalently 
tethered to one end of a DNA duplex, and as expected, yielded a bright steady-state emission when 
bound (Figure 7.1). However, when the rhodium intercalator [Rh(phi)2(bpy)]3+ was covalently 
tethered to the opposite end of the same duplex, complete quenching of the ruthenium emission 
was observed, due to electron transfer through the DNA helix from the ruthenium donor to the 
rhodium acceptor.  
Figure 7.1. DNA-mediated CT between transition metal intercalators. (Left) Following 
excitation, electron transfer from the Ru donor to the Rh acceptor occurs through the base stack. 
Reprinted with permission from ref. 2, © 2015 American Chemical Society. (Right) The 
Ru complex exhibits an intense steady-state emission when covalently tethered to a DNA 
duplex in the absence of the Rh acceptor. However, when the Rh intercalator is tethered to the 
opposite end of the same duplex, quenching of the Ru emission occurs. Reprinted with 
permission from ref. 4, © 1993 American Association for the Advancement of Science.     
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 DNA-mediated CT has been investigated with a number of different donor-acceptor pairs5,6 
and in the context of long-range guanine oxidation.7 Typically, these experiments rely on indirect 
biochemical assays and techniques that monitor rate of quenching of the donor. However, the 
ability to directly monitor the rate of charge arrival at the acceptor has remained elusive. If we 
wish to gain a deeper kinetic understanding of the excited-state species involved these systems, 
we must turn to other spectroscopic methods. UV-Visible transient absorption (TA) spectroscopy 
is one of the most common techniques for probing solution excited states. However, TA spectra 
are often broad and featureless with overlapping bands that might not yield much structural 
information on the excited states.8,9 Time-resolved vibrational spectroscopy – in particular time-
resolved infrared spectroscopy (TRIR) – produces well-resolved, high resolution transient IR 
bands following excitation that can distinguish individual molecular species and provide insight 
into the structure and electronic distribution of excited-state intermediates.9   
 Perhaps the most widely-studied molecules in the context of TRIR are rhenium tricarbonyls 
of the type [Re(CO)3(N,N)(L)]n, where N,N is generally a bipyridine-type ligand and L is a 
monodentate axial ligand.10 These complexes have garnered much attention owing to the strongly 
IR-active nature of the CO ligands. Another family of complexes that has been studied by TRIR 
include those with the general structure [M(N,N)2(L)2], in which M is typically Ru, N,N is some 
type of bipyridine, and L is NCS- or CN-.11,12  
 TRIR has also been used to study [Re(CO)3(dppz)(py’-OR)]+ and [Re(CO)3(F2dppz)Cl] 
(F2dppz = 11,12-difluorodipyrido[3,2-a:2’,3’-c]phenazine). These complexes intercalate into 
DNA via their phenazine ligands and are capable of oxidizing guanine upon photoexcitation.13,14 
Re(CO)3 complexes are thus attractive candidates owing to their ability to trigger electron transfer 
(ET) and the IR sensitivity of their CO ligands. A prior investigation found that the dppz-
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containing complex [Re(CO)3(dppz)(py’-OR)]+ preferentially populates a long-lived intraligand 
(3IL) excited state, and this 3IL state bears a very close TRIR spectral resemblance to the bands 
corresponding to the reduced-state Re complex. This overlap between the Re(CO)3 reduced state 
and 3IL excited state bands made TRIR spectra difficult to interpret. In the work presented in this 
chapter, two intercalating complexes were developed with the goal of using them as a donor-
acceptor pair to study ET through DNA by TRIR spectroscopy.  
 
7.2 Experimental Protocols  
7.2.1 Materials  
 All chemicals and starting materials were purchased from commercial vendors and used as 
received. Dipyrido[3,2-a:2’,3’-c]phenazine (dppz) was prepared according to the literature.15 
Ru(DMSO)4Cl2 was synthesized according to the literature16 (also commercially available, 
Sigma). UV-Visible spectra were recorded on a Beckman DU 7400 UV-Visible spectrophotometer 
(Beckman Coulter). Oligonucleotides were synthesized using standard phosphoramidite chemistry 
at Integrated DNA Technologies (Coralville, IA) and purified by HPLC using a C18 reverse-phase 
column (Varian, Inc.) on a Hewlett-Packard 1100 HPLC. 
7.2.2 Synthesis 
[Re(CO)3(phendione)Cl].  253 mg of Re(CO)5Cl (0.70 mmol) and 147 mg of phendione 
(0.70 mmol) were dissolved in 30 mL of anhydrous toluene. The reaction was stirred and refluxed 
for 4.5 h under argon. The orange precipitate was filtered out and purified by silica gel 
chromatography (THF). 260 mg of product were obtained (72%). 
[Re(CO)3(dppn)Cl]. 98 mg of [Re(CO)3(phendione)Cl] (0.19 mmol) and 60 mg of 2,3-
diaminonaphtalene (0.34 mmol) were suspended in 10 mL ethanol. The solution was refluxed for 
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2 h. After cooling down to room temperature, the orange precipitate was filtered and washed with 
water, diethyl ether, and cold ethanol. The product did not require any a further purification. 105 
mg of product were obtained (87%). 1H NMR (500 MHz, CD3CN) δ 9.91 (dd, J = 8.2, 1.4 Hz, 
2H), 9.51 (dd, J = 5.2, 1.4 Hz, 2H), 9.19 (s, 2H), 8.44 (dd, J = 6.4, 3.3 Hz, 2H), 8.19 (dd, J = 8.2, 
5.2 Hz, 2H), 7.83 (dd, J = 6.7, 3.1 Hz, 2H). 
PyOEt (ethyl 3-(pyridine-4-yl)propanoate). This ligand was synthesized by the 
esterification of 4-pyridinepropionic acid: 250 mg of 4-pyridineproprionic acid (1.65 mmol) and 
1.93 mL of ethanol (1.52 g, 33 mmol) were mixed in 28 mL of toluene. One drop of concentrated 
HCl was added and the mixture was refluxed for 5 h using a Dean Stark apparatus. After cooling, 
the reaction mixture was evaporated to dryness, yielding an oil. 
[Re(CO)3(pyOEt)(dppn)]X (X = PF6 or Cl). 105 mg of [Re(dppn)(CO)3Cl] (0.16 mmol) 
were dissolved in 16 mL anhydrous DMF under argon. The solution was stirred and heated to 
50°C, then solid AgPF6 (166 mg, 0.66 mmol) was added, and the solution was heated at 50°C 
under argon for 5 minutes. Meanwhile, 186 mg of pyOEt (1.0 mmol) was added dropwise to the 
solution, and the reaction was heated at 70°C for 6 h. The reaction was then cooled and filtered to 
remove AgCl. The crude product was purified on a silica column first using 1:9 MeCN:CHCl3, 
followed by a second silica column utilizing a gradient of 1% to 8% MeOH in CHCl3. The orange 
product was re-crystallized via vapor diffusion from 1:1 DCM:MeCN with Et2O. 1H NMR (500 
MHz, CD3CN) δ 9.89 (dd, J = 8.2, 1.4 Hz, 2H), 9.67 (dd, J = 5.2, 1.4 Hz, 2H), 9.09 (s, 2H), 8.35 
(dd, J = 6.5, 3.2 Hz, 2H), 8.33 – 8.24 (m, 4H), 7.79 – 7.72 (m, 2H), 7.19 – 7.13 (m, 2H), 3.91 (q, 
J = 7.1 Hz, 2H), 2.79 (t, J = 7.3 Hz, 2H), 2.49 (t, J = 7.3 Hz, 2H), 1.02 (t, J = 7.1 Hz, 3H). ESI(+)MS 
(m/z): [M]+ calc. 782.14, found 782.14. The PF6 counter-ion was exchanged to Cl using Sephadex 
QAE anion exchange resin. (Note: the final complex is susceptible to decomposition by 
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substitution of the pyOEt ligand by Cl in the presence of excess Cl. Anion exchanges of the final 
product should be conducted quickly, and at low MgCl2 concentrations (e.g. 0.05 M). It is not 
known whether performing anion exchanges in the dark will help).  
[Ru(tpy)(DMSO)(Cl2)]. A mixture of ethanol (95%, 20 mL) and methanol (6 mL) was 
slowly stirred as Ru(DMSO)4Cl2 (1.26 g, 2.2 mmol) was added. The mixture was stirred and 
refluxed under an inert argon atmosphere for 15 min. A separate mixture of ethanol (95%, 10 mL) 
and terpyridine (tpy, 0.600 g, 2.6 mmol) was prepared and added dropwise under argon. The 
resulting brown mixture was refluxed and stirred under argon for another 8.5 h. The precipitate 
was collected by vacuum filtration. The solid was washed with cold water, cold ethanol, and ether. 
800 mg of red solid were obtained (75% yield). 
[Ru(tpy)(dppz)(Cl)]Cl. A mixture of 0.30 g (0.65 mmol) [Ru(tpy)(DMSO)(Cl)2] and 0.485 
g (1.6 mmol) dppz was added to dry DMF (30 mL). The resulting solution was stirred and heated 
for 30 h at 130°C under argon. After the reaction was cooled to room temperature, the dark purple 
mixture was brought to dryness under vacuum, and directly engaged in the next reaction step. 
[Ru(tpy)(dppz)(CN)]PF6. The solid obtained from the previous reaction was dissolved in 
50 mL of Milli-Q water containing 0.2 g NaOH and 420 mg KCN (10 eq). The mixture was 
refluxed for 8 h. After cooling, the complex was precipitated by addition of 1.2 equivalents of 
KPF6 and the solid was washed with water. The product, contaminated with dppz ligand, can be 
purified by HPLC using an isocratic eluent of 45% MeCN 55% Water (with 1%TFA) on a Zorbax 
SB-C18 column. 1H NMR (300 MHz, CD3CN) δ 10.48 (d, J = 5.3 Hz, 1H), 9.84 (d, J = 8.1 Hz, 
1H), 9.44 (d, J = 8.0 Hz, 1H), 8.58 (d, J = 8.1 Hz, 2H), 8.53 – 8.36 (m, 5H), 8.25 (t, J = 8.1 Hz, 
1H), 8.13 (dt, J = 6.5, 2.8 Hz, 2H), 7.93 (t, J = 7.8 Hz, 2H), 7.75 (t, J = 5.6 Hz, 3H), 7.59 (dd, J = 
8.1, 5.2 Hz, 1H), 7.22 (t, J = 6.5 Hz, 2H). ESI(+)MS (m/z): [M]+ calc. 643.09, found 643.19. The 
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purified complex was converted to its Cl salt by Sephadex QAE anion exchange.  
7.2.3 Luminescence Measurements  
Steady-State Luminescence. Luminescence spectra were recorded on an ISS-K2 
spectrofluorometer at 25°C. The Re complex was excited at 398 nm, and the Ru complex at 460 
nm. The Cl salts of the complexes were used for all experiments with DNA. Stock solutions of the 
complexes were prepared in water with a small portion (less than 10%) of methanol added to assist 
in solubility.  
 
7.3 Results and Discussion 
7.3.1 Designing the Donor-Acceptor System for TRIR Analysis of DNA-Mediated CT 
 The goal of this work was to use TRIR to study a DNA-mediated electron transfer reaction 
between donor and acceptor metal complexes intercalated into DNA. The chemical structures of 
the compounds investigated here are provided in Figure 7.2. [Ru(tpy)(CN)(dppz)]+ (tpy = 
terpyridine) was developed to serve as a charge donor in a DNA-mediated CT reaction with the 
charge acceptor [Re(CO)3(pyOEt)(dppn)]+ (pyOEt = ethyl 3-(pyridine-4-yl)propanoate; dppn = 
benzodipyridophenazine). In theory, by monitoring time-dependent changes in the TRIR spectra 
of the IR-active CN and CO ligands, one can measure rates of charge injection by the donor and 
charge arrival at the acceptor.    
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 In previous investigations it was found that observing the reduced state of 
[Re(CO)3(pyOEt)(dppz)]+ by TRIR is hindered by the persistence of lowest excited state 3IL dppz 
bands, which overlap with the reduced Re(CO)3 bands.13 Thus, optimizations of the Re structure 
must be made with the intent of generating a complex which possesses an MLCT lowest excited 
state; from a TRIR perspective, a Re(CO)3 complex with an MLCT lowest excited state would be 
a more useful probe owing to more spectrally-distinct TRIR bands compared to 3IL-dominant 
species.13 It has been reported that incorporating dppn into Re(CO)3 systems lowers the energy of 
the MLCT and IL absorption bands owing to the more extended π –conjugation of the dppn ligand 
relative to dppz.17 In fact, complexes of the type [Re(CO)3(py-R)(dppn)]+ (py-R = pyridine or 
Figure 7.2. (Top) Chemical structures of TRIR probes investigated in this work, 
[Ru(tpy)(CN)(dppz)]+ and [Re(CO)3(pyOEt)(dppn)]+. (Bottom) Following intercalation of the IR-
active probes into DNA, excitation of the ruthenium donor will result in electron transfer through 
the base stack to the rhenium acceptor. TRIR can be used to monitor the changes in CN and CO 
stretching frequencies corresponding to charge injection and charge arrival, respectively.  
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modified pyridine) exhibit broad, structureless steady-state emission bands with peak maxima at 
ca. 587-595 nm, comparable to other Re(I) polypyridine 3MLCT emitters.18,19 Experimental 
evidence suggests that emission from [Re(CO)3(py-R)(dppn)]+ includes both 3IL(dppn) and 
3MLCT dπ(Re)-π*(dppn) excited-state character.17 Thus, it was proposed that 
[Re(CO)3(pyOEt)(dppn)]+ (Figure 7.2) might possess more distinct MLCT TRIR spectral signals 
compared to its dppz derivative. However, like dppz, dppn is a strong DNA intercalator; thus, 
Re(CO)3 complexes bearing this ligand are readily capable of binding to DNA.20,21  
7.3.2 Synthesis and Photophysical Characterization  
 The [Re(CO)3(pyOEt)(dppn)]+ complex is synthesized in an analogous fashion to that 
reported for its dppz counterpart (Scheme 7.1).22,23 In experiments with DNA, the final product 
[Re(CO)3(pyOEt)(dppn)](PF6) is converted to its Cl salt to assist in water solubility; however, 
[Re(CO)3(pyOEt)(dppn)]Cl still exhibits relatively poor solubility in water. The synthesis of 
[Ru(tpy)(CN)(dppz)](PF6) is relatively straightforward, although caution should be applied in the 
final reaction ([Ru(tpy)(Cl)(dppz)]+ with KCN), because KCN is quite hazardous (NaOH is 
included in the reaction to minimize the formation of HCN vapors). This final step is based on a 
literature protocol for the synthesis of [Ru(tpy)(CN)(bpy)]+ (Scheme 7.1).24 Again, 
[Ru(tpy)(CN)(dppz)](PF6) is converted to its Cl salt for investigations with DNA, although this 
complex is also sparingly soluble in aqueous solution.  
 The absorption profile of [Re(CO)3(pyOEt)(dppn)]+ (Figure 7.3) bears very close 
resemblance to dppz- and dppn-containing Re(CO)3 complexes.20-23,25,26 The complex exhibits 
absorption maxima at ca. 400 and 420 nm and a weak tail extending in the visible to approximately 
500 nm. The absorption maxima at 400 and 420 nm are tentatively assigned to π-π* (dppn) 
intraligand (IL) transitions, considering the fact that free dppn absorbs at relatively low energies  
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(391 and 413 nm in CH2Cl2).17,20,21 However, the lower-energy tail that extends into the visible 
region, along with the red-shift of the 400 and 420 nm bands relative to free dppn, is indicative of 
a dπ(Re)-π*(dppn) MLCT transition.25,26 As anticipated for Re(CO)3 complexes of dppz and dppn,  
the steady-state emission of [Re(CO)3(pyOEt)(dppn)]+ is quenched in aqueous solution (Figure 
7.3).20-23 Conversely, excitation of the compound in acetonitrile yields an extremely bright, broad, 
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Scheme 7.1. (Top) Synthesis of [Re(CO)3(pyOEt)(dppn)]+. The complex is isolated as its PF6 salt 
from the final reaction. (Bottom) Synthesis of [Ru(tpy)(CN)(dppz)]+. The complex is precipitated 
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structureless emission band with maximum at 595 nm, in agreement with the previously reported 
[Re(CO)3(py)(dppn)]+ bearing an unmodified pyridine.21  
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Figure 7.3. (Top) Chemical structures of TRIR probes investigated in this work, 
[Ru(tpy)(CN)(dppz)]+ and [Re(CO)3(pyOEt)(dppn)]+. (Middle-Left) UV-Visible spectrum of 
[Re(CO)3(pyOEt)(dppn)](PF6) in acetonitrile. (Bottom-left) Steady-state emission spectra of the 
Re complex in acetonitrile and water (PF6 and Cl salts, respectively; 398 nm excitation, ~10 µM 
Re. (Middle-Right) UV-Visible spectrum of [Ru(tpy)(CN)(dppz)](PF6) in acetonitrile. (Bottom-
right) Steady-state emission spectra of [Ru(tpy)(CN)(dppz)]+ in acetonitrile (PF6 salt) and water 
(Cl salt). Sample absorbances of ~0.1 at 460 nm wavelength used for excitation, or ~10 µM).  
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 Literature precedent for compounds of the type [Ru(tpy)(CN)(dppz)]+ is more limited than 
the Re(CO)3 complexes discussed above. However, the UV-Visible spectrum of 
[Ru(tpy)(CN)(dppz)]+ shares features of that reported for [Ru(tpy)(CN)(bpy)]+, including the 
ligand centered π-π* transitions in the UV and an intense low-energy absorption at ca. 485 nm 
corresponding to an MLCT.24 The dppz ligand π-π* also manifests at ca. 350-360 nm. Similarly 
to the [Re(CO)3(pyOEt)(dppn)]+ complex, the emission of [Ru(tpy)(CN)(dppz)]+ is entirely 
quenched in water (Figure 7.3). Interestingly, the emission in acetonitrile is extremely weak; in 
fact, [Ru(tpy)(CN)(bpy)]+ was previously reported to be a weak emitter in acetonitrile, producing 
an MLCT luminescence with low quantum yield27  of 1.5 x 10-4  vs. [Ru(bpy)3]2+ (ɸem = 0.06)28 
and an excited state emission lifetime of ~6 ns.24 Comparatively, the [Re(CO)3(pyOEt)(dppn)]+ 
complex possesses a nearly 500-fold brighter steady-state emission intensity in acetonitrile than 
the ruthenium complex for samples of approximately equal metal concentration (Figure 7.3).  
Samples of [Re(CO)3(pyOEt)(dppn)]+ and [Ru(tpy)(CN)(dppz)]+ were sent to our 
collaborator Tony Vlcek (Queen Mary University of London) for TRIR analysis. 
[Re(CO)3(pyOEt)(dppn)]+ only exhibited bands corresponding to π-π*(dppn) intraligand excited 
states; there was no distinct TRIR signature for an MLCT state. Thus, from a TRIR perspective, 
this dppn derivative is not an improvement over the previously-studied [Re(CO)3(pyOEt)(dppz)]+ 
complex. The excited-state TRIR spectrum of [Ru(CN)(tpy)(dppz)]+ in DMF is very indistinctive, 
because the excited-state ν(CN) absorption is weak and strongly overlaps with the bleach. 
Additionally, the excited-state lifetime of the ν(CN) stretch is very sensitive to increasing water 
content, limiting this probe’s utility in aqueous solutions with DNA. Future work will focus on 
methylating the CN group of [Ru(CN)(tpy)(dppz)]+ to generate the isocyanide derivative [Ru(CN-
CH3)(tpy)(dppz)]2+ with the hopes of attenuating quenching of the excited state by water.  
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7.3.3 Quenching of [Re(CO)3(pyOEt)(dppn)]+ Luminescence by [Ru(CN)(tpy)(dppz)]+ 
when Bound to DNA  
 
 While [Re(CO)3(pyOEt)(dppn)]+ and [Ru(CN)(tpy)(dppz)]+ will not be a useful donor-
acceptor pair to monitor DNA-mediated CT by TRIR as originally designed, basic steady-state 
luminescence experiments can still be performed to investigate whether the Ru complex is capable 
of quenching the [Re(CO)3(pyOEt)(dppn)]+ emission via DNA-mediated electron transfer, as 
demonstrated previously by M. Arkin et al. for Ru(II)/Os(II) and Rh(III) noncovalent donor-
acceptor pairs.29 Re(CO)3 complexes of dppn intercalate into DNA and exhibit bright emission 
when bound to AT-rich sequences, but are quenched in the presence of GC DNA.20 This 
phenomenon is also observed for [Re(CO)3(pyOEt)(dppz)]+ and is attributed to quenching of the 
metal excited state by guanine.13  
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Figure 7.4. Steady-state emission spectra of [Re(CO)3(pyOEt)(dppn)]Cl (5 µM) in the presence 
of AT and GC 30-mer DNA duplexes (5 µM duplex or 150 µM  base pair). Samples were prepared 
in 10 mM NaPi, 50 mM NaCl, pH 7.0 buffer and excited at 398 nm. 
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 Here, two 30-mer AT and GC DNA duplexes were generated and the emission of 
[Re(CO)3(pyOEt)(dppn)]+ in the presence of both sequences was measured (Figure 7.4). As 
expected, the emission is entirely quenched when bound to the GC sequence but luminescence is 
observed with the AT sequence. We then investigated whether addition of the 
[Ru(CN)(tpy)(dppz)]+ complex leads to quenching of the Re emission when bound to the AT DNA 
duplex. Following excitation of the Re complex, we would expect quenching of its emission when 
[Ru(CN)(tpy)(dppz)]+ is intercalated into the same duplex as a result of electron transfer. Samples 
were prepared containing 5 µM Re and 250 µM base pair AT DNA (50:1 base pairs:Re) and the 
Ru complex was titrated in to 0.4, 0.8, 1.2, and 1.6 equivalents. The 50:1 base pair:Re 
concentration ratio was chosen such that the compounds were relatively dilute on the helix.29 
Dramatic quenching of the Re emission is observed (Figure 7.5). However, it must be noted that 
the two complexes under study possess absorption spectra that overlap significantly with each 
other - that is, there is no wavelength at which the Re complex absorbs that the Ru complex does 
not (refer to Figure 7.3). Such a wavelength would be ideal for the system so as to selectively 
Figure 7.5. (Left) Steady-state luminescence quenching of [Re(CO)3(pyOEt)(dppn)]Cl (5 µM) by 
[Ru(CN)(tpy)(dppz)]Cl in the presence of the AT DNA sequence (250 µM base pair). Ru was 
titrated into the solution to 0.4, 0.8, 1.2, and 1.6 Ru:Re equivalents. Samples were prepared in 10 
mM NaPi, 50 mM NaCl, pH 7.0 buffer and excited at 398 nm. (Right) Ru was titrated into a 5 µM 
acetonitrile solution of the Re complex in the same fashion, exciting at 398 nm.  
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excite the Re complex. As a control, samples of the Re compound were prepared in acetonitrile 
and the Ru was titrated in with no DNA present (Figure 7.5). This was performed to see whether 
the decrease in Re emission intensity observed upon Ru addition with the AT sequence was the 
result of true quenching or simply a “filtering” effect resulting from the Ru compound absorbing 
the excitation light. We see that upon adding Ru to the Re alone, there is only a small decrease in 
emission intensity (Figure 7.5). As such, the quenching observed for [Re(CO)3(pyOEt)(dppn)]+ 
when bound to the AT sequence is likely a DNA-mediated transfer mechanism. 
  
7.4 Conclusions  
 In this work, [Re(CO)3(pyOEt)(dppn)]+ and [Ru(CN)(tpy)(dppz)]+, which bear IR-active 
CO and CN ligands, were synthesized with the intention of using them as TRIR probes to monitor 
the kinetics of DNA-mediated electron transfer. It was originally hypothesized that the Re complex 
might have an MLCT lowest excited state, which would provide a TRIR signature that is spectrally 
distinct from the reduced-state complex. However, TRIR analysis of [Re(CO)3(pyOEt)(dppn)]+ 
revealed no evidence of an MLCT; the complex, like its dppz derivative studied previously, 
exhibits intense bands corresponding to intraligand excited states, which makes TRIR spectral 
analysis of the reduced-state complex challenging. From a TRIR perspective, this dppn derivative 
is not an improvement over [Re(CO)3(pyOEt)(dppz)]+. Additionally, the CN stretching band of 
[Ru(CN)(tpy)(dppz)]+ is highly solvent-sensitive, owing to hydrogen bonding with water 
molecules. This leads to rapid quenching of the excited state as observed by TRIR. Synthesis of a 
methylated [Ru(CN-Me)(tpy)(dppz)]2+ isocyanide derivative may enhance this compound’s 
excited state lifetime and alleviate the rapid quenching by water. 
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 Because of the unfavorable TRIR properties exhibited by these two probes, further TRIR 
experiments with DNA were not conducted. However, steady-state luminescence experiments 
were performed to see whether electron transfer between this donor-acceptor pair was capable of 
quenching the [Re(CO)3(pyOEt)(dppn)]+ emission when bound to AT DNA. Upon titrating 
[Ru(CN)(tpy)(dppz)]+ into solutions of the Re complex with AT DNA, quenching of the Re 
emission was observed, consistent with a DNA-mediated electron transfer mechanism.  
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The work described in this thesis involves the design, synthesis, and characterization of 
transition metal complexes that bind to DNA through non-covalent interactions, with a focus on 
developing luminescent ruthenium compounds that specifically target DNA base pair mismatches. 
Chapter 2 presented the light switch complex [Ru(Me4phen)2(dppz)]2+, which makes use of its 
bulky Me4phen ligands to discriminate against intercalation at well-matched base pairs and thus 
favor metalloinsertion at a mismatch. The complex possesses a higher binding affinity for a DNA 
mismatch compared to well-matched base pairs, and exhibits a longer excited-state emission 
lifetime when bound to a mismatch. Furthermore, it was found that ∆-[Ru(Me4phen)2(dppz)]2+ is 
the enantiomer which imparts all mismatch selectivity, consistent with the handedness of B-form 
DNA.  
The work presented in Chapter 3 represents an alternate approach for achieving mismatch 
specificity. Instead of incorporating bulky ancillary ligands, [Ru(bpy)2(BNIQ)]2+ possesses a 
sterically expansive aromatic inserting ligand (BNIQ) that is capable of selectively undergoing 
metalloinsertion at a mismatch. This design strategy is more akin to the development of mismatch-
targeting rhodium metalloinsertors such as [Rh(bpy)2(chrysi)]3+. In Chapter 4, we rationalized that 
perhaps incorporating extra steric bulk into the dppz ligand to generate tetramethyl-dppz (tmdppz) 
might also improve mismatch selectivity compared to the parent [Ru(bpy)2(dppz)]2+. However, we 
quickly learned that even the addition of simple methyl groups into dppz can lead to a loss of the 
light switch effect due to the close proximity of the methyl substituents to the phenazine nitrogen 
atoms. Through this same mechanism, we see that all luminescence discrimination for mismatched 
vs. well-matched DNA is lost.  
In Chapter 5, we explored the biological activity of the mismatch-specific ruthenium 
complexes and used confocal microscopy to visualize [Ru(Me4phen)2(dppz)]2+ in MMR-proficient 
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and MMR-deficient cancer cells. Visualization of [Ru(Me4phen)2(dppz)]2+ in live and fixed cells 
revealed that the complex does localize significantly to mitochondria, and is capable of staining 
cytoplasmic regions of the cell. However, the compound does exhibit nuclear entry. Furthermore, 
much still needs to be learned regarding the mechanism of cell death induced by rhodium 
metalloinsertors such as [Rh(phen)(chrysi)(PPO)]2+, specifically with respect to what proteins and 
pathways are activated that cause a DNA damage response. In this context, a mismatch-specific 
luminescent probe may have utility, and current efforts are investigating the in cellulo co-
localization of [Ru(Me4phen)2(dppz)]2+ with proteins involved in the DNA damage response.  
Chapter 6 described work that was conducted to improve the efficacy of an earlier-
generation rhodium metalloinsertor, [Rh(HDPA)2(chrysi)]3+, through amino acid conjugation. 
Interestingly, this resulted in a loss of cell-selective activity, possibly due to altered uptake and 
localization. Since these investigations, metalloinsertors that are more robust to functionalization, 
such as [Rh(phen)(chrysi)(PPO)]2+, have been established, and are currently being developed as 
antibody drug conjugates to improve tumor specificity.  
Lastly, outside the realm of mismatch-targeting – but still under the umbrella of DNA-
binding transition metal complexes – a portion of work was devoted to the study of ruthenium and 
rhenium intercalators that were designed as TRIR probes to investigate the kinetics of DNA-
mediated CT. While [Ru(tpy)(CN)(dppz)]+  and [Re(CO)3(pyOEt)(dppn)]+ do not possess the 
spectral properties to allow for the desired analysis by TRIR, steady-state luminescence 
experiments do suggest that this donor-acceptor pair is capable of undergoing DNA-mediated 
electron transfer. However, there is still room for optimizing the structures of these complexes to 
improve their TRIR spectral response.   
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Taken together, the work described here illustrates the incredible utility of octahedral 
transition metal complexes for probing DNA structure. Importantly, we have learned that through 
the logical design of new ligands and the modification of existing ligand scaffolds, we can achieve 
recognition of specific biomarkers such as DNA mismatches. Mismatch-targeting rhodium and 
ruthenium complexes represent a new strategy for therapeutic and diagnostic design, and we hope 
that the work presented here will fuel future research endeavors aimed at developing therapeutic 
and diagnostic small molecule agents directed towards MMR-deficient cancers.  
In a broader sense, this work speaks to the incredible value of conducting scientific research 
in an interdisciplinary setting. The opportunity to 1) rationally design and synthesize novel small 
molecules, 2) explore their spectroscopic properties, and 3) investigate their biological activity in 
clinically relevant cancer cells has truly been a rewarding experience. There is a definite 
satisfaction that comes with synthesizing a compound at the benchtop and then directly studying 
its potential therapeutic or diagnostic utility. The interdisciplinary nature of our research has forced 
me to acquire a diverse scientific skill set, which has been extremely gratifying. Furthermore, 
through collaborations with other research groups, we have been able to answer key questions that 
otherwise would have been difficult to approach in our lab alone, allowing us to push the 
boundaries of scientific discovery at a rapid, exciting pace.  
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Appendix 
 
A.1 [Ru(Me4phen)2(dppz)]2+ DNA Titrations  
 
The luminescence intensity of the complex upon addition of DNA (well-matched or 
mismatched duplexes) was used to determine the binding affinity of rac-[Ru(Me4phen)2(dppz)]2+ 
towards well-matched and mismatched DNA base pair sites. For the titration with well-matched 
DNA, the binding affinity was evaluated using the McGhee-Von Hippel method,1 and a value of 
6.8 x 104 M-1 per well-matched base pair was obtained with an occupational factor, p, of 2.3 (also 
known as the size-covering parameter; that is, the consecutive base pair residues covered or 
occupied by a single bound complex. A value of p = 2 corresponds to nearest-neighbor exclusion).2 
In order to evaluate the binding affinity of the complex for the mismatched site, we must 
consider two competing equilibria (expressed below) for the intercalation at well-matched sites 
and insertion at the CC mismatch.  
 
Figure A1: Steady-state luminescence titrations of rac-[Ru(Me4phen)2(dppz)]2+ with well-matched 
(green) and mismatched (red) 27-mer DNA duplexes (ODN). Samples were run in 5 mM tris, 200 
mM NaCl, pH 7.5. [Ru] = 2 µM, lex = 440 nm. Emission spectra were integrated from 564-820 nm.  
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    𝐶 + 𝐵𝑃	   ⇌ [𝐶_𝐵𝑃] 	  	  	  𝐾+,, = 	   [._/0]. 	   /0  
              	  𝐶 + 𝑀𝑀	   ⇌ [𝐶_𝑀𝑀] 	  	  	  𝐾22 = 	   [._22]. 	   22  
Kass describes the binding equilibrium between the complex, C, and well-matched base pair sites, 
BP, in the DNA. KMM describes the binding equilibrium between the complex and the mismatched 
site, MM.  
Next, we will express the total concentration of complex as Cc; this is kept constant 
throughout the titration. We can then define the various molar fractions for the complex as follows:  
  𝑓 = 	   [.].4 , the molar fraction of free complex. 
 𝑏 = 	   [._/0].4 , the molar fraction of complex bound to WM base pairs. 
 𝑚 =	   [._22].4 , the molar fraction of complex bound to MM sites. 
Additionally, we express the total concentration of duplex as CODN; this value increased throughout 
the titration. The variable R is introduced as being equal to the ratio CODN/CC, and in our titration 
the luminescence of the complex is measured as the value of R is increased. The luminescence 
intensity, I/I0, can be expressed as a function of R as follows:  𝐼 𝐼8 = 𝑓 + 𝛼	  𝑏 + 	  𝛽	  𝑚 
where 𝛼 and 𝛽 are equal to the relative emissivity of complex when bound to BP and MM, 
respectively.  
We must define a few more final parameters: x is the ratio of mismatched sites to total base 
pairs in the duplex (so 1/27, or 0.037); p, as mentioned above, is the occupational factor which 
takes into account the possible inhibition of binding by two complexes in close vicinity; and n is 
the total number of base pairs in the duplex (27). We can now express the equilibrium 
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concentrations of free BP and MM sites as follows:  𝐵𝑃 = 	  𝑛	   1 − 𝑥 	  𝐶?@A − 	  𝑝	   𝐶_𝐵𝑃 = 	  	  𝑛	   1 − 𝑥 	  𝐶?@A − 𝑝	  𝑏	  𝐶.  𝑀𝑀 = 	  𝑛	  𝑥	  𝐶?@A −	   𝐶_𝑀𝑀 = 	  	  𝑛	  𝑥	  𝐶?@A − 𝑚	  𝐶.  
Thus, 	  [/0].4 = 	  𝑛	   1 − 𝑥 	  𝑅 − 𝑝	  𝑏 and [22].4 = 	  𝑛	  𝑥	  𝑅 − 	  𝑚 
The binding equilibrium equations are thus rewritten as: 𝐾+,, = 	   DE	  .4 F	   GHI 	  JHK	  D  and 𝐾22 = 	   LE	  .4 F	  I	  JHL  
The expression of b and m as functions of f can thus be obtained: 𝐾+,,	  𝑓	  𝐶. 𝑛	   1 − 𝑥 	  𝑅 − 𝑝	  𝑏 − 𝑏 = 0 
𝑏 = 	  𝐾+,,	  𝐶.	  𝑛	   1 − 𝑥 	  𝑅	  𝑓1 + 𝐾+,,	  𝐶.	  𝑝	  𝑓  𝐾22	  𝑓	  𝐶. 𝑛	  𝑥	  𝑅 − 𝑚 −𝑚 = 0 
𝑚 =	  𝐾22	  𝐶.	  𝑛	  𝑥	  𝑅	  𝑓1 + 𝐾+,,	  𝐶.	  𝑓  
With 1 = 𝑓 + 𝑏 +𝑚 
0 = 𝑓 − 1 + 𝐾+,,	  𝐶.	  𝑛	   1 − 𝑥 	  𝑅	  𝑓1 + 𝐾+,,	  𝐶.	  𝑝	  𝑓 + 𝐾22	  𝐶.	  𝑛	  𝑥	  𝑅	  𝑓1 + 𝐾+,,	  𝐶.	  𝑓  0 = 𝑓 − 1 1 + 𝐾+,,	  𝐶.	  𝑝	  𝑓 1 + 𝐾+,,	  𝐶.	  𝑓 + 𝐾+,,	  𝐶.	  𝑛	   1 − 𝑥 	  𝑅	  𝑓	  (1 + 𝐾+,,	  𝐶.	  𝑓)+ 𝐾22	  𝐶.	  𝑛	  𝑥	  𝑅	  𝑓 1 + 𝐾+,,	  𝐶.	  𝑝	  𝑓  
The expression of the intensity of luminescence, I/I0 can be written as follows: 𝐼 𝐼8 = 	  𝑓 + 𝛼	   𝐾+,,	  𝑓	  𝐶.	  𝑛	   1 − 𝑥 	  𝑅1 + 	  𝑝	  𝐾+,,	  𝑓	  𝐶. + 	  𝛽	   𝐾22	  𝑓	  𝐶.	  𝑛	  𝑥	  𝑅1 + 𝐾22	  𝑓	  𝐶.  
 
(eq. 2) 
(eq. 1) 
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The fitting process using equation 2 is realized by an iterative solving to the expression of f using 
equation 1. Moreover, a global fitting approach is used to fit the data on both the CC mismatch 
sequence and the well-matched sequence. The binding affinity 𝐾+,, and the factors p and 𝛼 are 
linked for the global fit. In the case of the well-matched sequence (x=0), the parameters 𝐾22 and 𝛽 are kept constant at 1 and 0, respectively. 
A global fitting on the data obtained from the well-matched and mismatched titrations is 
performed and yield the values of Kass = 6.8 104 M-1 per well-matched base pair and KMM = 1.8 
106 M-1 per mismatched site. The errors are evaluated to be equal to 10%.  
 
A.2 [Ru(bpy)2(BNIQ)]2+ DNA Titrations  
 
The global fitting on the three data sets is performed (occupational factor set to 2) and 
yields the values of Ka = 7.3 103 M-1 per well-matched base pair, Ka = 3.5 106 M-1 per CC mismatch, 
and Ka = 3.8 106 M-1 per abasic site. The emissivities for the complex associated with these sites, 
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Figure A2: Steady-state luminescence titrations of rac-[Ru(bpy)2(BNIQ)]2+ (4 µM) with well-
matched (blue), mismatched (red), and abasic (pink) DNA. Samples were prepared in 5 mM Tris, 
200 mM NaCl, pH 7.5. [Ru] = 4 µM, lex = 440 nm. [DNA] reflects the concentration of full 
sequence. Emission spectra were integrated from 590-850 nm. 
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relative to the luminescence of the free complex, are estimated to be 1.36, 1.42 and 1.46 for well-
matched, mismatched, and abasic sites, respectively. The errors are evaluated to be equal to 10%.  
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